Viral infections evidence library
Human Papillomavirus Infection
A living PubMed evidence library for HPV prevention, vaccination, persistent infection, precancer treatment, recurrence, and therapeutic research.
PubMed only
Research ranked
Conflicts shown
Data downloadable
Living evidence synopsis
What the current PubMed collection shows.
Alexandria currently organizes 623 non-retracted PubMed-indexed records for Human Papillomavirus Infection. The structured collection includes 14 guideline or consensus records, 109 evidence syntheses/systematic reviews/meta-analyses, and 87 randomized or phase III studies. 126 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 489 of 623 included records.
Evidence data
Research landscape
Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.
Publication activity
Latest 12 represented yearsRecords by publication year
1
2013
1
2014
1
2017
2
2018
3
2019
2
2020
8
2021
4
2022
10
2023
10
2024
73
2025
507
2026
Evidence composition
Study designs
Transparency
Conflict-of-interest reporting
Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.
Abstract result signals
Extracted result direction
Reported outcomes
Numerical results extracted from PubMed abstracts
Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.
Non-pooled ratio measures
Reference = 1.0
Hazard, risk, and odds ratios reported in abstracts
0.250.51.02.04.0
View extracted numerical results 60
| Publication | Outcome | Measure | Reported value | Source |
|---|---|---|---|---|
| Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 | not_reported | Hazard Ratio | 0.9 95% CI 0.47–1.73 | PMID 40277212 |
| Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 | not_reported | Odds Ratio | 3.0 | PMID 40356381 |
| Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 | adverse events | Percentage Comparison | 82.0percent vs 60.0percent P = .027 | PMID 40356381 |
| Efficacy and Safety of Ionic Contra-viral Therapy (Digoxin-furosemide) in the Treatment of Multiple Cutaneous Warts: A Systematic Review, Meta-analysis, and Trial Sequential Analysis.Current drug research reviews · 2026 | not_reported | Risk Ratio | 13.27 95% CI 2.93–60.17 p = 0.0018 | PMID 40873359 |
| Efficacy and Safety of Ionic Contra-viral Therapy (Digoxin-furosemide) in the Treatment of Multiple Cutaneous Warts: A Systematic Review, Meta-analysis, and Trial Sequential Analysis.Current drug research reviews · 2026 | not_reported | Risk Ratio | 0.66 95% CI 0.09–5.09 p = 0.69 | PMID 40873359 |
| Efficacy and Safety of Ionic Contra-viral Therapy (Digoxin-furosemide) in the Treatment of Multiple Cutaneous Warts: A Systematic Review, Meta-analysis, and Trial Sequential Analysis.Current drug research reviews · 2026 | not_reported | Risk Ratio | 1.33 95% CI 0.47–3.79 p = 0.59 | PMID 40873359 |
| Efficacy and Safety of Ionic Contra-viral Therapy (Digoxin-furosemide) in the Treatment of Multiple Cutaneous Warts: A Systematic Review, Meta-analysis, and Trial Sequential Analysis.Current drug research reviews · 2026 | not_reported | Risk Ratio | 1.45 95% CI 0.29–7.22 p = 0.65 | PMID 40873359 |
| FDG-PET-Based Selective Deescalation of Chemoradiation in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 | progression-free survival | Hazard Ratio | 1.052 P = 0.023 | PMID 41385605 |
| FDG-PET-Based Selective Deescalation of Chemoradiation in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 | progression-free survival | Hazard Ratio | 1.038 P = 0.023 | PMID 41385605 |
| The 'see-and-treat' approach in the treatment of preneoplastic cervical lesions.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 | not_reported | Odds Ratio | 3.57 | PMID 41442739 |
| The 'see-and-treat' approach in the treatment of preneoplastic cervical lesions.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 | not_reported | Odds Ratio | 4.5 P < 0.0001 | PMID 41442739 |
| The 'see-and-treat' approach in the treatment of preneoplastic cervical lesions.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 | not_reported | Odds Ratio | 2.97 P < 0.0001 | PMID 41442739 |
| Human Papillomavirus-Related Anal Precancerous Lesions in Men Who Have Sex With Men: A Comparative Study of Pre-exposure Prophylaxis Users and HIV-Positive Individuals.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 | not_reported | Odds Ratio | 0.6 | PMID 41488971 |
| Human Papillomavirus-Related Anal Precancerous Lesions in Men Who Have Sex With Men: A Comparative Study of Pre-exposure Prophylaxis Users and HIV-Positive Individuals.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 | not_reported | Odds Ratio | 2.39 95% CI 1.03–5.55 | PMID 41488971 |
| Phase 2 Prospective Trial of Personalized Radiation Therapy Fractionation in Human Papillomavirus Positive Oropharyngeal Cancer.International journal of radiation oncology, biology, physics · 2026 | not_reported | Odds Ratio | 60.0 | PMID 41519405 |
| SOX1/PAX1 Methylation for Triage of HPV-Positive Women in Cervical Cancer Screening: A Cohort Study.BJOG : an international journal of obstetrics and gynaecology · 2026 | not_reported | Hazard Ratio | 12.0 | PMID 41555581 |
| Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial.Nature communications · 2026 | not_reported | Odds Ratio | 5.0 | PMID 41605945 |
| Diagnostic and prognostic significance of circulating HPV cfDNA in cervical cancer: A systematic review and meta-analysis.Critical reviews in oncology/hematology · 2026 | not_reported | Odds Ratio | 71.31 | PMID 41619873 |
| Diagnostic and prognostic significance of circulating HPV cfDNA in cervical cancer: A systematic review and meta-analysis.Critical reviews in oncology/hematology · 2026 | progression-free survival | Hazard Ratio | 8.5 | PMID 41619873 |
| Human Papillomavirus vaccine knowledge and recommendation practice among primary care providers, Almaty, Kazakhstan - 2023.Human vaccines & immunotherapeutics · 2026 | not_reported | Odds Ratio | 1.52 95% CI 1.06–2.18 | PMID 41623232 |
| Human Papillomavirus vaccine knowledge and recommendation practice among primary care providers, Almaty, Kazakhstan - 2023.Human vaccines & immunotherapeutics · 2026 | not_reported | Odds Ratio | 1.47 95% CI 1.03–2.07 | PMID 41623232 |
| Human Papillomavirus vaccine knowledge and recommendation practice among primary care providers, Almaty, Kazakhstan - 2023.Human vaccines & immunotherapeutics · 2026 | not_reported | Odds Ratio | 1.63 95% CI 1.14–2.32 | PMID 41623232 |
| Human Papillomavirus vaccine knowledge and recommendation practice among primary care providers, Almaty, Kazakhstan - 2023.Human vaccines & immunotherapeutics · 2026 | not_reported | Odds Ratio | 1.65 95% CI 1.12–2.47 | PMID 41623232 |
| Human Papillomavirus vaccine knowledge and recommendation practice among primary care providers, Almaty, Kazakhstan - 2023.Human vaccines & immunotherapeutics · 2026 | not_reported | Odds Ratio | 3.07 95% CI 2.11–4.54 | PMID 41623232 |
| Phase I/II clinical study of next-generation photodynamic therapy (L-PDT) using talaporfin sodium (Laserphyrin®) for cervical intraepithelial neoplasia: Efficacy, safety, and fertility preservation.Photodiagnosis and photodynamic therapy · 2026 | not_reported | Odds Ratio | 100.0 | PMID 41638379 |
| Evaluation of the Quality and Suitability of Self-Collected Vaginal and Urine Samples for Human Papillomavirus Testing: A Prospective Matched Study.BJOG : an international journal of obstetrics and gynaecology · 2026 | not_reported | Odds Ratio | 2.0 | PMID 41639581 |
| A meta-analysis of photodynamic therapy in the treatment of cervical intraepithelial neoplasia: Based on randomized controlled trials.Photodiagnosis and photodynamic therapy · 2026 | HPV clearance | Odds Ratio | 2.27 P < 0.05 | PMID 41740824 |
| A meta-analysis of photodynamic therapy in the treatment of cervical intraepithelial neoplasia: Based on randomized controlled trials.Photodiagnosis and photodynamic therapy · 2026 | HPV clearance | Odds Ratio | 1.99 P < 0.05 | PMID 41740824 |
| Long-term cervical cancer risk following negative hrHPV-based versus negative cytology-based screening: A population-based study.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Hazard Ratio | 0.5 | PMID 41759414 |
| Long-term cervical cancer risk following negative hrHPV-based versus negative cytology-based screening: A population-based study.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Hazard Ratio | 0.4 | PMID 41759414 |
| Long-term cervical cancer risk following negative hrHPV-based versus negative cytology-based screening: A population-based study.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Hazard Ratio | 3.4 | PMID 41759414 |
| The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial.Cancer research communications · 2026 | not_reported | Hazard Ratio | 1.83 | PMID 41790036 |
| The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial.Cancer research communications · 2026 | not_reported | Odds Ratio | 1.41 | PMID 41790036 |
| The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial.Cancer research communications · 2026 | not_reported | Odds Ratio | 0.6 | PMID 41790036 |
| Transoral robotic surgery versus definitive (Chemo)radiotherapy in early HPV-positive oropharyngeal cancer: A systematic review and meta-analysis of oncologic outcomes.Oral oncology · 2026 | not_reported | Hazard Ratio | 1.24 p = 0.60 | PMID 41806530 |
| Transoral robotic surgery versus definitive (Chemo)radiotherapy in early HPV-positive oropharyngeal cancer: A systematic review and meta-analysis of oncologic outcomes.Oral oncology · 2026 | not_reported | Hazard Ratio | 3.11 p = 0.09 | PMID 41806530 |
| Transoral robotic surgery versus definitive (Chemo)radiotherapy in early HPV-positive oropharyngeal cancer: A systematic review and meta-analysis of oncologic outcomes.Oral oncology · 2026 | not_reported | Percentage Comparison | 1.6percent vs 8.5percent | PMID 41806530 |
| Impact of male genital tract infections on semen quality: a systematic review and meta-analysis.Fertility and sterility · 2026 | not_reported | Odds Ratio | 10.63 | PMID 41825760 |
| Impact of male genital tract infections on semen quality: a systematic review and meta-analysis.Fertility and sterility · 2026 | not_reported | Odds Ratio | 1.43 | PMID 41825760 |
| HPV vaccine awareness and uptake among women attending cervical screening in health-resource-limited areas of China: A multicenter cross-sectional study.Human vaccines & immunotherapeutics · 2026 | not_reported | Percentage Comparison | 40.66percent vs 51.34percent | PMID 41830505 |
Research transparency
Funding and conflicts of interest
Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.
NCI NIH HHS91
NIDCR NIH HHS20
National Natural Science Foundation of China19
NIH HHS16
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR)9
NIAID NIH HHS8
National Cancer Institute (NCI)7
National Institutes of Health (NIH)7
View records with declared financial or industry relationships 12
Case Report: Functional characterization of lymphocyte populations in a pediatric patient with WHIM syndrome.
MMa, FA-N, KZ, LK and SZ were employees of X4 Pharmaceuticals (Austria) GmbH and shareholders of X4 Pharmaceuticals. MMi is on the X4 Pharmaceuticals Advisory Board: Clinical Development of Mavorixafor in People with Chronic Neutropenia. The remaining authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author MMi declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
PMID 42445192 · 2026ASO Special Article: Proceedings of the Inaugural Joint US-India Cancer Dialogue: Accelerating Collaboration to Advance Cancer Prevention, Early Detection, Treatment, and Care.
Disclosure: Dr. Parikh has held Equity in C2i Genomics, Khora, OneCell, XGenomes, Cadex, and Parithera. In the last 36 months, she has served as an advisor/consultant for Zola, CVS, Phesi, Xilio, 3T Biosciences, Do More Diagnostics, Summit Therapeutics, Pfizer, Regeneron, GSK, Foundation Medicine, Careset, Value Analytics Labs, Naterara, Adroya, Astra Zeneca, Scare, Hookipa, Guardant, Abbvie, Seagen, Mirati, Takeda, PMV, Kahr, Sirtex, Eli Lilly, Merck, Amgen, Delicate, Exact, Caris, BMS, Incyte, Pheon, Neogenomics, J & J, Exact, Boehringer Ingelheim, Novartis, Third Rock Ventures, MPM Capital, and Science For America. She is Chief Scientist of Reversing Early Recurrence. She receives fees from Up to Date. She has received travel fees from Karkinos Healthcare. She has received research funding to the Institution from PMV Pharmaceuticals, BMS, Mirati, Erasca, Genentech, Daiichi Sankyo, Syndax, Revolution Medicine, Lily, Xilio, and Parthenon.
PMID 42166060 · 2026Women's preference for HPV self-sampling devices: a programme-embedded, large-scale paired comparative study within the cervical cancer screening programme in the Capital Region of Denmark.
Competing interests: EKA, AA, BTP, HP, TDN, PF and RS: None declared. JB: Institution has received research funding and/or consumables at reduced price or for free to support research from BD Diagnostics (USA) and Seegene (South Korea). JB has received honoraria for lectures from BD Diagnostics, Copan and Seegene. The Capital Region of Denmark holds patent P6825EP00 (SensiGrip).
PMID 42156147 · 2026Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.
Conflict of Interest Disclosures: Dr Mirallas reported receiving writing assistance from Roche; speaker fees from MSD, Merck, Janssen Pharmaceuticals, Pfizer, and AstraZeneca; and travel assistance from Takeda and Recordati during the conduct of the study. Dr Yap reported receiving grants from Acrivon, Artios, AstraZeneca, Bayer, BeiGene, BioNTech, Blueprint, Bristol Myers Squibb, Boundless Bio, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GSK, Genentech, Haihe, Ideaya, ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tango, Tesaro, Vivace, Zenith, the National Cancer Institute (NCI), US Department of Defense, V Foundation, and the National Institutes of Health; personal fees from AbbVie, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, BeiGene, Biocity Pharma, Blueprint, Boxer, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics, Diffusion, Duike Street Bio, 858 Therapeutics, EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, F-star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Ideaya Biosciences, Idience, Ignyta, I-Mab, Immunesensor, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI Pharma, Mereo, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics, Nexys, Nimbus, Novocure, Odyessy, OHSU, OncoSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, PER, Pfizer, Piper-Sandler, Pliant Therapeutics, Prolynx, Radiopharma Theranostics, Repare, resTORbio, Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals, Tolremo, Tome, Thryv Therapeutics, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Voronoi Inc, Xinthera, Zai Labs, and ZielBio outside the submitted work. Dr Rodón reported receiving travel support from the European Society for Medical Oncology, American Society of Medical Oncology, Dava Oncology, and STOP Cancer; consulting and travel fees from Ellipses Pharma, Ionctura, Amgen, MonteRosa, Bridgebio, Debiopharm, Bristol Myers Squibb, and BioHybrid Solutions (including serving on the scientific advisory board); receiving consulting fees from Vall d’Hebron Institute of Oncology, AstraZeneca, Boxer Capital LLC, Ecor1, Tang Advisors LLC, Guidepoint, and Bayer; receiving research funding from Blueprint Medicines, Merck Sharp & Dohme, Hummingbird, AstraZeneca, 280 Bio, Vall d’Hebron Institute of Oncology/Cancer Core Europe, and Bristol Myers Squibb; and serving as investigator in clinical trials with Cancer Core Europe, Pfizer, Kelun-Biotech, Roche Pharmaceuticals, 280 Bio, Bicycle Therapeutics, ForeBio, Ideaya, Amgen, Tango Therapeutics, Bristol Myers Squibb, MonteRosa, Debiopharm, BeiGene, Relay, Novartis, Scorpion Therapeutics, Incyte, Parabilis Pharmaceuticals, Tyra, Nuvectis Pharma, Adcentrix, Vividion, AstraZeneca, Alnylam, Immuneering Corp, Alterome, Exelixis, Ensem, Bridgebio, Cogent, Biohaven, Insilico Medicines, Ipsen, Eli Lilly, Seed, Zai Labs, Merk Serono, Dewpoint Therapeutics, Elevar Therapeutics, and Servier. Dr Piha-Paul reported receiving grants from NCI and Cancer Prevention Research Institute of Texas Precision Oncology Decision Support Core and a Clinical and Translational Science Award during the conduct of the study; clinical trial research support from ABM Therapeutics, ENB Therapeutics, Alkermes, Aminex Therapeutics, Boehringer Ingelheim, Cullinan Oncology, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Day One Biopharmaceuticals, Daiichi Sankyo, Epigenetix, Genmab US, Gilead Sciences, Hengrui Pharmaceuticals, Immunity Bio, Immunome, Immunomedics, Incyte, Innovent Biologics, iTeos Belgium SA, Jazz Pharmaceuticals, Johnson & Johnson, Loxo Oncology, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma America, Nectin Therapeutics, Nested Therapeutics, NRG Oncology, Nurix, OncoNano Medicine, Pyxis Oncology, Pieris Pharmaceuticals, Pfizer, Phanes Therapeutics, Puma Biotechnology, Purinomia Biotech, Replimune, Roche/Blueprint, Solve Therapeutics, Tallac Therapeutics, Toragen Therapeutics, TransThera Bio, Xencor, Axcynsis Therapeutics, BioMarin Pharmaceutical, and Strand Therapeutics outside the submitted work; and consultant fees from Mitsubishi Tanabe Pharma America. Dr Fu reported receiving research funding and instrumentation from Novocure during the conduct of this study and clinical trial research support and grant funding through his institution from NCI, Abbisko, Antengene, BeiGene, BeyondSpring Pharmaceuticals, Biotheus, Boehringer Ingelheim, Coherent Biopharma, Crossignal Therapeutics, CUE Biopharma, DEKA Biosciences, Eli Lilly, Exelixis, Fore Biotherapeutics, Greenfire Bio, Hookipa Biotech, IMV, Innovent Biologics, Jazz Pharmaceuticals, K-Group Beta, Lantern Pharma, Lyvgen Biopharm, MacroGenics, MediLink Therapeutics, Millennium Pharmaceuticals, Nerviano Medical Sciences, NeuPharma, NextCure, Ningbo NewBay Technology Development, Novartis, NovoCure, Nykode Therapeutics AS, Parexel International, PharmaMar USA, Pionyr Immunotherapeutics, PureTech Health, Qurgen, Shanghai Huaota Biopharmaceutical, Sellas Life Sciences Group, Soricimed Biopharma, SQZ Biotechnologies, Sumitomo Dainippon, Taiho Oncology, NCCN, Tigermed Group, TransCode Therapeutics, Treadwell Therapeutics, Turnstone Biologics, Tyligand Bioscience, and Virogin Biotech. Dr Champiat reported receiving speaker fees from Amgen, Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Genmab, Janssen, Merck KGaA, Merck, Novartis, Roche, and Servier; grants from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bolt Biotherapeutics, Centessa Pharmaceuticals, Cytovation, Eisai, Exelixis, GSK, Imcheck Therapeutics, Immunocore, Kumquat Biosciences, Marengo Therapeutics, Molecular Partners, Merck, OncoC4, Ose Immunotherapeutics, Owkin, Pheast Therapeutics, Pierre Fabre, Replimune, Roche, Sanofi Aventis, Seagen, SOTIO, Transgene, Trutino Biosciences, and Vir Biotechnology; advisory board or consulting fees from AccessTrial, Alderaan Biotechnology, Amgen, AstraZeneca, Aummune, Avacta, Bayer, BeiGene, Biocodex, BioNTech, Boehringer Ingelheim, Celanese, Compugen, Domain Therapeutics, Ellipses Pharma, GE Healthcare, Genmab, Guardant Health, Immunicom, Ipsen Biopharmaceuticals, Mariana Oncology, Mima Health, Nanobiotix, Nextcure, NetCancer, Oncovita, Pharma Mar, Pierre Fabre, Replimune, Seagen, Takeda, Tatum Bioscience, Tollys, and UltraHuman8; travel support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GE Healthcare, Merck, Ose Immunotherapeutics, Roche, and SOTIO; and stock in Avacta outside the submitted work. Dr Akhave reported receiving consulting fees from Acendo and Pfizer and nonfinancial contracted research support from Innocare Pharma, Bicara Therapeutics, Seagen, Aveo Oncology, Metaclipse Therapeutics, and Tuhura Biosciences outside the submitted work. Dr Ferrarotto reported receiving advisory board or steering committee fees from Bicara, Johnson & Johnson, Pyxis, Natera, and RAPT and consulting fees from Rgenta outside the submitted work. Dr Hong reported receiving research and grant funding to his institution from AbbVie, Acendo, Adagene, Adaptimmune, Adlai-Nortye, Alterome, Amgen, Arvinas, AstraZeneca, Bayer, BeiGene USA, Bridge-Bio, Bristol Myers Squibb, Chong Kun, D3 Bio, Deciphera, Eli Lilly, Endeavor, Erasca, Exelixis, F. Hoffmann-LaRoche/Genentech, Immunogenesis, Inhibrix, Kestrel, Kumquat, KURA, NCI Cancer Therapy Evaluation Program, Pfizer, Quanta Therapeutics, Revolution Medicine, VelaVagio, Verastem, and VM Oncology; travel expenses from the American Association for Cancer Research, Immunogenesis, Medscape, and Telperian; consulting or speaker fees from or advisory roles with AbbVie, Acuta, Alpha Insights, Amgen, Axiom, Blueprint, BeiGene, Boxer Capital, BVF, ClearView Oncology, COR2ed, Cogent Therapeutics, CureBio, Ecor1, Erasca, GLG, Guidepoint, Immunogenesis, Kanaph Therapeutics, Kayak Therapeutics, Kestrel Therapeutics, Medscape, Morgan-Stanley, Nextech Ventures, Pfizer, PharmaResearch, Revolution Medicine, T-Knife, and WebMD; and ownership interests with BreakThrough Bio (advisor), CrossBridge Bio (advisor), Molecular Match (advisor), OncoResponse (founder, advisor), Telperian (founder, advisor), and Interact Therapeutics (advisor). Dr Meric-Bernstam reported receiving consulting fees from AstraZeneca, Becton Dickinson, Biocartis, Novartis, Boehringer Ingelheim, Calibr (a division of Scripps Research), Crossbridge Bio, Daiichi Sankyo, Dava Oncology, Debiopharm International, DEM BioPharma, EcoR1 Capital, eFFECTOR Therapeutics, Elevation Oncology, Exelixis, GT Aperion, Incyte, Jazz Pharmaceuticals, LigaChem Biosciences (formally LegoChem), Menarini Group, ModeX Therapeutics, Molecular Templates, Precede Biosciences, Protai Bio, Ribometrix, SystImmune, Tacalyx, TEMPUS, TORL BioTherapeutics, Vir Biotechnology, and Zymeworks; advisory committee fees from Cybrexa Therapeutics, DEM BioPharma, Go Therapeutics, Guardant Health, Harbinger Health, Illumen Therapeutics, Kivu Biosciences, Loxo Oncology, OnCusp Therapeutics, Seagen (formerly Seattle Genetics), Sutro Biopharma, Theratechnologies Inc, and Zentalis Pharmaceuticals; grants from AstraZeneca, Daiichi Sankyo, Debiopharm International, eFFECTOR Therapeutics, Guardant Health, Jazz Pharmaceuticals, and Zymeworks; honoraria from Dava Oncology and Physician Education Resource; and travel support from Cholangiocarcinoma Foundation, Dava Oncology, European Society for Medical Oncology, and Physician Education Resource outside the submitted work. Dr Naing reported receiving research funding to his institution from NCI, EMD Serono, MedImmune, Healios Oncology Nutrition, Atterocor/Millendo, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Eli Lilly, Kymab, PsiOxus, Arcus Biosciences, NeoImmuneTech, Immune-Onc Therapeutics, Surface Oncology, Monopteros Therapeutics, BioNTech, Seven & Eight Biopharma, SOTIO, GV 20 Therapeutics, Sanofi, Orionics, Novatek, BeOne, and Summit; receiving consulting fees from CTI, Deka Biosciences, Janssen Biotech, NGM Bio, PsiOxus Therapeutics, Immune-Onc Therapeutics, STCube Pharmaceuticals, OncoSec KEYNOTE-695, Genome & Company, CytomX Therapeutics, Nouscom, Merck Sharp & Dohme, Servier, Lynx Health, AbbVie, and Mural Oncology; receiving travel support from ARMO BioSciences, NeoImmuneTech, and NGM Biopharmaceuticals; receiving speaker fees from AKH, The Lynx Group, Society for Immunotherapy of Cancer, Korean Society of Medical Oncology, Scripps Cancer Care Symposium, ASCO Direct Highlights, European Society for Medical Oncology, and CME Outfitters; and being founder of KN Foundation USA outside the submitted work. Dr Naing’s spouse is an advisory board member for Cogent, Pharming, and the Immune Deficiency Foundation; has grant funding from the Jeffrey Modell Foundation, Pharming, Takeda, and the Immune Deficiency Foundation; and has received speaker fees from WebMd. No other disclosures were reported.
PMID 42461627 · 2026Recurrent respiratory papillomatosis: is patient well-being related to anatomical manifestation?
Declarations. Prof. F.G. Dikkers is a consultant for Carl Reiner, Precigen, Inovio, UV Smart and MSD. There has not been any financial support or funding.
PMID 41652204 · 2026Clinical and dosimetric dataset of time-to-event normal tissue complication probability for osteoradionecrosis.
Competing interests: CDF has received unrelated grant support from Elekta AB and holds unrelated patents licensed to Kallisio, Inc. (US PTO 11730561) through the University of Texas, from which they receive patent royalties. CDF has also received unrelated travel and honoraria from Elekta AB, Philips Medical Systems, Siemens Healthineers/Varian, and Corewell Health. Additionally, CDF has served in an unpaid advisory capacity for Siemens Healthineers/Varian and has served on the guidelines/scientific committee for Osteoradionecrosis for the American Society of Clinical Oncology. VCS is a consultant and equity holder in Femtovox Inc and a consultant for PDS Biotechnology. KAW serves as an Associate Editor for Physics and Imaging in Radiation Oncology. The authors declare that no other competing interests exist.
PMID 41513675 · 2026Examining Artificial Intelligence Chatbots' Responses in Providing Human Papillomavirus Vaccine Information for Young Adults: Qualitative Content Analysis.
Conflicts of Interest: MLK has received investigator-initiated research funding from Merck, administered through Purdue University, and has served as a consultant to Merck.
PMID 41707197 · 2026The Vaccine Trust Framework: mixed-method development of a tool for understanding and quantifying trust in health systems and vaccines.
Declaration of interests DHB, LC, WA, EL, MH, and CV are employees of ReD Associates who received the grants from the Gates Foundation on which this work was funded. TJ was a program officer at the Gates Foundation for the grant that funded this work.
PMID 40845881 · 2025Screening for Cervical Cancer: A Recommendation From the Women's Preventive Services Initiative.
Financial Disclosure Alex Vosooney is a board member of the Minnesota Academy of Family Physicians and reports past payment from the American Academy of Family Physicians. Heidi D. Nelson reports ongoing royalties payment from Elsevier and Wolters Kluwer, and payment to her institution by the Agency for Healthcare Research & Quality (AHRQ). Nancy Byatt reports receiving past payment from The Kinitex Group; JBS, International; VentureWell; honorarium from James Bell Associates; payment from Elsevier for serving as an editor; and payment from Reproductive Mental Health Consultants for serving as a consultant. May Lau reports past payment from the American Academy of Pediatrics and past payment from the Coalition to Expand Contraceptive Access. Julie K. Wood reports past payment from the American Academy of Family Physicians and US Against Alzheimers. Linda Humphrey receives royalties from UpToDate. Margot L. Savoy reports payment from Merck for authorship of the immunization chapter for Merck Manual and from Novo Nordisk in the form of travel and honorarium for serving on an obesity advisory panel on behalf of AAFP. Kimberly Gregory reports payment to her institution from the California Dept of Public Health California Healthcare Foundation NCQA. The other authors did not report any potential conflicts of interest. Participation in the Advisory Panel, Multidisciplinary Steering Committee, WPSI or authorship of this document does not constitute organizational or individual endorsement of the recommendations or conclusions. This information or content and conclusions are those of the authors and should not be construed as the official position nor policy of, nor should any endorsements be inferred by HRSA, HHS, or the U.S. Government. All financial and intellectual disclosures of interest were declared, and potential conflicts were discussed and managed following the conflict of interest process of the American College of Obstetricians & Gynecologists ( https://www.womenspreventivehealth.org/wp-content/uploads/Methodology-August-2025.pdf ).
PMID 42024880 · 2026IPVS Consensus Statement on The Natural History of Cervical Human Papillomavirus Infection.
Potential conflicts of interest. A. H. has received reagents from Roche Diagnostics, Denmark, and an honoraria from Exeltis, outside the submitted work. A. F. R. is currently employed by Hologic, although this work was undertaken as part of her faculty appointment at Johns Hopkins School of Public Health; Hologic had no role in writing, reviewing, or funding this work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
PMID 41239758 · 2026Evaluation of the Efficacy of Human Papillomavirus Screening Compared With Cytology Screening in Pregnant Women: Protocol for a Prospective Multicenter Trial.
Conflicts of Interest: EM received honoraria for lectures and leaflet supervision from Roche Diagnostics Japan; Hologic Japan; and Merck and Co, Inc. TM received honoraria for lectures and leaflet supervision from Merck and Co, Inc, and Roche Diagnostics Japan. All other authors declare no other conflicts of interest.
PMID 42348863 · 2026Human Papillomavirus-Related Anal Precancerous Lesions in Men Who Have Sex With Men: A Comparative Study of Pre-exposure Prophylaxis Users and HIV-Positive Individuals.
Potential conflicts of interest. The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. M. S. receives a grant from MSD for an investigator-initiated research project on anal HPV infection and has received consulting fees, speaker fees and support for attending meetings from MSD. M. S. also serves as the European representative for the Growing the Workforce group of the International Anal Neoplasia Society (IANS). M. V. received a grant from the Willy Gepts Scientific Fund (WGWF). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
PMID 41488971 · 202601
Current Standard-of-Care Sources
Alexandria uses this label only for PubMed-indexed guidelines or consensus documents. These are source publications, not individualized recommendations.
Screening for Cervical Cancer.
Obstetrics and gynecology · 2026
PMID 42024877Clinical practice guideline for high-risk human papillomavirus testing in cervical cancer screening: a consensus statement from the Korean Society of Gynecologic Oncology.
Journal of gynecologic oncology · 2026
PMID 41834415International Society of Urological Pathology (ISUP) Multidisciplinary Consensus on Premalignant and Putative Precursor Lesions of Penile Cancer: Working Group 5 report on Terminology, Grading, and Molecular Testing Practices.
The American journal of surgical pathology · 2026
PMID 40826809Australian guidelines for anal cancer screening using anal human papillomavirus testing with cytology triage in people living with HIV.
HIV medicine · 2025
PMID 41130598Updated clinical practice guidelines for human papillomavirus vaccination: the Korean Society of Gynecologic Oncology recommendations.
Journal of gynecologic oncology · 2026
PMID 41775253Screening for Cervical Cancer: A Recommendation From the Women's Preventive Services Initiative.
Obstetrics and gynecology · 2026
PMID 42024880SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
PMID 41843267[Cervical cancer screening : implementation of the hr-HPV test].
Revue medicale de Liege · 2025
PMID 41229231Radiotherapy for penile cancers: 2025 update.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025
PMID 41205450Management of women with abnormal cervical cytology: Update of French guidelines after the implementation of HPV screening.
European journal of obstetrics, gynecology, and reproductive biology · 2025
PMID 40957151Role of radiotherapy in the management of anal canal cancer: Recommendations of the Société française de radiothérapie oncologique.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025
PMID 41273885High-Risk HPV Testing in Head and Neck Carcinoma: Key Updates from the 2025 College of American Pathologists Guideline.
Head and neck pathology · 2025
PMID 4102108202
Highest-Priority Research
Screening for Cervical Cancer.
Obstetrics and gynecology · 2026
This committee statement announces the American College of Obstetricians & Gynecologists' qualified endorsement of the 2026 Women's Preventive Services Initiative's (WPSI) updated cervical cancer screening guidelines and addresses cervical cancer screening for patients at average risk in the following age categories: 21-29 years, 30-65 years, and older than 65 years. This committee statement discusses specific qualifications to the WPSI guidelines, particularly regarding self-collection for primary high-risk human papillomavirus screening, among other implementation considerations.
PMID 42024877Clinical practice guideline for high-risk human papillomavirus testing in cervical cancer screening: a consensus statement from the Korean Society of Gynecologic Oncology.
Journal of gynecologic oncology · 2026
High-risk human papillomavirus (hrHPV) is a necessary cause of cervical cancer, and hrHPV testing has increasingly been recognized as an effective screening tool that overcomes the limitations of cytology-based screening. However, standardized clinical guidance for the use of hrHPV testing in cervical cancer screening has been limited in Korea, resulting in variability in clinical practice. This consensus-based clinical practice guideline was developed under the auspices of the Korean Society of Gynecologic Oncology through multidisciplinary collaboration involving experts in gynecology, pathology, laboratory medicine, and public health. Relevant domestic and international evidence was syste…
PMID 41834415International Society of Urological Pathology (ISUP) Multidisciplinary Consensus on Premalignant and Putative Precursor Lesions of Penile Cancer: Working Group 5 report on Terminology, Grading, and Molecular Testing Practices.
The American journal of surgical pathology · 2026
The classification and diagnosis of penile intraepithelial neoplasia (PeIN) remains inconsistent among pathologists, despite its recognized role and understanding as a precursor to penile squamous cell carcinoma (PSCC). The International Society of Urological Pathology (ISUP) convened a consensus group of multidisciplinary thought leaders to assess current global practices regarding the usage of terminology, grading, and molecular testing in penile cancer precursor lesions. A preconference survey was distributed to ISUP members in 2024, collecting responses from 112 pathologists, predominantly genitourinary specialists, to evaluate the use of penile cancer precursor lesion classification sys…
PMID 40826809Australian guidelines for anal cancer screening using anal human papillomavirus testing with cytology triage in people living with HIV.
HIV medicine · 2025
OBJECTIVES: To develop Australian anal cancer screening guidelines for people living with HIV. METHODS: In 2023, ASHM Health assembled a committee to create guidelines, based on existing international guidelines and utilizing data from the Study of the Prevention of Anal Cancer (SPANC). SPANC provided Australian-specific data on different screening methodologies for the detection of anal high-grade squamous intraepithelial lesions. RESULTS: The guidelines were released in March 2025. They recommend primary high-risk human papillomavirus (HRHPV) testing with cytology triage for high-resolution anoscopy. Gay, bisexual and other men who have sex with men (GBM) and trans-women living with HIV sh…
PMID 41130598Sex and human papillomavirus in oropharyngeal cancer: A systematic review and meta-analysis.
American journal of otolaryngology · 2024
INTRODUCTION: While the presence of human papillomavirus (HPV) is known to affect the outcomes of oropharyngeal squamous cell carcinoma (OPSCC), there is a significant gap in research regarding the potential sex-based differences. This systematic review-metanalysis (SR-MA) aims to evaluate if sex is a prognostic factor in HPV-associated OPSCC. METHODS: A systematic review and meta-analysis was performed. COCHRANE Library, CINAHL, PubMed, and Scopus were searched for English-language articles from 1966 to October 2023. Studies with multivariable analysis of overall survival (OS) based on sex were included. Adjusted hazard ratios (aHRs) with a 95 % confidence interval (CI) were presented for t…
PMID 39106680Updated clinical practice guidelines for human papillomavirus vaccination: the Korean Society of Gynecologic Oncology recommendations.
Journal of gynecologic oncology · 2026
The Korean Society of Gynecologic Oncology (KSGO) first developed clinical guidelines for the appropriate administration of human papillomavirus (HPV) vaccines tailored to the Korean context in 2016. In 2019, additional guidelines were introduced following the development of the nonavalent HPV vaccine. The 2021 revision included recommendations for vaccination in middle-aged women and men, as well as the potential benefits of vaccination following conization. In this latest revision, the guidelines focus on the necessity of HPV vaccination in middle-aged men, the Society's position on the single-dose schedule recently recommended by the World Health Organization to expand global vaccine cove…
PMID 41775253Comparative performance of HPV self-sampling and conventional screening methods: A systematic review and bivariate meta-analysis.
Gynecologic oncology · 2026
BACKGROUND: Cervical cancer is a major public health challenge, especially in low-resource settings with suboptimal screening. HPV self-sampling (SS) is a promising strategy to overcome logistical barriers, but its diagnostic accuracy relative to clinician-collected (CC) sampling, Visual Inspection with Acetic Acid (VIA), and Papanicolaou (Pap) cytology requires rigorous validation. METHODS: Following PRISMA-DTA guidelines, we searched PubMed/Medline, Scopus, Embase, and the Cochrane Library through March 2025 for studies comparing high-risk HPV SS against CC, VIA, or Pap cytology, using biopsy-confirmed CIN2+ as the reference standard. A bivariate random-effects model pooled sensitivity and…
PMID 42217258Screening for Cervical Cancer: A Recommendation From the Women's Preventive Services Initiative.
Obstetrics and gynecology · 2026
The Women's Preventive Services Initiative (WPSI) expanded its previous cervical cancer screening recommendation for average-risk women by including patient-collected high-risk human papillomavirus (hrHPV) screening tests and additional follow-up testing needed to complete the screening process. To update the previous recommendation, the WPSI identified new evidence demonstrating that primary hrHPV screening increases detection of precancerous lesions compared with cytology screening. New studies indicate that patient-collected hrHPV testing has similar test accuracy for precancer detection compared with clinician-collected samples and may reduce barriers to screening. Consistent with the pr…
PMID 42024880The association of fungal infection in cervical cancer: a systematic review and meta-analysis.
BMC women's health · 2026
BACKGROUND: Emerging evidence suggests a potential link between the fungal mycobiome and carcinogenesis. However, the relationship between fungal infection and cervical cancer progression remains inconclusive. This meta-analysis aimed to determine the pooled prevalence of fungal infection across different cervical pathological stages and assess its association with cervical lesions and HPV infection. PROSPERO CRD42024588513 is the registration number for the systematic review. METHODS: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines. We systematically searched PubMed, Web of Science, and Embase for studies published between January 1, 2004, and Decembe…
PMID 41992269Human papillomavirus-based vs. cytology for cervical cancer screening: a systematic review with meta-analysis.
Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2026
OBJECTIVE: To evaluate the performance of HPV-based testing compared to cytology in primary cervical cancer screening. STUDY SELECTION: This meta-analysis included randomized trials comparing HPV-based screening with cytology in women aged 20-69 with at least one year of follow-up. Studies with overlapping populations, combining screening methods, lacking outcomes of interest, or study protocols were excluded. CENTRAL, PubMed/MEDLINE, and Embase were searched on April 12, 2025. The main outcome is the detection rate of cervical neoplasia grade 2 or worse (CIN2+). DATA COLLECTION: Analyses followed Cochrane and PRISMA guidelines. DATA SYNTHESIS: A total of 1,707 articles were identified. Afte…
PMID 41988240SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
Squamous cell carcinoma of the lip, oral cavity, oropharynx, hypopharynx, and larynx comprises the ninth most common cancer in Spain. While alcohol and tobacco use have long been the primary etiological factors, the role of human papillomavirus (HPV) in oropharyngeal cancer is increasing. Diagnoses and relapses should always be discussed by an expert multidisciplinary team. For localized stages, surgery or radiotherapy should be used as single-modality treatments, while locoregional stages require combined modality approaches. In the case of recurrent or metastatic disease, curative intent should be considered for patients with local recurrence or oligometastatic disease, while systemic trea…
PMID 41843267[Cervical cancer screening : implementation of the hr-HPV test].
Revue medicale de Liege · 2025
Cervical cancer remains the fourth most common cancer in women. Recognition of the involvement of viral infection by human papillomavirus (HPV) in the carcinogenesis of lesions has enabled the evolution and adaptation of screening methods. Early detection of pre-invasive lesions and their treatment ultimately led to a reduction in the incidence and mortality of cervical cancer. In Belgium, the transition to primary screening is validated since January 1st, 2025. Let us nevertheless remember the importance of primary prevention through recommended vaccination for girls and boys.
PMID 4122923103
Latest Research — Last 24 Months
2026
SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · PMID 41843267
2026
The impact of HIV coinfection on mpox patients: a systematic review and meta-analysis.
Emerging microbes & infections · PMID 42461714
2026
Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes.
European urology focus · PMID 41519649
2026
Understanding the roots of hesitancy to unlock the game-changing impact of HPV vaccination: Insights from a global qualitative evidence synthesis.
Human vaccines & immunotherapeutics · PMID 42334459
2026
Efficacy of focused ultrasound for HPV clearance and cervical LSIL treatment: a meta-analysis.
Scientific reports · PMID 41904252
2026
Diagnostic accuracy of HPV DNA in oral gargle and rinse samples for Head and neck squamous cell carcinoma: A systematic review and meta-analysis.
The Japanese dental science review · PMID 42211773
2026
The population impact of human papillomavirus vaccination on cancer and pre-cancer outcomes: An umbrella review of meta-analyses.
Human vaccines & immunotherapeutics · PMID 42409728
2026
Intralesional human papillomavirus vaccination for cutaneous verrucae: a systematic review and meta-analysis of therapeutic efficacy.
The Journal of dermatological treatment · PMID 42370553
2026
Strategies implemented to increase HPV vaccine uptake and confidence among men who have sex with men and transgender people: A systematic review.
Human vaccines & immunotherapeutics · PMID 42216453
2026
Population-level impact of HPV vaccination: a global systematic review of ecological, cross-sectional, and cohort studies.
Expert review of vaccines · PMID 42053091
2026
Serious adverse events following human papillomavirus vaccination: A systematic review and meta-analysis of post-marketing evidence.
Human vaccines & immunotherapeutics · PMID 41759030
2026
Acceptance and the willingness to pay for human papilloma virus (HPV) vaccine: A systematic review.
Human vaccines & immunotherapeutics · PMID 41636135
2026
Human papillomavirus vaccination among Asian Americans and Pacific Islanders: Scoping review and meta-analysis of descriptive and correlational studies.
Human vaccines & immunotherapeutics · PMID 41627233
2026
2026
Diagnostic Accuracy of p16 Immunohistochemistry as a Marker of High-Risk HPV in Invasive Laryngeal Squamous Cell Carcinoma: A Systematic Review.
Medicina (Kaunas, Lithuania) · PMID 42512914
04
Treatment Options Studied in the PubMed Collection
These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.
higher-confidence evidence
Papillomavirus Vaccines
115 linked PMIDs238243 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, cervical cancer, mortality, adverse events, CIN2+, serious adverse events, recurrence, genital warts
- Populations represented
- general population; children; CIN2; HPV DNA; advanced; genital HPV infection; CIN2
- Mechanism
- This study examined how current pharmacy vaccination practices align with parent expectations and identified modifiable behavioral and implementation targets to improve uptake WeChat-based interventions guided by the Information - Motivation - Behavioral Skills (IMB) model offer a theory-driven approach by targeting knowledge, motivation, social norms, and self-efficacy
higher-confidence evidence
HPV vaccine
71 linked PMIDs120339 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, cervical cancer, mortality, adverse events, recurrence, persistent infection, CIN2+, overall survival
- Populations represented
- general population; children; CIN2; metastatic; first-line; second-line; high-risk HPV infection; anal HPV infection; HPV16; CIN3; persistent HPV infection
- Mechanism
- This study examined how current pharmacy vaccination practices align with parent expectations and identified modifiable behavioral and implementation targets to improve uptake WeChat-based interventions guided by the Information - Motivation - Behavioral Skills (IMB) model offer a theory-driven approach by targeting knowledge, motivation, social norms, and self-efficacy
preliminary evidence
DNA, Viral
23 linked PMIDs5548 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, cervical cancer, recurrence, mortality, overall survival, progression-free survival, response rate, CIN2+
- Populations represented
- general population; HPV DNA; HPV DNA; HPV16; HPV18; p16; p16; CIN3; HPV DNA; HPV16; HPV DNA; HPV16; p16
- Mechanism
- Furthermore, while current assays exploit the analytical simplicity of viral targets, host-derived fragmentomics remains an overlooked compartment that warrants exploration to determine its true clinical value regarding underlying tumor dynamics METHODS AND RESULTS: A new set of primers targeting amplification of approximately 391 base pairs of the L1 capsid protein gene of camel papillomavirus was designed, and PCR conditions were optimized
preliminary evidence
Oncogene Proteins, Viral
14 linked PMIDs1048 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- cervical cancer, persistent infection, reported clinical outcomes, CIN2+, CIN3+
- Populations represented
- HPV16; general population; HPV16; HPV18; HPV DNA; HPV16; p16; HPV DNA; HPV16; CIN2; CIN3
- Mechanism
- BACKGROUND: The zinc-binding sites within the human papillomavirus (HPV) E6/E7 oncoproteins play a critical role in maintaining structural stability and represent promising therapeutic targets due to their cysteine-mediated Zn2+ coordination SIGNIFICANCE: This study established a novel approach to evaluate zinc-site-targeting drug candidates in live-cell systems, bridging the gap between molecular targeting and cellular efficacy
preliminary evidence
Biomarkers, Tumor
12 linked PMIDs264 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, cervical cancer, CIN3+, recurrence, progression-free survival, overall survival
- Populations represented
- general population; p16; p16; CIN3; high-risk HPV infection; metastatic; HPV DNA; early-stage
- Mechanism
- Furthermore, while current assays exploit the analytical simplicity of viral targets, host-derived fragmentomics remains an overlooked compartment that warrants exploration to determine its true clinical value regarding underlying tumor dynamics Notably, TRMT112 expression inversely correlated with cytotoxic T-cell infiltration, mechanistically linking it to the formation of "cold" tumors
moderate-confidence evidence
cryotherapy
9 linked PMIDs750 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- recurrence, quality of life, adverse events, genital warts, reported clinical outcomes, response rate
- Populations represented
- general population; children; first-line; second-line; previously treated
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Papillomavirus E7 Proteins
8 linked PMIDs461 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- cervical cancer, persistent infection
- Populations represented
- HPV16; general population; HPV16; HPV18
- Mechanism
- BACKGROUND: The zinc-binding sites within the human papillomavirus (HPV) E6/E7 oncoproteins play a critical role in maintaining structural stability and represent promising therapeutic targets due to their cysteine-mediated Zn2+ coordination SIGNIFICANCE: This study established a novel approach to evaluate zinc-site-targeting drug candidates in live-cell systems, bridging the gap between molecular targeting and cellular efficacy
preliminary evidence
Repressor Proteins
8 linked PMIDs— reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- cervical cancer, reported clinical outcomes
- Populations represented
- general population; HPV16; HPV16; HPV18
- Mechanism
- Among viral oncoproteins, the HPV-16 E6 protein plays a pivotal role in carcinogenesis by targeting tumor suppressor pathways, making it an attractive therapeutic target BACKGROUND: The zinc-binding sites within the human papillomavirus (HPV) E6/E7 oncoproteins play a critical role in maintaining structural stability and represent promising therapeutic targets due to their cysteine-mediated Zn2+ coordination
moderate-confidence evidence
human papillomavirus vaccine
7 linked PMIDs2207 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, adverse events, cervical cancer
- Populations represented
- general population; children; high-risk HPV infection
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
E6 protein, Human papillomavirus type 16
7 linked PMIDs— reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- cervical cancer, reported clinical outcomes
- Populations represented
- HPV16; general population; HPV16; HPV18
- Mechanism
- BACKGROUND: The zinc-binding sites within the human papillomavirus (HPV) E6/E7 oncoproteins play a critical role in maintaining structural stability and represent promising therapeutic targets due to their cysteine-mediated Zn2+ coordination SIGNIFICANCE: This study established a novel approach to evaluate zinc-site-targeting drug candidates in live-cell systems, bridging the gap between molecular targeting and cellular efficacy
moderate-confidence evidence
Antineoplastic Agents
6 linked PMIDs436 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- cervical cancer, HPV clearance, objective response rate, response rate, reported clinical outcomes
- Populations represented
- general population; locally advanced; advanced; stage III
- Mechanism
- Among viral oncoproteins, the HPV-16 E6 protein plays a pivotal role in carcinogenesis by targeting tumor suppressor pathways, making it an attractive therapeutic target SIGNIFICANCE: We identify a novel mechanism by which the small-molecule inhibitor AOH1996 targets cancer-associated PCNA to induce mitotic death in cervical cancer cells
moderate-confidence evidence
Antiviral Agents
5 linked PMIDs842 reported cumulative sample signal
- Research status
- mostly supportive
- Outcomes represented
- reported clinical outcomes, adverse events, serious adverse events, cervical cancer, persistent infection
- Populations represented
- general population
- Mechanism
- This review analyses the molecular pathways of viral oncogenesis critically and discusses the clinical translation and a promising future potential of phytochemicals derived from medicinal plants like Phyllanthus emblica, Datura stramonium, Cannabis sativa, Andrographis paniculata, Aegle marmelos, Calotropis procera, and Prosopis cineraria proven to have bioactive compounds functioning as antivirals, immune-modulator, pro-apoptotic, and cell cycle regulatory effects in the preclinical models along with multi-targets
moderate-confidence evidence
Antibodies, Monoclonal, Humanized
5 linked PMIDs692 reported cumulative sample signal
- Research status
- mostly neutral
- Outcomes represented
- overall survival, objective response rate, response rate, cervical cancer, event-free survival, recurrence, progression-free survival, adverse events
- Populations represented
- metastatic; first-line; second-line; locally advanced; advanced; stage III; metastatic; advanced; metastatic; advanced; HPV18; p16
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Circulating Tumor DNA
5 linked PMIDs246 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- progression-free survival, recurrence, quality of life, overall survival, response rate
- Populations represented
- HPV DNA; early-stage; early-stage; stage I; p16; advanced; metastatic
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
moderate-confidence evidence
9-valent HPV vaccine
4 linked PMIDs2659 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, serious adverse events, reported clinical outcomes, persistent infection
- Populations represented
- general population; children
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
moderate-confidence evidence
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
4 linked PMIDs2428 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, recurrence, serious adverse events
- Populations represented
- general population
- Mechanism
- RESULTS: Vaccination induced robust neutralizing antibody responses against four HPV types in both seronegative and seropositive participants In the baseline seropositive group, more than 91% of participants achieved a ≥4-fold increase in neutralizing antibody titers for all four HPV types
preliminary evidence
Cisplatin
4 linked PMIDs414 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, quality of life, adverse events, reported clinical outcomes, progression-free survival
- Populations represented
- locally advanced; advanced; HPV16; p16; advanced; general population; HPV DNA; p16
- Mechanism
- PURPOSE: Tolinapant is an inhibitor of apoptosis protein antagonist that enhances apoptotic pathways
preliminary evidence
oncogene protein E7, Human papillomavirus type 16
4 linked PMIDs— reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- cervical cancer
- Populations represented
- HPV16; HPV16; HPV18
- Mechanism
- BACKGROUND: The zinc-binding sites within the human papillomavirus (HPV) E6/E7 oncoproteins play a critical role in maintaining structural stability and represent promising therapeutic targets due to their cysteine-mediated Zn2+ coordination SIGNIFICANCE: This study established a novel approach to evaluate zinc-site-targeting drug candidates in live-cell systems, bridging the gap between molecular targeting and cellular efficacy
05
Conflicting Research
higher-confidence evidence
95 studiesPapillomavirus Vaccines · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 84null: 7mixed: 1harm: 2benefit: 1
higher-confidence evidence
65 studiesHPV vaccine · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 60null: 4mixed: 1
preliminary evidence
3 studiesCyclin-Dependent Kinase Inhibitor p16 · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: p16. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
benefit: 1unknown: 1harm: 1
preliminary evidence
3 studiesPhotosensitizing Agents · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 1benefit: 1null: 1
moderate-confidence evidence
1 studiesPaired Box Transcription Factors · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: HPV16; CIN2. Comparator: women with a normal baseline cytology or negative HPV16/18 (8.4% vs.
- The records report different endpoints or outcome definitions.
- Some abstracts do not state whether the primary endpoint was met.
mixed: 1
moderate-confidence evidence
1 studiesPAX1 transcription factor · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: HPV16; CIN2. Comparator: women with a normal baseline cytology or negative HPV16/18 (8.4% vs.
- The records report different endpoints or outcome definitions.
- Some abstracts do not state whether the primary endpoint was met.
mixed: 1
moderate-confidence evidence
1 studiesSOX1 protein, human · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: HPV16; CIN2. Comparator: women with a normal baseline cytology or negative HPV16/18 (8.4% vs.
- The records report different endpoints or outcome definitions.
- Some abstracts do not state whether the primary endpoint was met.
mixed: 1
moderate-confidence evidence
1 studiesSOXB1 Transcription Factors · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: HPV16; CIN2. Comparator: women with a normal baseline cytology or negative HPV16/18 (8.4% vs.
- The records report different endpoints or outcome definitions.
- Some abstracts do not state whether the primary endpoint was met.
mixed: 1
moderate-confidence evidence
1 studiesSuppositories · reported clinical outcomes
Status: mixed evidence. Population: high-risk HPV infection; HPV16; HPV18. Comparator: group A (P < 0.001), and there.
- Some abstracts do not state whether the primary endpoint was met.
mixed: 1
moderate-confidence evidence
1 studiesPlant Oils · reported clinical outcomes
Status: mixed evidence. Population: high-risk HPV infection; HPV16; HPV18. Comparator: group A (P < 0.001), and there.
- Some abstracts do not state whether the primary endpoint was met.
mixed: 1
06
Failed or Negative Trials
Design and initial findings of a natural history study of anal HPV and associated lesions among young adult women in Costa Rica.
randomized controlled trial · 2025 · PMID 40815549
Ripple effect of temporary self-sampling HPV test on screening uptake in the next round: A secondary analysis of the ACCESS randomized controlled trial.
randomized controlled trial · 2026 · PMID 40567147
Evaluation of primary HPV-based cervical screening among older women: Long-term follow-up of a randomized healthcare policy trial in Sweden.
randomized controlled trial · 2024 · PMID 39700313
Randomized Controlled Trial of Impact of Mobile Health Technologies on Human Papillomavirus Vaccination Uptake in Mothers of Vaccine-Eligible Girls in Lagos, Nigeria (mHealth-HPVac).
randomized controlled trial · 2025 · PMID 40924973
The importance of spontaneous thought in the willingness to receive the human papillomavirus vaccine.
randomized controlled trial · 2025 · PMID 40712321
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.
randomized controlled trial · 2026 · PMID 41570275
Genotype distribution of human papillomavirus (HPV) types in oral gargle specimens among men living with HIV in Mexico, Brazil, and Puerto Rico: A cross-sectional study.
randomized controlled trial · 2026 · PMID 42070588
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.
randomized controlled trial · 2025 · PMID 39841939
The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial.
randomized controlled trial · 2026 · PMID 41790036
A multicentre pragmatic randomized controlled trial comparing 50% salicylic acid, liquid nitrogen, 5% 5-fluorouracil cream, and 5% imiquimod cream in previously treated plantar warts. The VRAIE (VeRrues plAntaIres en villE) study.
randomized controlled trial · 2025 · PMID 40743833
07
Emerging and Experimental Research
Video-based interventions to promote HPV vaccination among individuals aged 9 to 26: a systematic review and meta-analysis.
meta analysis · 2026 · PMID 41826914
Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.
randomized controlled trial · 2026 · PMID 41834413
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.
randomized controlled trial · 2026 · PMID 41570275
Immunogenicity and safety of a quadrivalent recombinant human papillomavirus vaccine (type 6/11/16/18) (Hansenula polymorpha): A randomized controlled phase 2 non-inferiority clinical trial.
randomized controlled trial · 2026 · PMID 41932289
Efficacy and safety of a topical nitric oxide-releasing solution (NORS) as a noninvasive treatment for plantar warts (verrucae plantaris).
randomized controlled trial · 2026 · PMID 41493215
A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions.
randomized controlled trial · 2026 · PMID 41403292
The effect of podcasts delivered to female university students on HPV knowledge, awareness, and anxiety levels: A randomized controlled trial.
randomized controlled trial · 2026 · PMID 42314452
A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence.
randomized controlled trial · 2026 · PMID 42249801
Effect of coriolus versicolor-based vaginal gel on clearance of human papillomavirus and cervical dysplasia - a scoping review.
randomized controlled trial · 2026 · PMID 41507892
Technological innovations in head and neck radiotherapy: What does the future hold?
preclinical or laboratory · 2026 · PMID 42001737
08
Evidence Gaps
Detailed risk-of-bias assessment remains limited
PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.
R
Complete Ranked PubMed Index
The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.
Current Standard Of Care60 records
Rank116.6
Screening for Cervical Cancer.
Obstetrics and gynecology · 2026 · PMID 42024877
This committee statement announces the American College of Obstetricians & Gynecologists' qualified endorsement of the 2026 Women's Preventive Services Initiative's (WPSI) updated cervical cancer screening guidelines and addresses cervical cancer screening for patients at average risk in the following age categories: 21-29 years, 30-65 years, and older than 65 years. This committee statement discusses specific qualifications to the WPSI guidelines, particularly regarding self-collection for primary high-risk human …
Rank112.0
International Society of Urological Pathology (ISUP) Multidisciplinary Consensus on Premalignant and Putative Precursor Lesions of Penile Cancer: Working Group 5 report on Terminology, Grading, and Molecular Testing Practices.
The American journal of surgical pathology · 2026 · PMID 40826809
The classification and diagnosis of penile intraepithelial neoplasia (PeIN) remains inconsistent among pathologists, despite its recognized role and understanding as a precursor to penile squamous cell carcinoma (PSCC). The International Society of Urological Pathology (ISUP) convened a consensus group of multidisciplinary thought leaders to assess current global practices regarding the usage of terminology, grading, and molecular testing in penile cancer precursor lesions. A preconference survey was distributed to…
Rank112.0
Australian guidelines for anal cancer screening using anal human papillomavirus testing with cytology triage in people living with HIV.
HIV medicine · 2025 · PMID 41130598
OBJECTIVES: To develop Australian anal cancer screening guidelines for people living with HIV. METHODS: In 2023, ASHM Health assembled a committee to create guidelines, based on existing international guidelines and utilizing data from the Study of the Prevention of Anal Cancer (SPANC). SPANC provided Australian-specific data on different screening methodologies for the detection of anal high-grade squamous intraepithelial lesions. RESULTS: The guidelines were released in March 2025. They recommend primary high-ris…
Rank112.0
Clinical practice guideline for high-risk human papillomavirus testing in cervical cancer screening: a consensus statement from the Korean Society of Gynecologic Oncology.
Journal of gynecologic oncology · 2026 · PMID 41834415
High-risk human papillomavirus (hrHPV) is a necessary cause of cervical cancer, and hrHPV testing has increasingly been recognized as an effective screening tool that overcomes the limitations of cytology-based screening. However, standardized clinical guidance for the use of hrHPV testing in cervical cancer screening has been limited in Korea, resulting in variability in clinical practice. This consensus-based clinical practice guideline was developed under the auspices of the Korean Society of Gynecologic Oncolog…
Rank110.0
High-Risk HPV Testing in Head and Neck Carcinoma: Key Updates from the 2025 College of American Pathologists Guideline.
Head and neck pathology · 2025 · PMID 41021082
High-risk human papillomavirus (HPV) plays a significant role in the pathogenesis of certain head and neck (HN) cancers, especially squamous cell carcinomas (SCC) arising in the oropharynx. Distinction between HPV-independent and HPV-associated HNSCC has important implications for clinical management and patient prognosis in specific anatomic subsites of the head and neck. In 2018, the College of American Pathologists (CAP) issued 14 evidence-based guideline statements related to the testing, application, interpret…
Rank110.0
Screening for Cervical Cancer: A Recommendation From the Women's Preventive Services Initiative.
Obstetrics and gynecology · 2026 · PMID 42024880
The Women's Preventive Services Initiative (WPSI) expanded its previous cervical cancer screening recommendation for average-risk women by including patient-collected high-risk human papillomavirus (hrHPV) screening tests and additional follow-up testing needed to complete the screening process. To update the previous recommendation, the WPSI identified new evidence demonstrating that primary hrHPV screening increases detection of precancerous lesions compared with cytology screening. New studies indicate that pati…
Rank110.0
SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 41843267
Squamous cell carcinoma of the lip, oral cavity, oropharynx, hypopharynx, and larynx comprises the ninth most common cancer in Spain. While alcohol and tobacco use have long been the primary etiological factors, the role of human papillomavirus (HPV) in oropharyngeal cancer is increasing. Diagnoses and relapses should always be discussed by an expert multidisciplinary team. For localized stages, surgery or radiotherapy should be used as single-modality treatments, while locoregional stages require combined modality…
Rank110.0
[Cervical cancer screening : implementation of the hr-HPV test].
Revue medicale de Liege · 2025 · PMID 41229231
Cervical cancer remains the fourth most common cancer in women. Recognition of the involvement of viral infection by human papillomavirus (HPV) in the carcinogenesis of lesions has enabled the evolution and adaptation of screening methods. Early detection of pre-invasive lesions and their treatment ultimately led to a reduction in the incidence and mortality of cervical cancer. In Belgium, the transition to primary screening is validated since January 1st, 2025. Let us nevertheless remember the importance of primar…
Rank110.0
Updated clinical practice guidelines for human papillomavirus vaccination: the Korean Society of Gynecologic Oncology recommendations.
Journal of gynecologic oncology · 2026 · PMID 41775253
The Korean Society of Gynecologic Oncology (KSGO) first developed clinical guidelines for the appropriate administration of human papillomavirus (HPV) vaccines tailored to the Korean context in 2016. In 2019, additional guidelines were introduced following the development of the nonavalent HPV vaccine. The 2021 revision included recommendations for vaccination in middle-aged women and men, as well as the potential benefits of vaccination following conization. In this latest revision, the guidelines focus on the nec…
Rank110.0
Role of radiotherapy in the management of anal canal cancer: Recommendations of the Société française de radiothérapie oncologique.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025 · PMID 41273885
We present the updated recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) regarding the use of external beam radiotherapy and brachytherapy in the management of anal cancer. Anal cancer is a rare malignancy with an increasing incidence, largely due to the high prevalence of Human papillomavirus infection. It primarily affects females over 65years of age. The most common histological type is squamous cell carcinoma. The standard treatment involve…
Rank110.0
Management of women with abnormal cervical cytology: Update of French guidelines after the implementation of HPV screening.
European journal of obstetrics, gynecology, and reproductive biology · 2025 · PMID 40957151
OBJECTIVE: To update the French national cancer institute (INCa) guidelines for the management of women with abnormal cervical cytology. METHODS: In 2016, INCa published guidelines for the management of women with abnormal cervical cytology. In 2019, however, the national authority for Health (HAS) recommended that the test for human papillomavirus be used to screen for cervical cancer in women over 30. It therefore became necessary to update the initial management and follow-up of women who had a positive test fol…
Rank110.0
Radiotherapy for penile cancers: 2025 update.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025 · PMID 41205450
This article presents an update of the French national guidelines for the management of penile cancer, with recommendations on dose and volume for radiotherapy and brachytherapy. Multidisciplinary management and centralization in high-level of expertise centres is key for the management of this rare malignancy. For patients at high-risk of having micrometastatic disease (stage T1b or higher), a dynamic sentinel node biopsy should be offered as surgical staging and human papillomavirus status should be obtained. Org…
Rank109.4
Diagnostic testing accuracy of DNA methylation tests for detection of high-grade cervical intraepithelial neoplasia and cervical cancer: A systematic review and meta-analysis.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42235467
BACKGROUND: Human papillomavirus (HPV)-based cervical screening offers stronger protection against cervical intraepithelial neoplasia (CIN) than screening with cytology. DNA methylation tests have been proposed as an alternative triage test to cytology, although there is currently no consensus on the most accurate gene or gene panels ("markers"). METHODS: We conducted a meta-analysis of accuracy of human and HPV methylation markers to detect CIN2 or worse (CIN2+), CIN3+, and cervical cancer (CRD42022299760). We sys…
Rank108.0
Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline.
CA: a cancer journal for clinicians · 2026 · PMID 41342729
This update expands the 2020 American Cancer Society (ACS) cervical cancer screening guideline for average-risk women and individuals with a cervix who are at average risk, to include self-collection for human papillomavirus (HPV) testing and revised guidance for exiting cervical cancer screening. Self-collected vaginal specimens, a method of primary HPV testing, align with the ACS cervical cancer screening guideline. When clinician-collected cervical specimens are used for HPV testing, repeat screening is recommen…
Rank108.0
Italian guidelines for cervical cancer screening. Multisocietal recommendations on the use of biomarkers in HPV screening with risk-based approach and GRADE methodology.
British journal of cancer · 2025 · PMID 40931128
The European Council recommends adopting risk-based screening when relevant. In triaging HPV-positive women, it can be an effective strategy to reduce overtreatment and referral to colposcopy. HPV genotyping and p16/ki67 expression may allow a better risk stratification than cytology. In Italy, recommendations on their use (alone or combined) in screening were developed by a multi-professional (nine scientific societies) and multidisciplinary working group (including patients and decision makers). Grading of Recomm…
Rank107.4
The prognostic role of HPV status in penile squamous cell carcinoma: a systematic review and meta-analysis.
International journal of impotence research · 2025 · PMID 40770564
Penile squamous cell carcinoma (PSCC) is a rare but aggressive malignancy that can present as either Human papillomavirus (HPV)-associated or HPV-independent. Currently, there is no consensus on the prognostic value of HPV status in PSCC or its role in guiding treatment strategies. Therefore, in this systematic review and meta-analysis we aim to assess the impact of different methods of determining HPV status on cancer specific survival (CSS) and overall survival (OS) in patients with PSCC. Databases including MEDL…
Rank106.7
A Meta-analysis of Functional Outcomes and Recovery Metrics Comparing Transoral Robotic Surgery and (Chemo)Radiotherapy.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026 · PMID 41353736
OBJECTIVE: To assess patient outcomes with regard to swallowing, feeding tube dependence, tracheostomy use, pain levels, and recovery metrics between transoral robotic surgery and (chemo)radiotherapy. DATA SOURCES: Medline, EMBASE, Web of Science Core Collection, and the Cochrane Library. REVIEW METHODS: A meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines through a literature search of data sources (CRD42023464144). RESULTS: Sixteen stud…
Rank105.2
Efficacy and Safety of Ionic Contra-viral Therapy (Digoxin-furosemide) in the Treatment of Multiple Cutaneous Warts: A Systematic Review, Meta-analysis, and Trial Sequential Analysis.
Current drug research reviews · 2026 · PMID 40873359
INTRODUCTION: The primary objective of this systematic review was to evaluate the therapeutic efficacy and safety profile of intralesional Ionic Contra-Viral Therapy (ICVT)-a combination of digoxin and furosemide-in the treatment of multiple cutaneous warts. METHODS: This meta-analysis was conducted in accordance with PRISMA guidelines and was prospectively registered in PROSPERO (CRD42024544551). A comprehensive literature search was performed up to April 2024 across PubMed, MEDLINE, Scopus, Cochrane CENTRAL, Clin…
Rank103.2
Efficacy and Safety of Different Neoadjuvant Treatment Regimens in Locally Advanced Squamous Head and Neck Cancer.
Cancer reports (Hoboken, N.J.) · 2026 · PMID 41588993
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC), which constitutes approximately 90% of all head and neck cancers, represents a significant global health burden. A concerning trend is the rising incidence, particularly among younger populations, which has been partly attributed to human papillomavirus (HPV) infection. While treatment outcomes are favorable for early-stage disease, approximately 60% of patients are diagnosed with locally advanced HNSCC (LA-HNSCC), for whom prognosis remains suboptimal. Ind…
Rank102.8
Screening of human papilloma virus-related anogenital cancers in immunocompromised women: a systematic review of clinical practice guidelines.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2025 · PMID 41086515
OBJECTIVE: Human papillomavirus-related anogenital cancers disproportionately affect immunocompromised patients due to poor clearance rates and accelerated oncogenicity. This systematic review compares anogenital cancer screening Clinical Practice Guidelines among different subpopulations of immunocompromised women. METHODS: We conducted a systematic review of guidelines addressing cervical, anal, vaginal, and vulvar cancer screening among immunocompromised women published between 2004 and 2025, following the Prefe…
Rank100.0
Computational approaches of modelling human papillomavirus transmission and prevention strategies: a systematic review.
Journal of biological dynamics · 2025 · PMID 39823279
Human papillomavirus (HPV) infection is the most common sexually transmitted infection in the world. Persistent oncogenic HPV infection has been a leading threat to global health and can lead to serious complications such as cervical cancer. Prevention interventions including vaccination and screening have been proven effective in reducing the risk of HPV-related diseases. In recent decades, computational epidemiology has been serving as a very useful tool to study HPV transmission dynamics and evaluation of preven…
Rank100.0
Rapid Systematic Review-Informed Multidisciplinary Expert Consensus on the Management of HPV-Positive Women with Low-Grade Cervical Lesions and the Role of a Coriolus versicolor-Based Vaginal Treatment.
Medicina (Kaunas, Lithuania) · 2026 · PMID 42512825
Background and Objectives: Persistent human papillomavirus (HPV) infection is associated with the development of cervical intraepithelial neoplasia and cervical cancer. In women with low-grade cervical lesions, a conservative management approach is commonly recommended. However, a subset of patients may experience lesion progression, which can also be accompanied by psychological distress. Adjuvant therapies during the surveillance period have gained increasing clinical interest. This consensus aims to provide mult…
Rank85.0
Evaluation of the ESMO-magnitude of clinical benefit scale version 2.0 for the definitive treatment of HPV positive oropharynx cancer with radiation therapy.
Oral oncology · 2026 · PMID 42229021
BACKGROUND: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated tool for assessing the clinical benefit of systemic cancer therapies. However, application of the scale to radiotherapy (RT) remains limited. As part of an ongoing initiative to adapt the scale for RT, we applied Form 1a of ESMO-MCBS v2.0 to studies cited in the American Society for Radiation Oncology (ASTRO) guideline for Human Papillomavirus (HPV)-positive oropharyngeal cancer (OPC) to assess feasi…
Rank77.8
Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis.
The Lancet. Oncology · 2025 · PMID 40645195
BACKGROUND: Modernisation of the American Joint Committee on Cancer and Union for International Cancer Control (AJCC/UICC) staging for HPV-positive oropharyngeal carcinoma has strengthened its fundamental role to convey prognosis and guide treatment decisions. Implementation has nonetheless revealed imbalances. An AJCC committee reappraised HPV-positive oropharyngeal carcinoma pathological staging to advance prognostic accuracy and improve clinical applicability. METHODS: For this analysis, US registry data from th…
Rank72.0
Accuracy and Prognosis of Extranodal Extension on Radiologic Imaging in Human Papillomavirus-Mediated Oropharyngeal Cancer: A Head and Neck Cancer International Group (HNCIG) Real-world Study.
International journal of radiation oncology, biology, physics · 2025 · PMID 40286939
PURPOSE: Extranodal extension on radiology (iENE) is reported in single-center studies to be negatively prognostic in human papillomavirus-mediated oropharyngeal cancer (HPV + OPC) and is a major eligibility criterion for surgical treatment. However, studies report widely varying sensitivities, specificities, and interobserver correlation. In this research the prognostic power, sensitivity, and specificity of iENE in HPV + OPC in real-world practice are determined. METHODS AND MATERIALS: A retrospective cohort of 8…
Diagnosis And Screening87 records
Rank110.0
SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 41843267
Squamous cell carcinoma of the lip, oral cavity, oropharynx, hypopharynx, and larynx comprises the ninth most common cancer in Spain. While alcohol and tobacco use have long been the primary etiological factors, the role of human papillomavirus (HPV) in oropharyngeal cancer is increasing. Diagnoses and relapses should always be discussed by an expert multidisciplinary team. For localized stages, surgery or radiotherapy should be used as single-modality treatments, while locoregional stages require combined modality…
Rank107.1
Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes.
European urology focus · 2026 · PMID 41519649
BACKGROUND AND OBJECTIVE: Treatment options for metastatic or recurrent penile squamous cell carcinoma (PSCC) progressing after first-line platinum-based chemotherapy are limited, and no standard subsequent-line systemic therapy exists. We systematically reviewed the efficacy, safety, and survival outcomes of second- and later-line systemic treatments in this setting. METHODS: A systematic review, compliant with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, was performed across …
Rank102.2
Diagnostic accuracy of HPV DNA in oral gargle and rinse samples for Head and neck squamous cell carcinoma: A systematic review and meta-analysis.
The Japanese dental science review · 2026 · PMID 42211773
BACKGROUND: Early detection of head and neck squamous cell carcinoma (HNSCC) remains challenging because tissue biopsy is invasive and unsuitable for repeated monitoring or large-scale screening. This study systematically evaluated the diagnostic accuracy of human papillomavirus (HPV) DNA detection in oral gargle and rinse samples for HNSCC. METHODS: This meta-analysis followed PRISMA guidelines and included 10 studies with 1315 participants. Pooled sensitivity, specificity, summary receiver operating characteristi…
Rank100.0
Diagnostic Accuracy of p16 Immunohistochemistry as a Marker of High-Risk HPV in Invasive Laryngeal Squamous Cell Carcinoma: A Systematic Review.
Medicina (Kaunas, Lithuania) · 2026 · PMID 42512914
Background and Objectives: p16 immunohistochemistry (IHC) is widely used as a surrogate marker for high-risk human papillomavirus (HPV)-driven carcinogenesis in oropharyngeal squamous cell carcinoma. Diagnostic reliability in laryngeal squamous cell carcinoma (LSCC) is still up for debate, particularly because HPV DNA detection, p16 overexpression, and transcriptionally active HPV infection may be discordant at this anatomical site. This systematic review aimed to assess the diagnostic performance of p16 IHC as a s…
Rank100.0
Serious adverse events following human papillomavirus vaccination: A systematic review and meta-analysis of post-marketing evidence.
Human vaccines & immunotherapeutics · 2026 · PMID 41759030
Human papillomavirus (HPV) vaccines are a critical tool in cancer prevention, yet concerns about serious adverse events (SAEs) have fueled public hesitancy and constrained vaccination uptake. This systematic review aimed to determine the proportion of adverse events that were SAEs, rate of SAEs following HPV vaccination and their association from post-marketing observational studies. We conducted a search in PubMed, EMBASE, and Web of Science databases in March 2025. Studies published in English reporting SAEs afte…
Rank97.6
Efficacy and safety of a topical nitric oxide-releasing solution (NORS) as a noninvasive treatment for plantar warts (verrucae plantaris).
The Journal of dermatological treatment · 2026 · PMID 41493215
BACKGROUND: Plantar warts (verrucae plantaris), caused by human papillomavirus, are common and often resistant to standard therapies, which can be painful and damaging. Novel, noninvasive options are needed. OBJECTIVE: To evaluate the safety and preliminary efficacy of a topical nitric oxide-releasing solution (NORS) as a self-administered therapy for plantar warts. METHODS: In this Phase 2a, multicenter, randomized, double-blind, placebo-controlled trial, 20 participants with ≥3 plantar warts were randomized (1:1:…
Rank96.0
Integrative Analyses of Individual Patient Genomic-Data to Discover Novel Biomarkers: Application to Cervical Pre-Cancer DNA-Methylation Datasets.
Cancer informatics · 2026 · PMID 42542792
OBJECTIVE: The growing availability of public genomic repositories led to increased use of integrative and meta-analytic approaches to combine multi-omics datasets for biomarker discovery. Building on this framework, our study applies a molecular discovery approach to identify diagnostic biomarkers for cervical pre-cancer in high-risk HPV-positive women using aggregated genomic evidence across populations. METHODS: This study performed a secondary analysis of publicly available DNA-methylation datasets identified t…
Rank91.5
Loop electrosurgical excision procedure and perinatal outcomes post-human papillomavirus cervical screening: A longitudinal cohort study.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026 · PMID 41709079
OBJECTIVE: This study examines the associations between the loop electrosurgical excision procedure (LEEP) and the risk of adverse perinatal outcomes among women who have undergone primary human papillomavirus (HPV) screening. METHODS: In this longitudinal cohort study, women who received HPV screening and were followed up in a randomized trial in British Columbia (BC), Canada, were linked to a province-wide perinatal registry; those with a singleton live birth after screening (index birth) were included (N = 1765)…
Rank82.9
HPV vaccine awareness and uptake among women attending cervical screening in health-resource-limited areas of China: A multicenter cross-sectional study.
Human vaccines & immunotherapeutics · 2026 · PMID 41830505
Evidence shows HPV vaccination reduces infection, precancer and cervical cancer, yet coverage in health-resource-limited of China remains uncertain. We assessed awareness, uptake and correlates among women attending cervical screening, and examined associations with screening outcomes. We conducted a cross-sectional study in eight county sites in 2023-2024 among women aged 35-64 y. A standardized questionnaire captured sociodemographic factors, awareness and vaccination. Cervical samples were tested for hrHPV. Outc…
Rank70.0
Risk stratification and anal cancer screening in immunocompetent women with genital HPV: Value of multicentric HSIL and performance of HPV-based screening.
International journal of cancer · 2026 · PMID 41944777
The incidence of anal squamous cell carcinoma (ASCC) is rising, and women with genital human papillomavirus (HPV) infection or HPV-associated high-grade squamous intraepithelial lesions (HSIL) are at high risk of developing ASCC. We conducted a cross-sectional study including 354 immunocompetent women referred for anal evaluation because of HPV infection or HSIL of the lower genital tract between 2019 and 2024. Participants were categorized according to the genital site affected by HSIL (uterine cervix, vagina, vul…
Rank69.6
Cervical Cancer Screening With Human Papillomavirus Self-Collection Testing in an Opioid Treatment Program.
JAMA network open · 2026 · PMID 42525415
IMPORTANCE: Individuals with opioid use disorder and substance use disorder have lower cervical cancer screening rates than the general population. Human papillomavirus (HPV) self-collection testing provides opportunities to expand screening access to previously unreached patient populations. OBJECTIVES: To assess the feasibility and uptake of incorporating HPV self-collection testing for cervical cancer screening into routine care for patients with opioid use disorder and substance use disorder, and to track the r…
Rank64.3
Repeated Detection of Vaccine-Preventable Anal HPV Genotypes in a Screened Cohort: A Retrospective Observational Study.
Pathogens (Basel, Switzerland) · 2026 · PMID 42515057
The clinical relevance of concurrent vaccine-preventable anal HPV genotype infections, particularly for short-term repeated detection and cytologic outcomes in screened high-risk populations, remains uncertain. We performed a single-centre retrospective study of 145 adults with at least one 9-valent vaccine-preventable anal HPV genotype at baseline and repeat HPV DNA testing and cytology approximately 12 months later. Baseline infections were classified as single- or multiple-genotype infections. Outcomes included …
Rank55.0
Health Care Policy Implementation Trial of Primary Human Papillomavirus-Based Cervical Screening in Denmark.
International journal of cancer · 2026 · PMID 42046158
On mandate from the Danish Health Authority, a nationwide health care policy trial (HCP) of primary HPV screening for women aged 30-59 was initiated in 2021. The aim was to inform on the performance of HPV screening in comparison to existing cytology practice. The HCP trial included all Danish women between 30 and 59 years of age undergoing cervical cancer screening in 2021 (n = 178,323). Women with odd birthdays were screened with HPV screening (n = 91,517), while women born on even dates were screened with cytolo…
Rank54.5
Extended HPV typing as an efficient alternative within HPV-based screening programs.
International journal of cancer · 2026 · PMID 41902757
Extended high-risk human papilloma virus (hrHPV) typing emerges as a potential alternative for detecting cervical intraepithelial neoplasia 3 (CIN3), without additional triage tests. We evaluate the extended hrHPV typing as an alternative to improve CIN3 detection within an HPV-based screening program. Between January 2017 and August 2018, 5856 women aged 25-65 years were screened as part of a public cervical cancer screening program of the Tlalpan Sanitary Jurisdiction in Mexico City. HPV testing was performed by …
Rank54.3
Nationwide Study on the Cervical Cancer Screening Pathway in Estonia.
International journal of cancer · 2026 · PMID 41957967
Effective cervical cancer screening and progress toward WHO elimination targets depend on complete follow-up for women with positive primary screening tests. However, real-world data on this critical step in hrHPV-based screening programs in Eastern Europe are scarce. We conducted a nationwide, population-based retrospective cohort study in Estonia, analyzing records from the Estonian Health Insurance Fund and Population Register. We included 44,282 women aged 30-65 who were invited to hrHPV-based screening between…
Rank54.3
Neuraminidase-Associated Vaginal Dysbiosis Correlates with HPV Infection Across Oncogenic Risk Subtypes.
Infection and drug resistance · 2026 · PMID 42540841
BACKGROUND: Human papillomavirus (HPV) infection is a major cause of cervical cancer, and increasing evidence suggests that cervicovaginal microbial dysbiosis may influence HPV susceptibility. This study evaluated the association between microbial enzymatic markers and HPV infection across different risk subtypes. METHODS: A cross-sectional analysis was conducted in 43,426 women undergoing HPV screening. HPV status and subtype classification (high-, possible-, and low-risk) were determined using standardized genoty…
Rank52.2
Evaluating the Performance of Anal Cytology and Human Papillomavirus Testing for Detection of Anal Cancer and Pre-Cancerous Lesions.
Diagnostic cytopathology · 2026 · PMID 42135996
BACKGROUND: Anal squamous cell carcinoma (SCC) incidence is rising; however, anal cancer screening guidelines require further refinement. This study evaluated the accuracy of anal cytology and human papilloma virus (HPV) testing for anal cancer screening in our pathology service, identifying limitations of these tests when applied to this role. METHODS: Pathology records of all 240 patients who had undergone anal or perianal biopsy during 2023 were evaluated. Reports for 1364 smears, 817 biopsy procedures, and 1441…
Rank52.2
[Emerging role of primary care health visitors in population-based cervical screening].
Orvosi hetilap · 2025 · PMID 39955680
Introduction: Cervical screening policy update with primary human papillomavirus detection should cover women who rarely visit gynecologists. Education of registered health visitors in Hungary has incorporated cervical sampling since 2015. Objective: Analysis of data from a geographically representative high-risk human papillomavirus prevalence survey to explore target population characteristics and results of samples collected by health visitors (n = 905) compared to gynecologists (n = 3826). Method: Cervical samp…
Rank52.0
Human Papilloma Virus (HPV) prevalence and genotype distribution among women in Karachi, Pakistan.
Journal of virus eradication · 2026 · PMID 42404305
Human papillomavirus (HPV) epidemiological data from Pakistan remain limited, particularly in unscreened and unvaccinated populations. We performed a cross-sectional study in Karachi, Pakistan, to determine overall type- and age-specific HPV prevalence between May 2022 and November 2023. A total of 3119 women were invited to participate; 497 women gave consent, provided cervical samples and were included in the final analysis. HPV detection and genotyping were done using the highly sensitive INNO-LiPA HPV Genotypin…
Rank51.0
Genotype-Specific HPV E6/E7 mRNA Triage for Risk Stratification in HPV DNA-Positive Women with ASC-US/LSIL: A Population-Based Tromsø Cohort.
Pathogens (Basel, Switzerland) · 2026 · PMID 42515074
HPV DNA-positive women with ASC-US/LSIL cytology constitute a heterogeneous triage group. We evaluated genotype-specific HPV E6/E7 mRNA testing with PreTect HPV-Proofer'7 in a population-based cohort from Tromsø and compared the findings descriptively with a previously published cohort from Bodø. This retrospective quality-assurance study included 1006 HPV DNA-positive women with ASC-US/LSIL cytology screened between 2019 and 2024, with linkage to regional pathology records through 31 December 2025. The assay detec…
Rank50.9
The 'see-and-treat' approach in the treatment of preneoplastic cervical lesions.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 · PMID 41442739
This study evaluated the overtreatment rate (defined as a histological finding of low-grade intraepithelial lesion or negative after cervical excisional procedures) associated with the 'see-and-treat' approach in patients undergoing cervical conization for citology-detected suspected high-grade cervical lesions. The 'see-and-treat' strategy consists of colposcopy and immediate excision without prior cervical biopsy when a high-grade lesion is suspected based on colposcopic impression. Secondary objectives were to c…
Rank50.4
Histological outcomes and colposcopic findings in patients with persistent high-risk human papillomavirus infection without major cytological findings.
American journal of obstetrics and gynecology · 2026 · PMID 41895365
BACKGROUND: High-risk human papillomavirus-based screening demonstrates higher sensitivity but lower specificity than cytology for detecting high-grade squamous intraepithelial lesions. This has increased colposcopy referrals and introduced a new group of patients with persistent high-risk human papillomavirus infections and normal cytology. OBJECTIVE: In this population, we aimed to describe colposcopic findings, evaluate the diagnostic performance of systematic colposcopy using Swedescore, and assess the prevalen…
Rank50.4
Knowledge, Attitudes, and Behaviors Regarding HPV Vaccination and Self-Sampling Among US Young Adults.
Journal of cancer education : the official journal of the American Association for Cancer Education · 2026 · PMID 41044442
Given the high HPV and cervical cancer rates and related disparities, this study assessed correlates of HPV-prevention behaviors among US adults. Using the 2022 online survey data from 880 US adults (Mage = 27.62; 66.0% female, 43.8% sexual minority, 8.7% Hispanic, 73.9% White, 4.5% Black, 11.9% Asian, 9.7% other race), multivariable regression analyses assessed sociodemographic and HPV knowledge in relation to HPV vaccination, willingness to vaccinate one's child, and willingness to engage in HPV self-sampling (am…
Rank50.2
The importance of HPV testing in oropharyngeal cancer in two US populations.
Neoplasia (New York, N.Y.) · 2026 · PMID 42391786
BACKGROUND: HPV-positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) patients have improved survival compared to HPV-negative OPSCC (HPV-) patients (5-year survival rates of ∼80% versus ∼40%). The predictive value of p16 immunohistochemistry (IHC) for HPV+ OPSCC, the most widely used clinical test for HPV status, varies by HPV+ OPSCC prevalence in geographically different populations, but variation within a region is not well described. METHODS: We analyzed p16 IHC and survival in two geographically and de…
Rank50.2
Tiered Functional Screening Identifies an Autochthonous Vaginal Lactiplantibacillus plantarum Strain with Probiotic Potential.
Microorganisms · 2026 · PMID 42514031
Persistent high-risk human papillomavirus (HPV) infection drives cervical cancer, a leading cause of cancer-related mortality among women in low- and middle-income countries; its clinical course is shaped by the cervicovaginal microbiome, in which Lactobacillus-dominated communities are associated with enhanced viral clearance. Despite this, vaginal probiotic interventions often demonstrate limited colonization efficiency, and autochthonous strain libraries from Central Asia remain absent. We applied a tiered funct…
Evidence Syntheses62 records
Rank116.6
Screening for Cervical Cancer.
Obstetrics and gynecology · 2026 · PMID 42024877
This committee statement announces the American College of Obstetricians & Gynecologists' qualified endorsement of the 2026 Women's Preventive Services Initiative's (WPSI) updated cervical cancer screening guidelines and addresses cervical cancer screening for patients at average risk in the following age categories: 21-29 years, 30-65 years, and older than 65 years. This committee statement discusses specific qualifications to the WPSI guidelines, particularly regarding self-collection for primary high-risk human …
Rank112.0
International Society of Urological Pathology (ISUP) Multidisciplinary Consensus on Premalignant and Putative Precursor Lesions of Penile Cancer: Working Group 5 report on Terminology, Grading, and Molecular Testing Practices.
The American journal of surgical pathology · 2026 · PMID 40826809
The classification and diagnosis of penile intraepithelial neoplasia (PeIN) remains inconsistent among pathologists, despite its recognized role and understanding as a precursor to penile squamous cell carcinoma (PSCC). The International Society of Urological Pathology (ISUP) convened a consensus group of multidisciplinary thought leaders to assess current global practices regarding the usage of terminology, grading, and molecular testing in penile cancer precursor lesions. A preconference survey was distributed to…
Rank110.0
Comparative performance of HPV self-sampling and conventional screening methods: A systematic review and bivariate meta-analysis.
Gynecologic oncology · 2026 · PMID 42217258
BACKGROUND: Cervical cancer is a major public health challenge, especially in low-resource settings with suboptimal screening. HPV self-sampling (SS) is a promising strategy to overcome logistical barriers, but its diagnostic accuracy relative to clinician-collected (CC) sampling, Visual Inspection with Acetic Acid (VIA), and Papanicolaou (Pap) cytology requires rigorous validation. METHODS: Following PRISMA-DTA guidelines, we searched PubMed/Medline, Scopus, Embase, and the Cochrane Library through March 2025 for …
Rank110.0
The association of fungal infection in cervical cancer: a systematic review and meta-analysis.
BMC women's health · 2026 · PMID 41992269
BACKGROUND: Emerging evidence suggests a potential link between the fungal mycobiome and carcinogenesis. However, the relationship between fungal infection and cervical cancer progression remains inconclusive. This meta-analysis aimed to determine the pooled prevalence of fungal infection across different cervical pathological stages and assess its association with cervical lesions and HPV infection. PROSPERO CRD42024588513 is the registration number for the systematic review. METHODS: We conducted a systematic rev…
Rank110.0
Screening for Cervical Cancer: A Recommendation From the Women's Preventive Services Initiative.
Obstetrics and gynecology · 2026 · PMID 42024880
The Women's Preventive Services Initiative (WPSI) expanded its previous cervical cancer screening recommendation for average-risk women by including patient-collected high-risk human papillomavirus (hrHPV) screening tests and additional follow-up testing needed to complete the screening process. To update the previous recommendation, the WPSI identified new evidence demonstrating that primary hrHPV screening increases detection of precancerous lesions compared with cytology screening. New studies indicate that pati…
Rank110.0
SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 41843267
Squamous cell carcinoma of the lip, oral cavity, oropharynx, hypopharynx, and larynx comprises the ninth most common cancer in Spain. While alcohol and tobacco use have long been the primary etiological factors, the role of human papillomavirus (HPV) in oropharyngeal cancer is increasing. Diagnoses and relapses should always be discussed by an expert multidisciplinary team. For localized stages, surgery or radiotherapy should be used as single-modality treatments, while locoregional stages require combined modality…
Rank109.6
Global research trends and hotspots in human immunodeficiency virus-associated cervical cancer (1990-2025): a multi-database bibliometric analysis.
Frontiers in immunology · 2026 · PMID 42358990
BACKGROUND: Research on cervical cancer among WLWH represents a critical area for advancing long-term prevention and clinical management strategies. Yet as the volume of published literature in this field continues to grow rapidly, synthesizing and appraising the available evidence in a comprehensive manner has become increasingly challenging. OBJECTIVE: This study aims to map the global research landscape, identify leading contributors and collaborative networks, and delineate the knowledge base and emerging resea…
Rank109.4
Diagnostic testing accuracy of DNA methylation tests for detection of high-grade cervical intraepithelial neoplasia and cervical cancer: A systematic review and meta-analysis.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42235467
BACKGROUND: Human papillomavirus (HPV)-based cervical screening offers stronger protection against cervical intraepithelial neoplasia (CIN) than screening with cytology. DNA methylation tests have been proposed as an alternative triage test to cytology, although there is currently no consensus on the most accurate gene or gene panels ("markers"). METHODS: We conducted a meta-analysis of accuracy of human and HPV methylation markers to detect CIN2 or worse (CIN2+), CIN3+, and cervical cancer (CRD42022299760). We sys…
Rank108.8
P16/Ki67 dual staining versus cytology for identifying high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) in triage management of HR-HPV-positive women: a systematic review and meta-analysis.
Journal of gynecologic oncology · 2026 · PMID 41995269
OBJECTIVE: The co-expression of P16 and Ki67 suggests the presence of high-grade cervical intraepithelial neoplasia, which makes P16/Ki67 dual staining a promising marker in cervical cancer screening. This study provides a systemic review of the established evidence on the performance of P16/Ki67 versus cytology in detecting cervical intraepithelial neoplasia (CIN)2+/CIN3+ among high-risk human papillomavirus (HR-HPV)-positive women and HR-HPV-positive individuals with cytology-negative results for triage managemen…
Rank108.4
The impact of HIV coinfection on mpox patients: a systematic review and meta-analysis.
Emerging microbes & infections · 2026 · PMID 42461714
A substantial proportion of mpox cases occur in people with HIV, but how HIV coinfection and immune status affect clinical outcomes remains unclear. We systematically searched major databases up to March 2025 for observational studies comparing mpox patients with and without HIV coinfection. Pooled effect sizes were calculated using random-effects models. Risk ratios (RRs) or standardized mean differences (SMDs) with 95% confidence intervals were used for dichotomous or continuous outcomes. Post hoc subgroup analys…
Rank108.4
Investigation of Blood Folate and Vitamin B12 Levels in Women With Human Papillomavirus: A Systematic Review.
Journal of lower genital tract disease · 2026 · PMID 42132147
OBJECTIVES: Human papillomavirus (HPV) is a highly prevalent sexually transmitted infection. Discussions have arisen regarding reduced vitamin levels in patients. This review aims to gather evidence on blood folate and vitamin B12 levels in women with HPV. METHODS: A comprehensive search was conducted across multiple electronic databases, including Web of Science, Embase, Scopus, and PubMed, using keywords such as "human papillomavirus," "folate," and "vitamin B12". Combinations derived from MeSH and Emtree terms w…
Rank108.1
Determinants of human papillomavirus vaccination uptake in Nigeria: a mixed-methods systematic review.
BMC public health · 2026 · PMID 41942898
BACKGROUND: Human papillomavirus (HPV) vaccination coverage in Nigeria is hindered by multiple barriers, including limited awareness, socioeconomic constraints, cultural beliefs, systemic challenges, and policy gaps. As a result, the burden of cervical cancer and other HPV-associated malignancies continues to rise despite public health interventions. The current mixed-methods systematic review (SR) synthesizes evidence on the determinants of HPV vaccination uptake in Nigeria to inform context-specific strategies fo…
Rank107.9
The effectiveness of gender-neutral HPV vaccination programmes in preventing HPV-associated oral cancers: a systematic review.
BMC cancer · 2026 · PMID 41992160
BACKGROUND: Human papillomavirus infections are a significant risk factor for the development of oral cancers. While HPV vaccines have proven effective in preventing cervical cancers, their impact on oral cancers remains insufficiently examined. This systematic review assesses the effectiveness of gender-neutral HPV vaccination in reducing oral HPV rates, a key precursor to HPV-associated oral cancers, focusing exclusively on studies including gender-neutral samples. METHODS: Following PRISMA 2020 guidelines, a com…
Rank107.9
Diagnostic Accuracy of Urine and Vaginal Self-Sampling for Detection of High-Risk Human Papillomavirus: A Systematic Review and Meta-Analysis.
Viruses · 2026 · PMID 42357689
Cervical cancer remains a major public health challenge, particularly in low- and middle-income countries. The primary cause of cervical cancer is high-risk human papillomavirus (HPV), and screening using physician-collected samples is complicated by stigma, inconvenience, and access. There are non-invasive alternatives to the physician-collected samples, including self-sampling methods such as first-void urine and vaginal swabs. This systematic review and meta-analysis evaluated and compared the diagnostic accurac…
Rank107.1
Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes.
European urology focus · 2026 · PMID 41519649
BACKGROUND AND OBJECTIVE: Treatment options for metastatic or recurrent penile squamous cell carcinoma (PSCC) progressing after first-line platinum-based chemotherapy are limited, and no standard subsequent-line systemic therapy exists. We systematically reviewed the efficacy, safety, and survival outcomes of second- and later-line systemic treatments in this setting. METHODS: A systematic review, compliant with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, was performed across …
Rank107.1
Efficacy and safety of 5-aminolevulinic acid photodynamic therapy for cervical squamous intraepithelial lesion: a systematic review and meta-analysis.
Lasers in medical science · 2026 · PMID 42470528
To evaluate the efficacy and safety of 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) for cervical squamous intraepithelial lesion (SIL). We systematically searched PubMed and other databases to compare the effectiveness of 5-ALA PDT with observation, ablation, and conization. Outcomes included overall response rate (ORR), complete remission (CR) rate, HPV clearance rate, and other relevant endpoints. Single-arm analyses were additionally performed by lesion grade. A total of 3,354 patients were included ac…
Rank106.4
De-Escalation Treatment Strategies in HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An Umbrella Review of Systematic Reviews and Meta-Analyses.
Head & neck · 2026 · PMID 42230323
BACKGROUND: De-escalation strategies for human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) aim to reduce late morbidity while preserving cure rates, but evidence syntheses provide inconsistent conclusions and may be affected by overlap of primary studies. METHODS: We performed an umbrella review of systematic reviews (SRs) and meta-analyses (MAs) evaluating de-escalation approaches versus standard-of-care therapy in HPV-positive (or p16-positive) OPSCC. MEDLINE (PubMed), Embase, and …
Rank106.0
Biomarkers of neoadjuvant immunotherapy for locally advanced head and neck cancer: A systematic review and meta-analysis.
Medicine · 2026 · PMID 42363527
BACKGROUND: Despite the general advantages of neoadjuvant immunotherapy for locally advanced head and neck squamous cell carcinoma (LAHNSCC), many patients do not achieve successful clinical outcomes. Hitherto, there has been a lack of biomarkers to predict the effect of neoadjuvant immunotherapy in LAHNSCC. METHODS: We systematically searched PubMed, Embase, Web of Science, and Cochrane databases until June 2024 for studies related to neoadjuvant immunotherapy for LAHNSCC. We calculated the pathological response r…
Rank106.0
A meta-analysis of photodynamic therapy in the treatment of cervical intraepithelial neoplasia: Based on randomized controlled trials.
Photodiagnosis and photodynamic therapy · 2026 · PMID 41740824
OBJECTIVE: To systematically evaluate the efficacy and safety of photodynamic therapy (PDT) for HPV-infected cervical intraepithelial neoplasia (CIN) based on randomized controlled trials (RCTs). METHODS: A systematic search was performed across PubMed, EMBASE, Web of Science, and the Cochrane Library from 2000 to 2025, targeting RCTs that compared PDT with standard conization methods or placebo. The primary outcomes assessed included histopathological response, human papillomavirus (HPV) clearance, and the rate of…
Rank105.9
Prognostic Value of Pretreatment Circulating Tumor HPV DNA Load in HPV-Associated Cancers: A Systematic Review and Meta-Analysis.
International journal of molecular sciences · 2026 · PMID 42196246
The qualitative detection of circulating tumor human papillomavirus DNA (ctHPV) has shown promise in HPV-associated cancers. We performed a systematic review and meta-analysis to evaluate the association of pretreatment ctHPV levels with survival outcomes and quantitative tumor burden metrics. Databases were searched through 5 January 2026. Studies were eligible if they included patients with HPV-associated cancers and reported quantitative pretreatment ctHPV levels in relation to survival outcomes or tumor burden.…
Rank105.8
Transoral robotic surgery versus definitive (Chemo)radiotherapy in early HPV-positive oropharyngeal cancer: A systematic review and meta-analysis of oncologic outcomes.
Oral oncology · 2026 · PMID 41806530
INTRODUCTION: Although individual studies suggest similar oncologic outcomes between transoral robotic surgery (TORS) and definitive (chemo)radiotherapy (RT/CRT) for early-stage human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC), oncologic and functional outcomes have not been systematically synthesized. OBJECTIVE: To compare oncologic and functional outcomes of a primary surgery-based strategy versus a primary definitive RT/CRT strategy in early-stage HPV-OPSCC. METHODS: PubMed, Embase…
Rank105.1
Surgical and Voice Outcomes of Office-Based Recurrent Respiratory Papillomatosis Surgery: A Systematic Review.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026 · PMID 41848235
OBJECTIVE: To investigate the surgical and voice outcomes associated with office-based laryngeal surgery for the treatment of recurrent respiratory papillomatosis (RRP). DATA SOURCES: PubMed, Google Scholar, and Cochrane databases. REVIEW METHODS: Two independent investigators search databases for studies reporting surgical or voice quality outcomes of patients treated with office-based surgery for RRP according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Primary o…
Rank104.7
Cell-Free DNA Fragmentation Patterns as Biomarkers for Human Papillomavirus-Related Cancers: A Systematic Review of Methodological Diversity and Diagnostic Performance.
International journal of molecular sciences · 2026 · PMID 42511713
Novel blood biomarkers are crucial for HPV-related cancers to overcome the limitations of imaging and biopsies. This review evaluates the diagnostic performance of circulating cell-free DNA (cfDNA) fragmentomic patterns, distinguishing host-genome integrity from specific viral signatures. Following PRISMA guidelines, we searched PubMed, EMBASE, and Web of Science up to February 2026. Methodological quality was assessed via QUADAS-2, and diagnostic performance was synthesized using a random-effects model. From 489 r…
Rank104.5
Marjolin's Ulcer in Patients With Anogenital Lichen Planus: A Systematic Review.
Journal of cutaneous medicine and surgery · 2026 · PMID 41169103
Anogenital lichen planus (ALP) is a chronic inflammatory condition associated with significant morbidity and a potential risk of cutaneous squamous cell carcinoma (cSCC), specifically Marjolin ulcer (MU), a rare, but aggressive, life-threatening complication. This systematic review aimed to describe the clinical characteristics of patients developing MU within ALP and its treatment outcomes. MEDLINE and Embase (inception-November 2024) were searched, identifying studies reporting MU or squamous dysplasia arising wi…
Rank104.0
Understanding the roots of hesitancy to unlock the game-changing impact of HPV vaccination: Insights from a global qualitative evidence synthesis.
Human vaccines & immunotherapeutics · 2026 · PMID 42334459
The human papillomavirus (HPV) vaccine is one of the most powerful tools in cancer prevention and is central to global efforts to eliminate cervical cancer as a public health problem. Yet worldwide uptake remains suboptimal. Our 2025 Cochrane qualitative evidence synthesis - comprising 71 studies from diverse geographic and socioeconomic settings - provides the most comprehensive global understanding to date of caregivers' and adolescents' views and practices regarding HPV vaccination, and the reasons why some are …
Landmark Evidence53 records
Rank112.0
Sex and human papillomavirus in oropharyngeal cancer: A systematic review and meta-analysis.
American journal of otolaryngology · 2024 · PMID 39106680
INTRODUCTION: While the presence of human papillomavirus (HPV) is known to affect the outcomes of oropharyngeal squamous cell carcinoma (OPSCC), there is a significant gap in research regarding the potential sex-based differences. This systematic review-metanalysis (SR-MA) aims to evaluate if sex is a prognostic factor in HPV-associated OPSCC. METHODS: A systematic review and meta-analysis was performed. COCHRANE Library, CINAHL, PubMed, and Scopus were searched for English-language articles from 1966 to October 20…
Rank110.0
Human papillomavirus infection and the risk of cancer at specific sites other than anogenital tract and oropharyngeal region: an umbrella review.
EBioMedicine · 2024 · PMID 38744109
BACKGROUND: Despite numerous studies having evaluated the associations between human papillomavirus (HPV) infection and risk of specific cancers other than anogenital tract and oropharyngeal, the findings are inconsistent and the quality of evidence has not been systematically quantified. We aimed to summarise the existing evidence as well as to evaluate the strength and credibility of these associations. METHODS: We conducted an umbrella review of systematic reviews and meta-analyses of observational studies. PubM…
Rank110.0
SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 41843267
Squamous cell carcinoma of the lip, oral cavity, oropharynx, hypopharynx, and larynx comprises the ninth most common cancer in Spain. While alcohol and tobacco use have long been the primary etiological factors, the role of human papillomavirus (HPV) in oropharyngeal cancer is increasing. Diagnoses and relapses should always be discussed by an expert multidisciplinary team. For localized stages, surgery or radiotherapy should be used as single-modality treatments, while locoregional stages require combined modality…
Rank108.7
Human papillomavirus (HPV) vaccination in women with conisation.
The Cochrane database of systematic reviews · 2025 · PMID 40919695
RATIONALE: Cervical cancer is the fourth most common cancer affecting women worldwide, caused by persistent infection with oncogenic human papillomavirus (HPV) types. While HPV infections usually resolve spontaneously, persistent infections with high-risk HPV types can progress to premalignant glandular or - mostly - squamous intraepithelial lesions, usually classified in cervical intraepithelial neoplasia (CIN). Women with CIN 2 and CIN 3 (i.e. high-grade CIN) typically undergo cervical conisation to remove precan…
Rank108.1
Relationship between human papillomavirus and serum vitamin D levels: a systematic review.
BMC infectious diseases · 2024 · PMID 38216875
BACKGROUND: Human papillomavirus (HPV) is one of the most prevalent sexually transmitted diseases worldwide. The present review was conducted to accumulate evidence on the relationship between cervicovaginal human papillomavirus infection and serum vitamin D status. METHODS: Electronic databases including Web of Science, Embase, Scopus, and PubMed were searched by different combinations of keywords related to "human papillomavirus" and "vitamin D", obtained from Mesh and Emtree with AND, and OR operators without an…
Rank107.1
Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes.
European urology focus · 2026 · PMID 41519649
BACKGROUND AND OBJECTIVE: Treatment options for metastatic or recurrent penile squamous cell carcinoma (PSCC) progressing after first-line platinum-based chemotherapy are limited, and no standard subsequent-line systemic therapy exists. We systematically reviewed the efficacy, safety, and survival outcomes of second- and later-line systemic treatments in this setting. METHODS: A systematic review, compliant with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, was performed across …
Rank107.0
Effect of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: A systematic review and meta-analysis.
PloS one · 2024 · PMID 39739895
BACKGROUND: The prophylactic vaccines available to protect against infections by human papillomavirus (HPV) are well tolerated and highly immunogenic. This systematic review and meta-analysis aimed to explore the efficacy of HPV vaccination on the risk of HPV infection and recurrent diseases related to HPV infection in individuals undergoing local surgical treatment. METHODS: A literature search was performed using PubMed/MEDLINE, Embase, the Cochrane Library, Scopus, Web of Science, and bioRxiv/medRxiv from incept…
Rank106.8
Human Papillomavirus (HPV) prevalence in population younger than 12 years old: A meta-analysis and systematic review.
Journal of infection and public health · 2025 · PMID 40373662
BACKGROUND: The prevalence of HPV in children has been studied in different populations; however, the heterogeneity between the investigations is remarkable, and the total prevalence of HPV infection in this population is not well understood. METHODS: The conducted studies on the prevalence of HPV infection in the population < 12 years old were explored and analyzed through a systematic review and meta-analysis approach. The studies which investigated HPV detection in oropharyngeal, nasopharyngeal and/or anogenital…
Rank105.9
Monogenic etiologies of persistent human papillomavirus infections: A comprehensive systematic review.
Genetics in medicine : official journal of the American College of Medical Genetics · 2024 · PMID 37978863
PURPOSE: Persistent human papillomavirus infection (PHPVI) causes cutaneous, anogenital, and mucosal warts. Cutaneous warts include common warts, Treeman syndrome, and epidermodysplasia verruciformis, among others. Although more reports of monogenic predisposition to PHPVI have been published with the development of genomic technologies, genetic testing is rarely incorporated into clinical assessments. To encourage broader molecular testing, we compiled a list of the various monogenic etiologies of PHPVI. METHODS: …
Rank105.9
Characteristic of persistent human papillomavirus infection in women worldwide: a meta-analysis.
PeerJ · 2023 · PMID 38025679
OBJECTIVES: We aimed to estimate the genotype distribution of persistent human papillomavirus (HPV) infection in females worldwide, and provided a scientific basis for the prevention strategies of cervical cancer (CC) and the development of HPV vaccines. METHODS: Both English and Chinese databases were researched from the inception to July 2023. The pooled persistent HPV infection prevalence was calculated using a random effects model. The subgroup analysis was performed to explore the heterogeneity. Publication bi…
Rank104.9
Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies.
The lancet. HIV · 2021 · PMID 34339628
BACKGROUND: Robust age-specific estimates of anal human papillomavirus (HPV) and high-grade squamous intraepithelial lesions (HSIL) in men can inform anal cancer prevention efforts. We aimed to evaluate the age-specific prevalence of anal HPV, HSIL, and their combination, in men, stratified by HIV status and sexuality. METHODS: We did a systematic review for studies on anal HPV infection in men and a pooled analysis of individual-level data from eligible studies across four groups: HIV-positive men who have sex wit…
Rank104.4
The Prevalence of HPV in Oral Cavity Squamous Cell Carcinoma.
Viruses · 2023 · PMID 36851665
Human papillomavirus (HPV) is an important risk factor in a subset of head and neck squamous cell carcinomas (HNSCC), but the association with oral cavity squamous cell carcinomas (OCSCC) remains controversial. This study aimed to identify the prevalence of HPV infection in OCSCC. A systematic search on PubMed and EMBASE was performed, including articles assessing the prevalence of HPV-positive (HPV+) OCSCC published from January 2017 to December 2022. OCSCC was considered HPV+ by the detection of HPV DNA, HPV RNA,…
Rank103.8
HPV and lung cancer: A systematic review and meta-analysis.
Cancer reports (Hoboken, N.J.) · 2021 · PMID 33624444
BACKGROUND: Lung cancer has emerged as a global public health problem and is the most common cause of cancer deaths by absolute cases globally. Besides tobacco, smoke infectious diseases such as human papillomavirus (HPV) might be involved in the pathogenesis of lung cancer. However, data are inconsistent due to differences in study design and HPV detection methods. AIM: A systematic meta-analysis was performed to examine the presence of HPV-infection with lung cancer. METHODS AND RESULTS: All studies in all langua…
Rank103.5
Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis.
BMJ (Clinical research ed.) · 2022 · PMID 35922074
OBJECTIVE: To explore the efficacy of human papillomavirus (HPV) vaccination on the risk of HPV infection and recurrent diseases related to HPV infection in individuals undergoing local surgical treatment. DESIGN: Systematic review and meta-analysis DATA SOURCES: PubMed (Medline), Scopus, Cochrane, Web of Science, and ClinicalTrials.gov were screened from inception to 31 March 2021. REVIEW METHODS: Studies reporting on the risk of HPV infection and recurrence of disease related to HPV infection after local surgical…
Rank103.0
Efficacy of focused ultrasound for HPV clearance and cervical LSIL treatment: a meta-analysis.
Scientific reports · 2026 · PMID 41904252
Persistent high-risk human papillomavirus (hrHPV) infection is a major risk factor for high-grade squamous intraepithelial lesions (HSIL) and cervical cancer. Although HPV vaccines effectively prevent infections with vaccine-covered HPV types, they do not eliminate established infections. Additionally, not all HPV types associated with cervical cancer are covered by the vaccine. Therefore, treatment strategies for HPV-related cervical lesions remain an important clinical challenge. A systematic search was conducted…
Rank103.0
Cytology versus HPV testing for cervical cancer screening in the general population.
The Cochrane database of systematic reviews · 2017 · PMID 28796882
BACKGROUND: Cervical cancer screening has traditionally been based on cervical cytology. Given the aetiological relationship between human papillomavirus (HPV) infection and cervical carcinogenesis, HPV testing has been proposed as an alternative screening test. OBJECTIVES: To determine the diagnostic accuracy of HPV testing for detecting histologically confirmed cervical intraepithelial neoplasias (CIN) of grade 2 or worse (CIN 2+), including adenocarcinoma in situ, in women participating in primary cervical cance…
Rank102.8
Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis.
The Lancet. Global health · 2023 · PMID 37591583
BACKGROUND: The epidemiology of human papillomavirus (HPV) in women has been well documented. Less is known about the epidemiology of HPV in men. We aim to provide updated global and regional pooled overall, type-specific, and age-specific prevalence estimates of genital HPV infection in men. METHODS: We conducted a systematic review and meta-analysis to assess the prevalence of genital HPV infection in the general male population. We searched Embase, Ovid MEDLINE, and the Global Index Medicus for studies published…
Rank101.5
Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies.
BMC medicine · 2023 · PMID 37501128
BACKGROUND: Persistent infection by oncogenic human papillomavirus (HPV) is necessary although not sufficient for development of cervical cancer. Behavioural, environmental, or comorbid exposures may promote or protect against malignant transformation. Randomised evidence is limited and the validity of observational studies describing these associations remains unclear. METHODS: In this umbrella review, we searched electronic databases to identify meta-analyses of observational studies that evaluated risk or protec…
Rank101.1
Human papillomavirus infection and female infertility: a systematic review and meta-analysis.
Reproductive biomedicine online · 2020 · PMID 31987733
There is increasing evidence that human papillomavirus (HPV) infection affects reproductive health and fertility, although its impact on female fertility has not been thoroughly studied. MEDLINE, Embase, CENTRAL, Web of Science, CNKI, Wanfang, VIP and ClinicalTrials.gov databases were systematically searched for relevant articles. A meta-analysis was conducted of 11 studies including 15,450 female subjects that compared HPV prevalence between the infertile and general population, and evaluated the association betwe…
Rank100.9
Human papillomavirus and lung cancer: an overview and a meta-analysis.
Journal of cancer research and clinical oncology · 2019 · PMID 31236668
PURPOSE: This review is devoted to assessing the prevalence of human papillomavirus (HPV) in lung cancer (LC) in the world. HPV is recognized as the etiological factor of cervical cancer, however, there is widespread evidence that this virus is detected not only in gynecological carcinomas, but also in tumors of other organs, in particular the upper respiratory tract and digestive tract. MATERIALS AND METHODS: A search was conducted to a depth of 29 years in the PubMed, Web of Science, Scopus, databases. The review…
Rank100.6
Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis.
The aging male : the official journal of the International Society for the Study of the Aging Male · 2020 · PMID 29571270
Background: There is growing evidence showing a putative association between high-risk human papillomavirus (HR-HPV) infection and an increased risk of PCa.Objective: The aim of the current meta-analysis was to evaluate the association between HPV infection and PCa risk.Methods: This analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. We included all studies on HPV DNA or antibodies detected in biopsy tissues or sera. Available data were extracted f…
Rank100.0
Cellular Immune Response to High-Risk Human Papillomavirus Infection: A Systematic Review.
Critical reviews in immunology · 2025 · PMID 40460388
The relationship between human papillomavirus (HPV) and immune cells is vital for understanding the pathophysiology of infection and its role in neoplastic progression. High-risk human papillomavirus (HR-HPV) is the main cause of cervical cancer (CC). Thus, the association between immune response cells, the virus, and its behavior according to cervical disease development could provide new ways for understanding the entire process. Since the role and the presence of the immune response cells in the uterus cervix co…
Rank100.0
Co-managing the double burden: strategies for simultaneously tackling infectious and non-communicable diseases.
Infectious diseases of poverty · 2026 · PMID 42538553
BACKGROUND: Evidence increasingly shows close, bidirectional links between infectious diseases (IDs) and non-communicable diseases (NCDs). However, research, health policy, and prevention practices still largely address them in separate frameworks. This scoping review summarises the current evidence on the interconnections between IDs and NCDs and explores integrated strategies for their prevention and management. METHODS: This scoping review systematically searched PubMed, Web of Science, and Scopus for English-la…
Rank100.0
Life Experiences of Women Diagnosed With Cervical Cancer in Sub-Saharan Africa: A Systematic Review of Qualitative Studies.
Psycho-oncology · 2025 · PMID 40930811
BACKGROUND: Sub-Saharan Africa (SSA) bears the highest global burden of cervical cancer. Living with the disease is a complex experience, leading to significant changes across various biopsychosocial dimensions, which in turn affect the quality of life of affected women. AIMS: This review aimed to synthesize available scientific evidence on the life experiences of women diagnosed with cervical cancer in SSA in order to generate valuable insights into the care of the affected population. METHODS: Seven electronic da…
Rank100.0
Rapid Systematic Review-Informed Multidisciplinary Expert Consensus on the Management of HPV-Positive Women with Low-Grade Cervical Lesions and the Role of a Coriolus versicolor-Based Vaginal Treatment.
Medicina (Kaunas, Lithuania) · 2026 · PMID 42512825
Background and Objectives: Persistent human papillomavirus (HPV) infection is associated with the development of cervical intraepithelial neoplasia and cervical cancer. In women with low-grade cervical lesions, a conservative management approach is commonly recommended. However, a subset of patients may experience lesion progression, which can also be accompanied by psychological distress. Adjuvant therapies during the surveillance period have gained increasing clinical interest. This consensus aims to provide mult…
Most Effective Evidence Supported Treatments63 records
Rank110.0
SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 41843267
Squamous cell carcinoma of the lip, oral cavity, oropharynx, hypopharynx, and larynx comprises the ninth most common cancer in Spain. While alcohol and tobacco use have long been the primary etiological factors, the role of human papillomavirus (HPV) in oropharyngeal cancer is increasing. Diagnoses and relapses should always be discussed by an expert multidisciplinary team. For localized stages, surgery or radiotherapy should be used as single-modality treatments, while locoregional stages require combined modality…
Rank108.2
Efficacy and safety of photodynamic therapy for vaginal intraepithelial neoplasia: A systematic review and meta-analysis.
Photodiagnosis and photodynamic therapy · 2026 · PMID 41611005
OBJECTIVE: Vaginal Intraepithelial Neoplasia (VaIN) is a precancerous condition that can progress to vaginal cancer if untreated. Photodynamic Therapy (PDT), recognized for its minimally invasive nature and favorable side effect profile, is increasingly employed for VaIN treatment; however, comprehensive evidence synthesis on its efficacy and safety remains limited. This study aims to comprehensively evaluate the efficacy and safety of 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) in treating VaIN. …
Rank107.1
Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes.
European urology focus · 2026 · PMID 41519649
BACKGROUND AND OBJECTIVE: Treatment options for metastatic or recurrent penile squamous cell carcinoma (PSCC) progressing after first-line platinum-based chemotherapy are limited, and no standard subsequent-line systemic therapy exists. We systematically reviewed the efficacy, safety, and survival outcomes of second- and later-line systemic treatments in this setting. METHODS: A systematic review, compliant with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, was performed across …
Rank107.1
Efficacy and safety of 5-aminolevulinic acid photodynamic therapy for cervical squamous intraepithelial lesion: a systematic review and meta-analysis.
Lasers in medical science · 2026 · PMID 42470528
To evaluate the efficacy and safety of 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) for cervical squamous intraepithelial lesion (SIL). We systematically searched PubMed and other databases to compare the effectiveness of 5-ALA PDT with observation, ablation, and conization. Outcomes included overall response rate (ORR), complete remission (CR) rate, HPV clearance rate, and other relevant endpoints. Single-arm analyses were additionally performed by lesion grade. A total of 3,354 patients were included ac…
Rank106.4
De-Escalation Treatment Strategies in HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An Umbrella Review of Systematic Reviews and Meta-Analyses.
Head & neck · 2026 · PMID 42230323
BACKGROUND: De-escalation strategies for human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) aim to reduce late morbidity while preserving cure rates, but evidence syntheses provide inconsistent conclusions and may be affected by overlap of primary studies. METHODS: We performed an umbrella review of systematic reviews (SRs) and meta-analyses (MAs) evaluating de-escalation approaches versus standard-of-care therapy in HPV-positive (or p16-positive) OPSCC. MEDLINE (PubMed), Embase, and …
Rank106.0
A meta-analysis of photodynamic therapy in the treatment of cervical intraepithelial neoplasia: Based on randomized controlled trials.
Photodiagnosis and photodynamic therapy · 2026 · PMID 41740824
OBJECTIVE: To systematically evaluate the efficacy and safety of photodynamic therapy (PDT) for HPV-infected cervical intraepithelial neoplasia (CIN) based on randomized controlled trials (RCTs). METHODS: A systematic search was performed across PubMed, EMBASE, Web of Science, and the Cochrane Library from 2000 to 2025, targeting RCTs that compared PDT with standard conization methods or placebo. The primary outcomes assessed included histopathological response, human papillomavirus (HPV) clearance, and the rate of…
Rank106.0
Biomarkers of neoadjuvant immunotherapy for locally advanced head and neck cancer: A systematic review and meta-analysis.
Medicine · 2026 · PMID 42363527
BACKGROUND: Despite the general advantages of neoadjuvant immunotherapy for locally advanced head and neck squamous cell carcinoma (LAHNSCC), many patients do not achieve successful clinical outcomes. Hitherto, there has been a lack of biomarkers to predict the effect of neoadjuvant immunotherapy in LAHNSCC. METHODS: We systematically searched PubMed, Embase, Web of Science, and Cochrane databases until June 2024 for studies related to neoadjuvant immunotherapy for LAHNSCC. We calculated the pathological response r…
Rank105.8
Transoral robotic surgery versus definitive (Chemo)radiotherapy in early HPV-positive oropharyngeal cancer: A systematic review and meta-analysis of oncologic outcomes.
Oral oncology · 2026 · PMID 41806530
INTRODUCTION: Although individual studies suggest similar oncologic outcomes between transoral robotic surgery (TORS) and definitive (chemo)radiotherapy (RT/CRT) for early-stage human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC), oncologic and functional outcomes have not been systematically synthesized. OBJECTIVE: To compare oncologic and functional outcomes of a primary surgery-based strategy versus a primary definitive RT/CRT strategy in early-stage HPV-OPSCC. METHODS: PubMed, Embase…
Rank105.1
Surgical and Voice Outcomes of Office-Based Recurrent Respiratory Papillomatosis Surgery: A Systematic Review.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026 · PMID 41848235
OBJECTIVE: To investigate the surgical and voice outcomes associated with office-based laryngeal surgery for the treatment of recurrent respiratory papillomatosis (RRP). DATA SOURCES: PubMed, Google Scholar, and Cochrane databases. REVIEW METHODS: Two independent investigators search databases for studies reporting surgical or voice quality outcomes of patients treated with office-based surgery for RRP according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Primary o…
Rank104.5
Marjolin's Ulcer in Patients With Anogenital Lichen Planus: A Systematic Review.
Journal of cutaneous medicine and surgery · 2026 · PMID 41169103
Anogenital lichen planus (ALP) is a chronic inflammatory condition associated with significant morbidity and a potential risk of cutaneous squamous cell carcinoma (cSCC), specifically Marjolin ulcer (MU), a rare, but aggressive, life-threatening complication. This systematic review aimed to describe the clinical characteristics of patients developing MU within ALP and its treatment outcomes. MEDLINE and Embase (inception-November 2024) were searched, identifying studies reporting MU or squamous dysplasia arising wi…
Rank103.0
Efficacy of focused ultrasound for HPV clearance and cervical LSIL treatment: a meta-analysis.
Scientific reports · 2026 · PMID 41904252
Persistent high-risk human papillomavirus (hrHPV) infection is a major risk factor for high-grade squamous intraepithelial lesions (HSIL) and cervical cancer. Although HPV vaccines effectively prevent infections with vaccine-covered HPV types, they do not eliminate established infections. Additionally, not all HPV types associated with cervical cancer are covered by the vaccine. Therefore, treatment strategies for HPV-related cervical lesions remain an important clinical challenge. A systematic search was conducted…
Rank102.0
Efficacy and safety of superficial radiotherapy in the treatment of cutaneous warts: A meta-analysis.
The Journal of international medical research · 2026 · PMID 42333510
ObjectiveTo systematically evaluate clinical evidence concerning the efficacy and safety of superficial radiotherapy in the treatment of cutaneous warts.MethodsEight major international clinical literature databases were queried according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for superficial radiotherapy studies published prior to 9 August 2025. Randomized controlled trials, prospective/retrospective controlled studies, and case series with sample sizes ≥10 we…
Rank100.0
Intralesional human papillomavirus vaccination for cutaneous verrucae: a systematic review and meta-analysis of therapeutic efficacy.
The Journal of dermatological treatment · 2026 · PMID 42370553
OBJECTIVES: To evaluate the efficacy of intralesional human papillomavirus (HPV) vaccination in the management of cutaneous warts. METHODS: A comprehensive search of PubMed, MEDLINE, Embase, Scopus, and ClinicalTrials.gov was conducted in accordance with a registered PROSPERO protocol (CRD420251170324). Chronic or persistent warts were defined as lesions lasting more than six months or showing inadequate response to conventional therapies. The primary outcome was complete wart clearance, and pooled risk ratios (RRs…
Rank100.0
Diagnostic and prognostic significance of circulating HPV cfDNA in cervical cancer: A systematic review and meta-analysis.
Critical reviews in oncology/hematology · 2026 · PMID 41619873
IMPORTANCE: Human papillomavirus circulating free DNA (HPV cfDNA) is an emerging biomarker with potential utility in the detection and treatment monitoring of cervical cancer. OBJECTIVE: To conduct a systematic review and meta-analysis evaluating the diagnostic and prognostic performance of HPV cfDNA in cervical cancer. METHODS: A comprehensive literature search was conducted in PubMed, CINAHL, Cochrane Library, Scopus, and Embase through April 2025. Eligible studies reported or allowed calculation of diagnostic pe…
Rank100.0
Cervical Cancer Prevention and Treatment Disparities Among Native Hawaiian and Pacific Islanders: A Systematic Review and Meta-Analysis.
Journal of surgical oncology · 2026 · PMID 41607102
BACKGROUND: Native Hawaiian and Pacific Islander (NHPI) populations face significant disparities in cervical cancer prevention and treatment. This systematic review and meta-analysis examines cervical cancer prevention metrics, treatment disparities, and effective interventions among NHPI populations. METHODS: Following PRISMA guidelines, we systematically searched PubMed, Scopus, and Embase for studies published between 2000 and 2024 that reported cervical cancer prevention metrics in NHPI populations. Eligible st…
Rank100.0
Impact of male genital tract infections on semen quality: a systematic review and meta-analysis.
Fertility and sterility · 2026 · PMID 41825760
Male genitourinary (GU) infections have been proposed to adversely affect semen quality and reproductive outcomes; however, existing evidence remains heterogeneous. This systematic review and meta-analysis evaluated the association between GU infections and semen parameters, reproductive outcomes, and assisted reproductive technology (ART) outcomes using control-comparator studies identified through PubMed, Web of Science, and Embase. Studies compared men with documented GU infections with noninfected controls and …
Rank100.0
Oncologic, functional, and economic outcomes of transoral robotic surgery for HPV-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of pathology and treatment strategies.
Journal of robotic surgery · 2026 · PMID 42162526
The incidence of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) has increased substantially. Transoral robotic surgery (TORS) provides detailed pathological assessment that may support risk-adapted treatment strategies; however, integrated evidence on oncologic, functional, and economic outcomes remains limited. To systematically evaluate oncologic, functional, and economic outcomes of TORS-based treatment strategies in patients with HPV-positive OPSCC. A systematic review and met…
Rank100.0
Efficacy of topical treatments for high-risk human papillomavirus in preventing CIN II+ lesions: a systematic review.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026 · PMID 41951281
OBJECTIVE: This study aimed to systematically review the literature regarding topical therapies for reducing the risk of cervical intra-epithelial neoplasia (CIN) grade 2 or higher (CIN II+) lesions among women with high-risk human papillomavirus (HPV) infection and histologically confirmed CIN I or either no cervical lesions. METHODS: We conducted a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and registered the protocol in PROSPERO (CRD4202…
Rank100.0
Oral CXCR4 inhibition with mavorixafor: Emerging therapeutic applications in WHIM syndrome, chronic neutropenia, oncology, and stem cell mobilization.
Current research in translational medicine · 2026 · PMID 41936270
The CXCR4/CXCL12 signaling axis plays a central role in regulating immune cell trafficking, hematopoietic homeostasis, and organogenesis. However, dysregulation of this axis contributes to the pathogenesis of numerous disorders, highlighting CXCR4 inhibition as a promising therapeutic strategy. Mavorixafor, the first orally available small-molecule CXCR4 antagonist, recently received FDA approval for WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) and is currently being developed for add…
Rank100.0
Advancements in immunotherapy for oropharyngeal cancer: Current landscape and future prospects.
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2026 · PMID 40827652
Oropharyngeal cancer (OPC), affecting the tonsils, base of the tongue, and soft palate, has witnessed a notable increase in incidence, particularly among cases linked to human papillomavirus (HPV) infection. This epidemiological shift has led to changes in treatment strategies, with immunotherapy emerging as a promising alternative to conventional modalities such as surgery, radiation, and chemotherapy, which are often associated with significant toxicity. This systematic review aims to evaluate the current landsca…
Rank100.0
Co-managing the double burden: strategies for simultaneously tackling infectious and non-communicable diseases.
Infectious diseases of poverty · 2026 · PMID 42538553
BACKGROUND: Evidence increasingly shows close, bidirectional links between infectious diseases (IDs) and non-communicable diseases (NCDs). However, research, health policy, and prevention practices still largely address them in separate frameworks. This scoping review summarises the current evidence on the interconnections between IDs and NCDs and explores integrated strategies for their prevention and management. METHODS: This scoping review systematically searched PubMed, Web of Science, and Scopus for English-la…
Rank100.0
Rapid Systematic Review-Informed Multidisciplinary Expert Consensus on the Management of HPV-Positive Women with Low-Grade Cervical Lesions and the Role of a Coriolus versicolor-Based Vaginal Treatment.
Medicina (Kaunas, Lithuania) · 2026 · PMID 42512825
Background and Objectives: Persistent human papillomavirus (HPV) infection is associated with the development of cervical intraepithelial neoplasia and cervical cancer. In women with low-grade cervical lesions, a conservative management approach is commonly recommended. However, a subset of patients may experience lesion progression, which can also be accompanied by psychological distress. Adjuvant therapies during the surveillance period have gained increasing clinical interest. This consensus aims to provide mult…
Rank100.0
Life Experiences of Women Diagnosed With Cervical Cancer in Sub-Saharan Africa: A Systematic Review of Qualitative Studies.
Psycho-oncology · 2025 · PMID 40930811
BACKGROUND: Sub-Saharan Africa (SSA) bears the highest global burden of cervical cancer. Living with the disease is a complex experience, leading to significant changes across various biopsychosocial dimensions, which in turn affect the quality of life of affected women. AIMS: This review aimed to synthesize available scientific evidence on the life experiences of women diagnosed with cervical cancer in SSA in order to generate valuable insights into the care of the affected population. METHODS: Seven electronic da…
Rank99.8
Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.
Journal of gynecologic oncology · 2026 · PMID 41834413
BACKGROUND: Gastric-type endocervical adenocarcinoma (G-EAC) is a distinctive form of adenocarcinoma that is not associated with human papillomavirus. This neoplasm exhibits a low incidence, low screening and biopsy positivity, low preoperative diagnosis, and a high susceptibility to underdiagnosis and misdiagnosis. It is associated with a poor prognosis for patients. Currently, there is an absence of a standardized postoperative adjuvant treatment plan for G-EAC, which constitutes an urgent clinical problem that d…
Rank97.7
Genotype distribution of human papillomavirus (HPV) types in oral gargle specimens among men living with HIV in Mexico, Brazil, and Puerto Rico: A cross-sectional study.
The Journal of infection · 2026 · PMID 42070588
OBJECTIVES: Assess the distribution of oral HPV genotypes and examine their associations with age and HIV-related factors among men living with HIV. METHODS: This cross-sectional study analyzed baseline data from a randomized, double-blinded, placebo-controlled Phase III trial ('ULACNet-201'; NCT04255849) assessing the 9vHPV vaccine's efficacy in PLWH. Participants included men aged 20-50 years from Brazil, Mexico, and Puerto Rico, on antiretroviral therapy for ≥6 months. Oral HPV genotypes were assessed using the …
New Research Last 24 Months126 records
Rank110.0
SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 41843267
Squamous cell carcinoma of the lip, oral cavity, oropharynx, hypopharynx, and larynx comprises the ninth most common cancer in Spain. While alcohol and tobacco use have long been the primary etiological factors, the role of human papillomavirus (HPV) in oropharyngeal cancer is increasing. Diagnoses and relapses should always be discussed by an expert multidisciplinary team. For localized stages, surgery or radiotherapy should be used as single-modality treatments, while locoregional stages require combined modality…
Rank108.4
The impact of HIV coinfection on mpox patients: a systematic review and meta-analysis.
Emerging microbes & infections · 2026 · PMID 42461714
A substantial proportion of mpox cases occur in people with HIV, but how HIV coinfection and immune status affect clinical outcomes remains unclear. We systematically searched major databases up to March 2025 for observational studies comparing mpox patients with and without HIV coinfection. Pooled effect sizes were calculated using random-effects models. Risk ratios (RRs) or standardized mean differences (SMDs) with 95% confidence intervals were used for dichotomous or continuous outcomes. Post hoc subgroup analys…
Rank107.1
Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes.
European urology focus · 2026 · PMID 41519649
BACKGROUND AND OBJECTIVE: Treatment options for metastatic or recurrent penile squamous cell carcinoma (PSCC) progressing after first-line platinum-based chemotherapy are limited, and no standard subsequent-line systemic therapy exists. We systematically reviewed the efficacy, safety, and survival outcomes of second- and later-line systemic treatments in this setting. METHODS: A systematic review, compliant with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, was performed across …
Rank104.0
Understanding the roots of hesitancy to unlock the game-changing impact of HPV vaccination: Insights from a global qualitative evidence synthesis.
Human vaccines & immunotherapeutics · 2026 · PMID 42334459
The human papillomavirus (HPV) vaccine is one of the most powerful tools in cancer prevention and is central to global efforts to eliminate cervical cancer as a public health problem. Yet worldwide uptake remains suboptimal. Our 2025 Cochrane qualitative evidence synthesis - comprising 71 studies from diverse geographic and socioeconomic settings - provides the most comprehensive global understanding to date of caregivers' and adolescents' views and practices regarding HPV vaccination, and the reasons why some are …
Rank103.0
Efficacy of focused ultrasound for HPV clearance and cervical LSIL treatment: a meta-analysis.
Scientific reports · 2026 · PMID 41904252
Persistent high-risk human papillomavirus (hrHPV) infection is a major risk factor for high-grade squamous intraepithelial lesions (HSIL) and cervical cancer. Although HPV vaccines effectively prevent infections with vaccine-covered HPV types, they do not eliminate established infections. Additionally, not all HPV types associated with cervical cancer are covered by the vaccine. Therefore, treatment strategies for HPV-related cervical lesions remain an important clinical challenge. A systematic search was conducted…
Rank102.2
Diagnostic accuracy of HPV DNA in oral gargle and rinse samples for Head and neck squamous cell carcinoma: A systematic review and meta-analysis.
The Japanese dental science review · 2026 · PMID 42211773
BACKGROUND: Early detection of head and neck squamous cell carcinoma (HNSCC) remains challenging because tissue biopsy is invasive and unsuitable for repeated monitoring or large-scale screening. This study systematically evaluated the diagnostic accuracy of human papillomavirus (HPV) DNA detection in oral gargle and rinse samples for HNSCC. METHODS: This meta-analysis followed PRISMA guidelines and included 10 studies with 1315 participants. Pooled sensitivity, specificity, summary receiver operating characteristi…
Rank100.0
Diagnostic Accuracy of p16 Immunohistochemistry as a Marker of High-Risk HPV in Invasive Laryngeal Squamous Cell Carcinoma: A Systematic Review.
Medicina (Kaunas, Lithuania) · 2026 · PMID 42512914
Background and Objectives: p16 immunohistochemistry (IHC) is widely used as a surrogate marker for high-risk human papillomavirus (HPV)-driven carcinogenesis in oropharyngeal squamous cell carcinoma. Diagnostic reliability in laryngeal squamous cell carcinoma (LSCC) is still up for debate, particularly because HPV DNA detection, p16 overexpression, and transcriptionally active HPV infection may be discordant at this anatomical site. This systematic review aimed to assess the diagnostic performance of p16 IHC as a s…
Rank100.0
Serious adverse events following human papillomavirus vaccination: A systematic review and meta-analysis of post-marketing evidence.
Human vaccines & immunotherapeutics · 2026 · PMID 41759030
Human papillomavirus (HPV) vaccines are a critical tool in cancer prevention, yet concerns about serious adverse events (SAEs) have fueled public hesitancy and constrained vaccination uptake. This systematic review aimed to determine the proportion of adverse events that were SAEs, rate of SAEs following HPV vaccination and their association from post-marketing observational studies. We conducted a search in PubMed, EMBASE, and Web of Science databases in March 2025. Studies published in English reporting SAEs afte…
Rank100.0
Intralesional human papillomavirus vaccination for cutaneous verrucae: a systematic review and meta-analysis of therapeutic efficacy.
The Journal of dermatological treatment · 2026 · PMID 42370553
OBJECTIVES: To evaluate the efficacy of intralesional human papillomavirus (HPV) vaccination in the management of cutaneous warts. METHODS: A comprehensive search of PubMed, MEDLINE, Embase, Scopus, and ClinicalTrials.gov was conducted in accordance with a registered PROSPERO protocol (CRD420251170324). Chronic or persistent warts were defined as lesions lasting more than six months or showing inadequate response to conventional therapies. The primary outcome was complete wart clearance, and pooled risk ratios (RRs…
Rank100.0
Co-managing the double burden: strategies for simultaneously tackling infectious and non-communicable diseases.
Infectious diseases of poverty · 2026 · PMID 42538553
BACKGROUND: Evidence increasingly shows close, bidirectional links between infectious diseases (IDs) and non-communicable diseases (NCDs). However, research, health policy, and prevention practices still largely address them in separate frameworks. This scoping review summarises the current evidence on the interconnections between IDs and NCDs and explores integrated strategies for their prevention and management. METHODS: This scoping review systematically searched PubMed, Web of Science, and Scopus for English-la…
Rank100.0
Strategies implemented to increase HPV vaccine uptake and confidence among men who have sex with men and transgender people: A systematic review.
Human vaccines & immunotherapeutics · 2026 · PMID 42216453
Men who have sex with men (MSM) and transgender persons are disproportionately affected by HPV-related disease. The HPV vaccine effectively prevents infection, but vaccine uptake remains suboptimal in this group. Thus, this systematic review aimed to synthesize the literature on interventions and strategies implemented to increase HPV vaccine confidence and uptake among MSM and transgender persons. Six databases were searched in May 2025. We assessed risk of bias and extracted and descriptively summarized key data …
Rank100.0
Population-level impact of HPV vaccination: a global systematic review of ecological, cross-sectional, and cohort studies.
Expert review of vaccines · 2026 · PMID 42053091
BACKGROUND: Human papillomavirus (HPV) causes approximately 4.5% of cancers globally, with the highest burden in low- and middle-income countries (LMICs). Since their introduction in 2006, HPV vaccination programs have led to substantial declines in HPV-related outcomes, although impact varies across settings. RESEARCH DESIGN AND METHODS: We conducted a systematic review to evaluate the population-level impact of HPV vaccination on HPV infection, cervical intraepithelial neoplasia grade 2 or higher (CIN2+), genital…
Rank100.0
Human papillomavirus vaccination among Asian Americans and Pacific Islanders: Scoping review and meta-analysis of descriptive and correlational studies.
Human vaccines & immunotherapeutics · 2026 · PMID 41627233
Despite the proven effectiveness of the human papillomavirus (HPV) vaccine, vaccination intention and uptake remain low among Asian American and Pacific Islanders (AAPIs). Evidence was synthesized from descriptive and correlational studies that examined HPV vaccination intention and/or uptake among AAPIs in the United States. PubMed, CINAHL, PsycINFO, and Cochrane databases were searched. Risk of bias was assessed using Joanna Briggs Institute checklist. Forty-two studies published between 2010 and 2024 were includ…
Rank100.0
Acceptance and the willingness to pay for human papilloma virus (HPV) vaccine: A systematic review.
Human vaccines & immunotherapeutics · 2026 · PMID 41636135
Human papillomavirus (HPV) is a major global health concern due to its link to cervical and other cancers. Although HPV vaccination is highly effective, acceptance and willingness to pay (WTP) differ widely across populations. This review summarizes global evidence from 2015-2025. A systematic search of PubMed, Scopus, CENTRAL, Web of Science, and Google Scholar was conducted in 2025 following PRISMA guidelines. Studies reporting data on knowledge, acceptance, attitudes, and WTP across any population were included.…
Rank100.0
The population impact of human papillomavirus vaccination on cancer and pre-cancer outcomes: An umbrella review of meta-analyses.
Human vaccines & immunotherapeutics · 2026 · PMID 42409728
Despite widespread HPV vaccination, a comprehensive synthesis across populations and cancer outcomes is lacking. This umbrella review evaluates HPV vaccination's population impact on infection, precancerous lesions, and invasive cancers. We searched five databases for meta-analyses reporting prophylactic HPV vaccine outcomes up to Jan 2026. Two reviewers performed selection, data extraction, AMSTAR-2, and GRADE. From 34 meta-analyses, RCTs in HPV-naïve women showed 99% efficacy (95% CI: 98-99%) against HPV16/18 inf…
Rank100.0
Rapid Systematic Review-Informed Multidisciplinary Expert Consensus on the Management of HPV-Positive Women with Low-Grade Cervical Lesions and the Role of a Coriolus versicolor-Based Vaginal Treatment.
Medicina (Kaunas, Lithuania) · 2026 · PMID 42512825
Background and Objectives: Persistent human papillomavirus (HPV) infection is associated with the development of cervical intraepithelial neoplasia and cervical cancer. In women with low-grade cervical lesions, a conservative management approach is commonly recommended. However, a subset of patients may experience lesion progression, which can also be accompanied by psychological distress. Adjuvant therapies during the surveillance period have gained increasing clinical interest. This consensus aims to provide mult…
Rank100.0
Life Experiences of Women Diagnosed With Cervical Cancer in Sub-Saharan Africa: A Systematic Review of Qualitative Studies.
Psycho-oncology · 2025 · PMID 40930811
BACKGROUND: Sub-Saharan Africa (SSA) bears the highest global burden of cervical cancer. Living with the disease is a complex experience, leading to significant changes across various biopsychosocial dimensions, which in turn affect the quality of life of affected women. AIMS: This review aimed to synthesize available scientific evidence on the life experiences of women diagnosed with cervical cancer in SSA in order to generate valuable insights into the care of the affected population. METHODS: Seven electronic da…
Rank96.0
Integrative Analyses of Individual Patient Genomic-Data to Discover Novel Biomarkers: Application to Cervical Pre-Cancer DNA-Methylation Datasets.
Cancer informatics · 2026 · PMID 42542792
OBJECTIVE: The growing availability of public genomic repositories led to increased use of integrative and meta-analytic approaches to combine multi-omics datasets for biomarker discovery. Building on this framework, our study applies a molecular discovery approach to identify diagnostic biomarkers for cervical pre-cancer in high-risk HPV-positive women using aggregated genomic evidence across populations. METHODS: This study performed a secondary analysis of publicly available DNA-methylation datasets identified t…
Rank92.0
Assessment and Comparison of Efficacy and Safety of Monotherapy With Topical 50% Urea Cream and Combination Therapy With Topical 50% Urea Cream and Carboxytherapy in Treatment of Recalcitrant Common Wart: A Randomized, Single-Blinded, 2-Split Clinical Trial.
Journal of medical virology · 2026 · PMID 42541394
The treatment of common warts can occasionally be a challenge in recalcitrant cases, either recurrent ones or non-responders to treatment. In the current study, the efficacy and safety of monotherapy with topical 50% urea cream and combination therapy with topical 50% urea cream and carboxytherapy were assessed and compared in the treatment of recalcitrant common wart. Twenty subjects with recalcitrant common warts in the extremities (excluding the plantar surface) were selected. For the lesions of one side of the …
Rank82.9
HPV vaccine awareness and uptake among women attending cervical screening in health-resource-limited areas of China: A multicenter cross-sectional study.
Human vaccines & immunotherapeutics · 2026 · PMID 41830505
Evidence shows HPV vaccination reduces infection, precancer and cervical cancer, yet coverage in health-resource-limited of China remains uncertain. We assessed awareness, uptake and correlates among women attending cervical screening, and examined associations with screening outcomes. We conducted a cross-sectional study in eight county sites in 2023-2024 among women aged 35-64 y. A standardized questionnaire captured sociodemographic factors, awareness and vaccination. Cervical samples were tested for hrHPV. Outc…
Rank77.8
Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis.
The Lancet. Oncology · 2025 · PMID 40645195
BACKGROUND: Modernisation of the American Joint Committee on Cancer and Union for International Cancer Control (AJCC/UICC) staging for HPV-positive oropharyngeal carcinoma has strengthened its fundamental role to convey prognosis and guide treatment decisions. Implementation has nonetheless revealed imbalances. An AJCC committee reappraised HPV-positive oropharyngeal carcinoma pathological staging to advance prognostic accuracy and improve clinical applicability. METHODS: For this analysis, US registry data from th…
Rank77.0
Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab.
JAMA otolaryngology-- head & neck surgery · 2025 · PMID 40742583
IMPORTANCE: Neoadjuvant immunotherapy shows promise in the treatment of head and neck squamous cell carcinoma (HNSCC). Pathologic treatment effect (pTE) is one way to assess response to treatment; however, the association of this response with survival outcomes is not yet clear. The current study sought to determine whether treatment response to neoadjuvant nivolumab, as measured by pTE, correlates with survival outcomes. OBJECTIVE: To determine whether patients with HNSCC with pathologic response to neoadjuvant ni…
Rank73.0
REBACIN® can remove high-risk Human Papillomavirus (HPV) persistent infection efficiently as an effective non-invasive treatment: a multicenter prospective study.
World journal of surgical oncology · 2026 · PMID 42035080
OBJECTIVE: To evaluate the efficacy of REBACIN® as a non-invasive treatment for persistent high-risk HPV (HR-HPV) clearance compared with interferon and no treatment, identify optimal cutoff values for HPV E6/E7 mRNA/DNA assays, analyze clinical predictors, and validate REBACIN® as a safe alternative to invasive interventions for cervical cancer prevention. METHODS: According to the predefined inclusion and exclusion criteria, eligible patients were randomly selected and enrolled after obtaining their informed cons…
Rank72.0
Monitoring the safety of the adjuvanted human papillomavirus vaccine HPV-16/18-AS04 in association with pregnancy and potential immune-related diseases in China: A retrospective observational cohort study.
Human vaccines & immunotherapeutics · 2026 · PMID 42348585
Human papillomavirus (HPV) infection causes cervical cancer. The objective of the study is to monitor AS04-adjuvanted HPV-16/18 vaccine (Cervarix, GSK) safety in a real-world setting in China, using electronic health records from the Yinzhou Regional Health Information Platform (YRHIP). This retrospective observational cohort study included all permanent residents (males and females) aged 9-45 y with ≥12 months continuous YRHIP registration between 1 January 2010 and 31 December 2020. The study analyzed demographic…
Rank69.6
Cervical Cancer Screening With Human Papillomavirus Self-Collection Testing in an Opioid Treatment Program.
JAMA network open · 2026 · PMID 42525415
IMPORTANCE: Individuals with opioid use disorder and substance use disorder have lower cervical cancer screening rates than the general population. Human papillomavirus (HPV) self-collection testing provides opportunities to expand screening access to previously unreached patient populations. OBJECTIVES: To assess the feasibility and uptake of incorporating HPV self-collection testing for cervical cancer screening into routine care for patients with opioid use disorder and substance use disorder, and to track the r…
Preclinical Research61 records
Rank46.2
ORAL AND GASTRIC PLAQUES, PAPILLOMAS, SQUAMOUS CELL CARCINOMAS AND PAPILLOMAVIRUSES IN SLENDER-HORNED GAZELLES (GAZELLA LEPTOCEROS ).
Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians · 2026 · PMID 42405724
The slender-horned gazelle (SHG, Gazella leptoceros) is a small, sand-colored antelope native to northern Africa. It is endangered due to poaching and habitat loss. Limited reports describe health or disease in wild or zoo populations. Mucosal plaques in the oral cavity (n = 2), papillomas in the rumen (n = 3) or reticulum (n = 1), and squamous cell carcinoma in the oral cavity (n = 3), rumen (n = 4), or reticulum (n=1) were seen independently or concurrently in eight of 74 SHG postmortem examinations in a zoologic…
Rank45.0
Complete genome and phylogenetic characterization of a novel papillomavirus from Cuniculus paca in the Brazilian Amazon.
Archives of virology · 2026 · PMID 42096055
Wild rodents remain underrepresented in papillomavirus genomics, limiting current understanding of host range, tissue tropism, and evolutionary diversity. Here, we report the first papillomavirus identified in the spotted lowland paca, Cuniculus paca, from the Brazilian Amazon, provisionally designated Cuniculus paca papillomavirus 1 (CpPV1). Histopathological examination supported the diagnosis of a virally induced squamous papilloma. Broad-range L1 PCR (FAP59/64), rolling-circle amplification, and Illumina MiSeq …
Rank45.0
Virus infections and cancers: from mechanisms to therapeutics.
Molecular biomedicine · 2026 · PMID 42417944
Viral infections are a major contributor to global cancer incidence and mortality. However, integrative reviews that connect viral classification, carcinogenic mechanisms, tumor microenvironment remodeling, and translational strategies remain limited. This review summarizes the classification and epidemiological characteristics of major oncogenic viruses, including human papillomavirus (HPV), Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), Merkel cell polyomavirus (MCPyV), human T-lympho…
Rank45.0
Transcriptomic analysis of lncRNA-miRNA-mRNA competing endogenous RNA regulatory networks in radiation-induced mouse thymic degeneration.
Immunologic research · 2026 · PMID 42461346
Excessive or inappropriate radiation can seriously harm organisms. Radiation-induced thymus injury (RITI) is a severe complication driven by dysregulated RNA networks. However, current studies have mostly focused on single non-coding RNAs or late pathological stages, and a complete competing endogenous RNA (ceRNA) regulatory network had not been constructed. The thymus tissues of C57BL/6 mice exposed to 6 Gy X-ray radiation for 24 h were analyzed by RNA-sequencing (RNA-seq) with library construction. We functionall…
Rank45.0
Specific and sensitive detection of camel papilloma virus by polymerase chain reaction using novel oligonucleotide primer sequences.
Molecular biology reports · 2026 · PMID 42461455
BACKGROUND: Camel papillomatosis (CP) is caused by camel papillomavirus types 1 (CdPV1) and 2 (CdPV2), leading to noticeable lesions on the facial skin and eyes. Although seldom fatal, it can result in blindness and other deformities as lesions may spread to different body systems, similar to papillomaviruses infection in other animals. Cutaneous lesions in affected camel often resemble to those recorded in camel pox and camel contagious ecthyma (CCE), making accurate diagnosis a difficult task. The present study t…
Rank45.0
Spontaneous regression of equine sarcoids is an exceptional event.
Equine veterinary journal · 2026 · PMID 41814482
Sarcoids are benign, yet locally aggressive skin tumours that commonly affect horses and other equid species. The lesions are induced by bovine papillomavirus types 1, 2, and probably 13 in conjunction with other factors including trauma and a genetic predisposition. Although sarcoids have a substantial impact on the health and welfare of affected equids, information on the immune response to bovine papillomavirus infection and resulting sarcoids is limited. However, there is evidence that sarcoid disease is associ…
Rank45.0
Equine genital and ocular squamous cell carcinomas: clinical, histopathological, molecular and viral characterization with proposed histopathological classification system.
The veterinary quarterly · 2026 · PMID 41873836
Equine squamous cell carcinomas (eSCCs) are common, and a proportion are likely induced by Equus caballus papillomavirus 2 (EcPV-2). Accurate prediction of clinical outcomes is challenging with no recognized prognostic criteria or consistent histopathological classification scheme for eSCC. The aims of this study were to histopathologically subtype a large case series of eSCCs (genital and ocular) and correlate them with p16 and HER-2 expression, equine papillomavirus infection status, and various clinical and hist…
Rank45.0
Novel avian papillomaviruses identified in a south polar skua sampled on Ross Island, Antarctica.
Archives of virology · 2026 · PMID 42298252
Papillomaviruses are small circular DNA viruses that infect epithelial cells of their hosts. Avian papillomaviruses are poorly sampled/documented compared to those infecting humans. We used a viral metagenomic approach to identify viruses from the oral swab taken from a deceased south polar skua (Stercorarius maccormicki) found at Cape Royds, Ross Island, Antarctica in late 2024. We identified three papillomaviruses and determined their complete genomes, Stercorarius maccormicki papillomavirus (SmacPV) 1-3. SmacPV1…
Rank45.0
Viral etiology of orogenital papillomatosis and squamous cell carcinoma in bottlenose dolphins in the southeastern United States.
Virology · 2026 · PMID 42361430
Orogenital papillomatosis and squamous cell carcinoma is an emerging yet poorly understood complex disease of bottlenose dolphins (Tursiops truncatus and T. erebennus), both in the wild and under managed care. Previous studies have indicated a potential role of papillomaviruses and/or herpesviruses in the development of oncogenesis, although unbiased metagenomic approaches to examine the disease-associated virome in biopsied lesions have not been performed. Herein, we determined the viruses present in oral and geni…
Rank45.0
Detection of papillomavirus DNA in uterine flushing samples from healthy mares reveals diverse genotypes with differing host ranges.
Scientific reports · 2026 · PMID 42103858
A molecular study to assess the presence of some papillomaviruses was performed on 105 uterine flushing samples of healthy mares using real time quantitative polymerase chain reaction (qPCR) and digital PCR (dPCR). Bovine, equine, and ovine papillomavirus DNA was detected in 27 uterine flushing samples through dPCR (~ 25.71%); qPCR was able to detect 18 positive samples (~ 17.14%). Differences between the two molecular protocols were significant as shown by McNemar's test (p˂ 0.005). EcPV DNA was detected in 10 sam…
Rank35.0
Malignant epithelial tumors associated with Felis catus papilloma virus type 3 and type 4 infections at distinct anatomical sites in a domestic cat.
The Journal of veterinary medical science · 2026 · PMID 41882908
A 12-year-8-month-old neutered male cat presented with multiple nail bed masses and an ulcerative lip lesion. PCR identified Felis catus papillomavirus type 3 (FcaPV3) in the nail masses and type 4 (FcaPV4) in the lip lesion. Histopathology revealed basosquamous cell carcinoma (BSCC) in the digits and Bowenoid in situ carcinoma (BISC) in the lip. Immunohistochemistry showed that tumor cells in both BSCC and BISC were positive for p16 and p63 and weakly positive for pRb; p53 was negative in BSCC but weakly positive …
Rank35.0
Fatal 5-Fluorouracil Toxicity With Hyperammonemic Encephalopathy, Lactic Acidosis, and Pneumatosis Intestinalis Despite Uridine Triacetate Rescue: A Case Report.
Cureus · 2026 · PMID 42524480
5-Fluorouracil (5-FU) is among the most widely prescribed chemotherapeutic agents worldwide, yet severe toxicity can produce a life-threatening metabolic syndrome, most commonly associated with dihydropyrimidine dehydrogenase (DPD) deficiency. We report a fatal case of early-onset fluoropyrimidine toxicity characterized by severe metabolic derangements followed by severe myelosuppression. A 56-year-old male patient with stage III (primary tumor (T4), regional lymph nodes (cN2), distant metastasis (cM0), human papil…
Rank35.0
Case Report: Functional characterization of lymphocyte populations in a pediatric patient with WHIM syndrome.
Frontiers in immunology · 2026 · PMID 42445192
WHIM syndrome is a rare primary immunodeficiency disorder caused by gain-of-function mutations of the chemokine receptor CXCR4, leading to abnormal and exacerbated leukocyte trafficking. It is associated with severe neutropenia and lymphopenia, and recurrent infections. Few pediatric cases have been reported, but comprehensive analyses of the composition and function of peripheral lymphocyte populations in pediatric WHIM syndrome are lacking. Here we report the case of a 6-year-old male patient carrying a CXCR4 c.1…
Rank35.0
Vaginal microbiome and inflammation cytokines among Chinese women.
NPJ biofilms and microbiomes · 2026 · PMID 42162000
Human papillomavirus (HPV) infection, cervical intraepithelial neoplasia (CIN), pelvic organ prolapse (POP), cervical polyps, abnormal uterine bleeding, and vaginitis are common gynecological disorders. This study characterized the vaginal microbiome and its cytokine-mediated immune interactions in Chinese women with gynecological disorders. Vaginal swabs from 310 patients diagnosed with gynecological disorders and 112 healthy controls were analyzed via 16S rRNA gene sequencing and cytometric bead array (CBA) to ev…
Rank32.4
Prevalence and genotypic distribution of high-risk human papillomavirus in primary breast tumors in Western Uganda: a case-control study.
Scientific reports · 2026 · PMID 42103938
Although in vitro studies have demonstrated that HPV can immortalize mammary epithelial cells, its contribution to breast carcinoma development in living organisms remains debatable. Reports on HPV detection in breast tumors vary widely across regions, and data from East Africa are limited. This study investigated the prevalence and genotypic distribution of high-risk HPV in breast tumors in Western Uganda. This retrospective case-control study was conducted using archived formalin-fixed paraffin-embedded tissue sp…
Rank30.0
Estrogen receptor α (Esr1) mediates estrogen's ability to promote papillomavirus-induced cutaneous disease in male and female mice.
mBio · 2026 · PMID 42212803
Persistent papillomavirus infection is a key driver of neoplastic progression in both mucosal and cutaneous epithelia. Although estrogen is a well-established cofactor in HPV-associated cervical carcinogenesis, its role in cutaneous papillomavirus disease has remained poorly understood. Using a murine papillomavirus type 1 (MmuPV1) infection model in immunocompetent FVB/N mice, we investigated whether estrogen influences viral pathogenesis in infected cutaneous epithelia. Estrogen treatment significantly increased …
Rank30.0
Reconsidering immunotherapy resistance: the emerging role of the tumor microbiome in head and neck and lung cancers.
Annals of medicine and surgery (2012) · 2026 · PMID 42254101
Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized treatment for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), yet resistance limits durable responses in many patients. Emerging evidence implicates the intratumoral microbiome - comprising bacteria, fungi, and viruses within tumor tissues - as a key modulator of tumor biology, immune infiltration, and ICI sensitivity, beyond traditional tumor-intrinsic and immune factors. In HNSCC, human papillomavirus (…
Rank30.0
STING agonist 2'3'-cGAMP as an effective adjuvant for HPV16 peptide vaccine enhances anti-tumor immunity in TC-1 mice models.
Frontiers in cellular and infection microbiology · 2026 · PMID 42394822
BACKGROUND: Adjuvants are critical for enhancing vaccine immunogenicity. The agonists in cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway have demonstrated robust immune activation in preclinical models. Peptide vaccines targeting T cell epitopes of high-risk human papillomavirus (HPV) E6 and E7 represent a promising immunization strategy. To improve immunogenicity, we utilized the STING agonist 2'3'-cGAMP as an adjuvant and evaluated its ability to enhance immune responses an…
Rank30.0
Synergistic Interaction Between HPV-16 E7 Oncoprotein and Severe Vitamin A Deficiency in Regulating Adaptive Immunity in a Preclinical Cervical Cancer Model.
Journal of medical virology · 2026 · PMID 42266136
Persistent infection with High-Risk Human Papillomavirus (HR-HPV), particularly HPV-16, is the main driver of cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). However, HR-HPV infection alone is insufficient for malignant progression and nutritional cofactors such as Vitamin A deficiency, may influence cervical neoplasia progression through immune dysregulation. This study aimed to explore the interaction between HPV-16 E7 oncoprotein expression and severe Vitamin A Deficiency (VAD), as well as the…
Rank30.0
Nano-enabled targeted transdermal therapy for pain management in cervical cancer.
Journal of pharmaceutical sciences · 2026 · PMID 42092518
Cervical cancer, caused by persistent infection with high-risk human papillomavirus (HPV) types, remains one of the leading causes of cancer death among women. Pain is a significant concern in patients with advanced disease, due to the anatomical position of cervical cancer as well as struggles with major therapeutic pain management remedies. Opioids, which are the mainstay of pain control, are saddled with many drawbacks, including poor tolerance, serious side effects, and addiction over long-term use. Transdermal…
Rank30.0
Spatial cellular order underlies locally-confined mechanisms of immune resistance in oropharyngeal cancer.
Nature communications · 2026 · PMID 42288489
Oropharyngeal squamous cell carcinomas (OPSCCs) frequently result from oncogenic human papilloma virus (HPV) infections (HPV-OPSCC). The mechanisms underlying effective immune escape, despite abundant viral antigens, are incompletely understood. Here, we performed single-cell spatial gene expression profiling of HPV-OPSCC to characterize cellular organization and mechanisms of immune resistance. We describe distinct tumor-parenchymal immune foci that differ in cytokine expression, spatial location, immune cell infi…
Rank30.0
A low-dose self-amplifying mRNA vaccine encoding HPV16 E6/E7 induces potent T-cell immunity and antitumor protection in mice.
Cancer immunology, immunotherapy : CII · 2026 · PMID 42400858
BACKGROUND: Human papillomavirus (HPV), particularly high-risk types such as HPV16, is associated with several malignancies, including cervical cancer. Existing therapeutic vaccines targeting HPV oncoproteins E6 and E7 show limited immunogenicity and high production costs. Self-amplifying mRNA (saRNA) vaccines offer a promising alternative by enabling robust antigen expression at low doses. This study evaluated the immunogenicity and antitumor efficacy of a novel saRNA vaccine, JJ-saRNA-HPV01, targeting HPV16 E6/E7…
Rank30.0
A calreticulin-linked HPV-16 E7 minigene DNA vaccine elicits strong E7-specific CD8+ T-cell immunity and durable antitumor effects in a preclinical model.
Scientific reports · 2026 · PMID 42399330
Calreticulin (CRT) is an endoplasmic reticulum chaperone that facilitates antigen processing and presentation, making it an attractive fusion partner for enhancing tumor-specific T-cell responses in DNA vaccine development. However, the relative efficacy of CRT compared with other antigen-presentation-enhancing strategies has not been fully evaluated. We constructed a DNA vaccine encoding the immunodominant human papillomavirus (HPV)-16 E7 minigene epitope (aa 49-57) fused to the C-terminus of CRT (pcDNA3-CRT-E7(49…
Rank30.0
Innovative peptide-loaded hybrid membrane nanovaccine enables precise personalized immunotherapy for HPV-related cervical diseases.
Signal transduction and targeted therapy · 2026 · PMID 42236671
Human papillomavirus (HPV)-associated cervical diseases pose significant health risks to women worldwide. Current clinical interventions face challenges in achieving complete viral clearance and controlling disease progression, with limited efficacy and recurrence risks. To address this unmet need, we developed an innovative nanovaccine (HM-NPs@LP) designed to codeliver tumor cell membranes (TMs), bacterial cytoplasmic membranes (EMs), and HPV16 long peptides (LP) through PLGA nanoparticles to elicit antitumor immu…
Rank30.0
Preclinical evaluation of high-dose Griffithsin carrageenan fast-dissolving insert for HIV, HSV-2, and HPV prevention.
Microbiology spectrum · 2026 · PMID 42003587
Griffithsin (GRFT) is an antiviral lectin that blocks human immunodeficiency virus (HIV) entry. When combined with carrageenan (CG), GRFT has strong activity against herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV). We conducted a preclinical evaluation of a high-dose vaginal fast-dissolving insert (FDI) containing 3 mg GRFT-equivalent to 3× the clinical dose-and compared it with a 1 mg formulation. Studies included FDI disintegration (macaques, rabbits); GRFT pharmacokinetics, pharmacodynamics, a…
Promising Experimental Therapies61 records
Rank107.5
Video-based interventions to promote HPV vaccination among individuals aged 9 to 26: a systematic review and meta-analysis.
BMC public health · 2026 · PMID 41826914
Human papillomavirus (HPV) is the most prevalent sexually transmitted infection in the U.S. and is associated with approximately 40,000 new cancer cases each year, affecting both males (e.g., oropharyngeal, anal cancers) and females (e.g., cervical, vaginal cancers). The CDC recommends HPV vaccination for individuals aged 9 to 26, and studies have shown that HPV vaccines are effective in reducing the rates of cancers. Video-based interventions may be an effective strategy to increase vaccination uptake. This study …
Rank99.8
Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.
Journal of gynecologic oncology · 2026 · PMID 41834413
BACKGROUND: Gastric-type endocervical adenocarcinoma (G-EAC) is a distinctive form of adenocarcinoma that is not associated with human papillomavirus. This neoplasm exhibits a low incidence, low screening and biopsy positivity, low preoperative diagnosis, and a high susceptibility to underdiagnosis and misdiagnosis. It is associated with a poor prognosis for patients. Currently, there is an absence of a standardized postoperative adjuvant treatment plan for G-EAC, which constitutes an urgent clinical problem that d…
Rank98.6
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 41570275
PURPOSE: Patients with human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) and advanced stage and/or significant smoking history are at higher risk of relapse. Induction immunotherapy before chemoradiation (CRT) may improve outcomes. This randomized phase II trial assessed the feasibility and safety of induction nivolumab before CRT in this high-risk population. METHODS: Eligible patients had HPV-positive OPC with either T4 and/or N2/N3 disease or a smoking history >10 pack-years. Patients were randomly …
Rank98.5
Immunogenicity and safety of a quadrivalent recombinant human papillomavirus vaccine (type 6/11/16/18) (Hansenula polymorpha): A randomized controlled phase 2 non-inferiority clinical trial.
Vaccine · 2026 · PMID 41932289
OBJECTIVE: The randomized, double-blind, placebo-controlled Phase II non-inferiority clinical study aimed to evaluate the immunogenicity and safety of the quadrivalent recombinant human papillomavirus vaccine (type 6/11/16/18) (Hansenula polymorpha) in healthy females aged 9-45 years. METHODS: A total of 1800 participants were randomly assigned to the vaccine group and the placebo group in a 2:1 ratio. The immunobridging between the 9-17 and 18-45 age groups adopts a non-inferiority design with a non-inferiority ma…
Rank97.6
Efficacy and safety of a topical nitric oxide-releasing solution (NORS) as a noninvasive treatment for plantar warts (verrucae plantaris).
The Journal of dermatological treatment · 2026 · PMID 41493215
BACKGROUND: Plantar warts (verrucae plantaris), caused by human papillomavirus, are common and often resistant to standard therapies, which can be painful and damaging. Novel, noninvasive options are needed. OBJECTIVE: To evaluate the safety and preliminary efficacy of a topical nitric oxide-releasing solution (NORS) as a self-administered therapy for plantar warts. METHODS: In this Phase 2a, multicenter, randomized, double-blind, placebo-controlled trial, 20 participants with ≥3 plantar warts were randomized (1:1:…
Rank95.7
A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 · PMID 41403292
BACKGROUND: The clearance of high-risk oncogenic human papillomaviruses (hrHPV) and related cervical lesions is associated with the development of a robust T-cell response. Therapeutic vaccination that induces HPV antigen-specific T cells is a promising approach. METHOD: A 2-vector dosing strategy using Chimpanzee Adenovirus Oxford 1-HPV and Modified Vaccinia virus Ankara-HPV, both encoding the same multiantigen HPV cassette was given on a 0/28-day schedule to participants with persistent cervical hrHPV and a histo…
Rank92.0
A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence.
Oncotarget · 2026 · PMID 42249801
UNLABELLED: Copyright: © 2026 Bivens et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. OBJECTIVES: The main goals were to assess safety and efficacy (i.e., recurrence reduction). RESULTS: Seventeen patients were enrolled. The most common adverse events were grades 1 and 2 injection site reactions, and they oc…
Rank92.0
The effect of podcasts delivered to female university students on HPV knowledge, awareness, and anxiety levels: A randomized controlled trial.
Nurse education in practice · 2026 · PMID 42314452
AIM: The aim of this study was to evaluate the effect of podcast-based educational content delivered to students on their knowledge, awareness and anxiety levels regarding Human Papillomavirus (HPV). METHOD: This randomized controlled experimental study was conducted between 7 April 2025 and 6 June 2025, with a total of 211 students (99 in the intervention group and 112 in the control group) who were enrolled in the 2024-2025 academic year at the Faculty of Health Sciences, University of Health Sciences Gülhane and…
Rank89.5
Effect of coriolus versicolor-based vaginal gel on clearance of human papillomavirus and cervical dysplasia - a scoping review.
BMC women's health · 2026 · PMID 41507892
BACKGROUND: Cervical cancer, primarily caused by sexually transmitted high-risk Human Papillomavirus (HPV) infections, remains a major global health challenge. Despite significant advances in HPV vaccination and cervical cancer screening strategies, effective and non-invasive treatment options for HPV infections and cervical dysplasia. are still lacking. Current management strategies of cervical dysplasia vary from the “wait and see” strategy to surgical interventions. This scoping review aimed to map the existing …
Rank85.0
Technological innovations in head and neck radiotherapy: What does the future hold?
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2026 · PMID 42001737
Radiotherapy in head and neck oncology is advancing thanks to technologies that improve treatment precision, adaptation, and tolerance. The most promising approaches are discussed in this narrative review. The use of automatic segmentation through artificial intelligence (deep learning) now allows rapid delineation of organs at risk, thus reducing contouring time and the risk of errors. Several tools are already routinely used and are evaluated for replanning process. Imaging, acquired before each session, ensures …
Rank81.1
Phase 2 Prospective Trial of Personalized Radiation Therapy Fractionation in Human Papillomavirus Positive Oropharyngeal Cancer.
International journal of radiation oncology, biology, physics · 2026 · PMID 41519405
PURPOSE: We previously developed a model of pretreatment growth and on-treatment response dynamics, the proliferation saturation index (PSI) model, which derives the proliferating and radiosensitive proportion of a tumor based on clinically observed net growth before therapy. We hypothesized that personalization of fractionation using PSI would increase the percentage of patients achieving a rapid reduction in tumor size during radiation therapy (RT) for early-stage human papillomavirus related squamous cancers of …
Rank81.0
Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial.
Nature communications · 2026 · PMID 42098120
Circulating tumor DNA (ctDNA) has an expanding role in oncology. It is unknown whether on-treatment ctDNA can be used to personalize radiation dose. This phase 2 exploratory clinical trial enrolled 102 patients with human papillomavirus (HPV)-positive oropharyngeal carcinoma (OPC). Intermediate-risk patients (T4 disease or >10 pack-year smokers with pre-treatment HPV ctDNA scores >200) were reclassified as low-risk if HPV ctDNA cleared by >95% mid-treatment. All clinically low-risk and reclassified patients receive…
Rank80.5
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.
ESMO open · 2026 · PMID 41468684
BACKGROUND: Limited data are available on the role of human papillomavirus circulating tumor DNA (HPV-ctDNA) as a pharmacodynamic marker to monitor the response to treatment in the recurrent/metastatic (R/M) setting. Our study aimed to investigate the sensitivity and pharmacodynamic value of HPV-ctDNA levels during treatment in patients with R/M HPV-related squamous cell carcinoma (SCC) treated with pembrolizumab in combination with vorinostat (PEVO trial, NCT04357873). MATERIALS AND METHODS: Plasma samples were pr…
Rank80.2
A Phase 2 Exploratory Trial Evaluating Computed Tomography-Based Midtreatment Nodal Response to Select for De-escalated Chemoradiation Therapy in the Definitive Management of p16+ Oropharyngeal Cancer.
International journal of radiation oncology, biology, physics · 2026 · PMID 41101558
PURPOSE: This prospective, nonrandomized phase 2 single-arm pilot trial aimed to explore favorable midtreatment nodal response (FMNR) through computed tomography (CT) imaging to guide de-escalated chemoradiation therapy (CRT) in patients with favorable risk, node-positive human papillomavirus (HPV)-associated oropharyngeal cancer (OPC). METHODS AND MATERIALS: Eligible patients included p16+ OPC (AJCC 8th: cT1-3 N1 M0, <10 pack-year smokers). All patients were initially planned to receive 70 Gy with concurrent weekl…
Rank80.0
FDG-PET-Based Selective Deescalation of Chemoradiation in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41385605
PURPOSE: We conducted a phase II multicenter clinical trial to test the hypothesis that 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)-based chemoradiation (CRT) dose deescalation would provide noninferior locoregional control compared with historical controls among patients with early-stage p16+ oropharyngeal cancer. We also hypothesized that human papillomavirus (HPV) circulating tumor DNA (ctDNA) changes during treatment predict locoregional recurrence (LRR). PATIENTS AND METHODS: Patients with st…
Rank79.9
Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial.
Nature communications · 2026 · PMID 41605945
Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is characterised by hyperactivation of the cyclin-dependent kinase 4/6 (CDK4/6) pathway. As immunotherapy has become the first-line treatment for HNSCC, resistance to anti-programmed death-1 (PD-1) agents has emerged as a pivotal challenge. This prospective, single arm, phase II study (NCT05721443) evaluated the efficacy and safety of dalpiciclib, a CDK4/6 inhibitor, combined with cetuximab in patients with anti-PD-1-resistant, HPV-ne…
Rank77.0
Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM Syndrome.
Journal of clinical immunology · 2026 · PMID 41904735
BACKGROUND: WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) syndrome is an ultrarare inborn error of immunity caused by heterozygous, hyperfunctional CXCR4 mutations that impede leukocyte egress from bone marrow, resulting in panleukopenia. The CXCR4 antagonist plerixafor (AMD3100, Mozobil) durably reverses panleukopenia and in most WHIM patients also induces wart regression; however, its short half-life requires twice daily injection. OBJECTIVE: The aim of this study was to assess the safety and …
Rank77.0
Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab.
JAMA otolaryngology-- head & neck surgery · 2025 · PMID 40742583
IMPORTANCE: Neoadjuvant immunotherapy shows promise in the treatment of head and neck squamous cell carcinoma (HNSCC). Pathologic treatment effect (pTE) is one way to assess response to treatment; however, the association of this response with survival outcomes is not yet clear. The current study sought to determine whether treatment response to neoadjuvant nivolumab, as measured by pTE, correlates with survival outcomes. OBJECTIVE: To determine whether patients with HNSCC with pathologic response to neoadjuvant ni…
Rank77.0
Phase I/II clinical study of next-generation photodynamic therapy (L-PDT) using talaporfin sodium (Laserphyrin®) for cervical intraepithelial neoplasia: Efficacy, safety, and fertility preservation.
Photodiagnosis and photodynamic therapy · 2026 · PMID 41638379
BACKGROUND: PDT using Photofrin® (P-PDT) has been applied to over 900 gynecologic tumor cases since 1989, demonstrating excellent efficacy and fertility preservation; however, post-treatment photosensitivity has limited its clinical application for CIN and cervical cancer. This study aimed to establish a safe, effective, and fertility-preserving alternative to cervical conization. METHODS: To overcome photosensitivity, we conducted a prospective Phase I/II clinical study to evaluate the safety, efficacy, oncologica…
Rank68.2
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42102329
PURPOSE: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis, particularly those with human papillomavirus (HPV)-negative disease, in which elevated epidermal growth factor receptor and transforming growth factor-β impair tumor penetration of immune cells and lessen immunotherapy responses. METHODS: We present results from an expansion cohort of a first-in-human phase I/Ib trial (ClinicalTrials.gov identifier: NCT04429542) evaluating first-line treatment wit…
Rank55.0
Early effects of HPV vaccination on high-grade cervical intraepithelial neoplasia in Brazil: Evidence from outpatient data.
Human vaccines & immunotherapeutics · 2026 · PMID 42295873
Cervical cancer remains a leading cause of disease burden among women, despite being largely preventable. High-grade cervical intraepithelial neoplasia (CIN) is a key intermediate outcome for evaluating early population-level effects of HPV vaccination and is mainly managed in outpatient settings, which may provide a more timely signal than hospitalizations or cancer registry data. This study aimed to assess whether the introduction of quadrivalent HPV vaccination in Brazil in 2014 through its National Immunization…
Rank50.3
The role of E7 oncoprotein self-sampling and self-testing in cervical cancer screening.
BMC women's health · 2026 · PMID 41692769
OBJECTIVE: To preliminarily explore and validate the role of E7 oncoprotein self-sampling and self-testing in cervical cancer screening. METHODS: Approved by the Ethics Committee of Peking University First Hospital, 461 patients who underwent cervical cancer screening with abnormal screening results in the outpatient clinic from June 13, 2023 to August 29, 2023 were selected and participated in the clinical trial with informed consent. For E7 oncoprotein, the participants use self-sampling brushes to collect sample…
Rank50.0
Association of Intratumoral Microbiota with Prognosis in Head and Neck Squamous Cell Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41758690
PURPOSE: To evaluate whether intratumoral bacterial load and diversity are associated with survival outcomes in head and neck squamous cell carcinoma (HNSCC) and to examine their relationship with human papillomavirus (HPV) status. EXPERIMENTAL DESIGN: This retrospective cohort study included 312 adults with surgically treated, primary HNSCC at Montefiore Einstein Cancer Center (2000-2023). Intratumoral bacterial load was quantified via quantitative PCR (qPCR), and microbial diversity was assessed via 16S ribosomal…
Rank49.8
Effects of message framing on HPV Vaccination decision-making: A Survey experiment among Chinese male college students.
Human vaccines & immunotherapeutics · 2026 · PMID 41480936
Human papillomavirus (HPV) is a major public health concern affecting both sexes. China adopted a gender-neutral HPV vaccination strategy, expanding recommendations to include males. College students, a high-risk group for HPV exposure, were a priority target for vaccination campaigns. This study compares how four message frames (control, personal health risks, partner risks, both risks) influenced HPV vaccination intention, decisional readiness, and perceived responsibility among Chinese male college students. We …
Rank49.8
Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41870278
PURPOSE: Recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) is a heterogeneous clinical entity with a poor prognosis. The molecular and immune landscape of R/M SCCHN is underexplored. To offer a comprehensive view of the tumor microenvironment and molecular profile of R/M SCCHN, we performed an in-depth molecular and immune characterization, evaluating the impact of human papillomavirus (HPV) status, tobacco and alcohol history, primary tumor site, relapse pattern, and treatment …
Prospective Cohort Studies60 records
Rank106.3
Beyond the conventional: the efficacy of liquid biopsy in post-therapeutic monitoring of oropharyngeal cancer, a meta-analysis.
The Journal of laryngology and otology · 2026 · PMID 41376119
OBJECTIVES: This study aimed to evaluate the diagnostic and surveillance performance of circulating tumour human papillomavirus DNA for post-treatment monitoring of human papilloma virus-positive oropharyngeal squamous cell carcinoma. METHODS: Systematic review and meta-analysis of prospective studies (2019-2024) identified from PubMed, Web of Science and Scopus. Random-effects models were used to pool circulating tumour human papillomavirus DNA detectability and summarise lead-times to recurrence. RESULTS: Fifteen…
Rank100.6
Comparison of three different hpv self-sampling tools - a subanalysis of the prospective, randomized hannover self-collection study.
Archives of gynecology and obstetrics · 2026 · PMID 42347973
OBJECTIVE: Cervical cancer and its precursor lesions are treatable if detected early; however, screening participation for high-risk human papillomavirus infections (hr-HPV) remains low. In 2021, Germany recorded 4,544 new cervical cancer cases and 2,071 related deaths. The HaSCo study evaluates the feasibility of HPV self-testing to improve screening participation. This sub-study evaluates performance and acceptability of three self-testing tools. METHODS: This prospective, randomized sub-study examined Evalyn-Bru…
Rank99.8
Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.
Journal of gynecologic oncology · 2026 · PMID 41834413
BACKGROUND: Gastric-type endocervical adenocarcinoma (G-EAC) is a distinctive form of adenocarcinoma that is not associated with human papillomavirus. This neoplasm exhibits a low incidence, low screening and biopsy positivity, low preoperative diagnosis, and a high susceptibility to underdiagnosis and misdiagnosis. It is associated with a poor prognosis for patients. Currently, there is an absence of a standardized postoperative adjuvant treatment plan for G-EAC, which constitutes an urgent clinical problem that d…
Rank96.6
Evaluation of the Efficacy of Human Papillomavirus Screening Compared With Cytology Screening in Pregnant Women: Protocol for a Prospective Multicenter Trial.
JMIR research protocols · 2026 · PMID 42348863
BACKGROUND: Although the overall number of cervical cancer cases is declining worldwide, the incidence of this type of cancer is increasing in regions with low human papillomavirus (HPV) vaccination and cancer screening rates. In such regions, screening pregnant women can help improve the overall screening rate. Worldwide, cervical cancer screening is shifting from cervical cytology to HPV testing, which reduces the incidence of cervical cancer and, when negative, allows for longer screening intervals. Although HPV…
Rank96.4
Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 · PMID 40356381
BACKGROUND: The World Health Organization recommends 2 doses of human papillomavirus (HPV) vaccine for adults without human immunodeficiency virus (HIV) but 3 doses in persons with HIV. There are no immunogenicity data on the 2-dose schedule in women with HIV (WWH). METHODS: This was a prospective study comparing 2 doses (months 0 and 6) versus 3 (months 0, 2, and 6) doses of 9-valent vaccine (Gardasil 9, Merck Sharp & Dohme) in WWH (15-40 years), on antiretrovirals with HIV RNA <400 copies/mL, enrolled during 2018…
Rank89.9
Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 · PMID 40277212
This study aimed to evaluate the role of adjuvant HPV vaccination in women undergoing conization for cervical intraepithelial neoplasia. This prospective study assessed factors influencing recurrence in patients undergoing conization for high-grade cervical dysplasia. After conization, patients were counseled on the potential benefits of vaccination. We compared outcomes between two groups: women who underwent conization with adjuvant human papillomavirus (HPV) vaccination and observation versus conization with obs…
Rank85.0
Long-term human papillomavirus genotype-specific risk of cervical high-grade intraepithelial lesion and cancer-By age group and triage cytology.
International journal of cancer · 2026 · PMID 40888275
Human papillomavirus (HPV) genotypes possess different cervical high-grade intraepithelial lesion and cancer (CIN2+) risks. HPV genotyping is a promising method to increase the specificity of primary HPV screening, but the optimal management of the infections with different genotypes has not been established. We aimed to assess long-term HPV genotype-specific CIN2+ risks, stratified by age and triage cytology result in a population-based cervical cancer screening program. This is a prospective study of 5253 HPV-pos…
Rank85.0
Comparison of Moducare versus Wait-and-See approach for histologically proven Low-grade Cervical Intraepithelial Neoplasia (CIN1) (MODUCIN1 TRIAL) - Study protocol.
PloS one · 2026 · PMID 42441577
Human Papillomavirus (HPV) is causally associated with cervical cancer and precancerous lesions (dysplasias) of the cervix. The treatment of choice for low-grade lesions is monitoring with no-treatment, because the majority of them will regress spontaneously. However, this wait-and-see approach can be assisted by nutritional supplements for immune support, like Moducare. The hypothesis of the trial is that Moducare can enhance the natural regression of CIN1. MODUCIN1 is a prospective, open-label, randomized trial w…
Rank85.0
Increasing HPV vaccine promotion by dental providers: A clinical trial protocol.
Contemporary clinical trials · 2026 · PMID 41539537
BACKGROUND: Human papillomavirus is a prevalent DNA virus and the leading cause of both oropharyngeal and cervical cancer. Despite the availability of an effective vaccine (HPV-V), uptake is below national targets. A behavioral intervention, Increasing HPV Vaccine Uptake - Delivered in Dental Settings (HPV-V Uptake-DDS), was developed to support dental providers in promoting HPV-V to their patients to help close this gap. OBJECTIVES: This protocol for an efficacy trial of HPV-V Uptake-DDS is designed to increase HP…
Rank81.1
Phase 2 Prospective Trial of Personalized Radiation Therapy Fractionation in Human Papillomavirus Positive Oropharyngeal Cancer.
International journal of radiation oncology, biology, physics · 2026 · PMID 41519405
PURPOSE: We previously developed a model of pretreatment growth and on-treatment response dynamics, the proliferation saturation index (PSI) model, which derives the proliferating and radiosensitive proportion of a tumor based on clinically observed net growth before therapy. We hypothesized that personalization of fractionation using PSI would increase the percentage of patients achieving a rapid reduction in tumor size during radiation therapy (RT) for early-stage human papillomavirus related squamous cancers of …
Rank80.8
HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China.
Journal of clinical microbiology · 2026 · PMID 41711488
UNLABELLED: To evaluate the clinical performance of Hybribio's 14-type HPV real-time PCR with 16/18 genotyping (HBRT-H14) and its risk stratification utility among women with normal cytology (NILM). From 2017 to 2020, a multicenter cohort enrolled 8,401 women aged 30-64 years with NILM cytology. Baseline HPV testing used HBRT-H14. Women positive for HPV 16/18 were referred for colposcopy; follow-up was annual for 3 years or until the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Analyses…
Rank80.5
SOX1/PAX1 Methylation for Triage of HPV-Positive Women in Cervical Cancer Screening: A Cohort Study.
BJOG : an international journal of obstetrics and gynaecology · 2026 · PMID 41555581
OBJECTIVE: To establish a better triage strategy using SOX1/PAX1 methylation detection for high-risk HPV (hrHPV)-positive women than cytology. DESIGN: A cohort study. SETTING: Population-based cervical cancer (CC) screening cohort. POPULATION: A total of 5684 women were enrolled. METHODS: SOX1/PAX1 methylation was detected by quantitative methylation-specific PCR using cytologic residue from hrHPV-positive women at baseline in a 3-year CC screening cohort. Risk stratification ability was evaluated by the immediate …
Rank80.2
A Phase 2 Exploratory Trial Evaluating Computed Tomography-Based Midtreatment Nodal Response to Select for De-escalated Chemoradiation Therapy in the Definitive Management of p16+ Oropharyngeal Cancer.
International journal of radiation oncology, biology, physics · 2026 · PMID 41101558
PURPOSE: This prospective, nonrandomized phase 2 single-arm pilot trial aimed to explore favorable midtreatment nodal response (FMNR) through computed tomography (CT) imaging to guide de-escalated chemoradiation therapy (CRT) in patients with favorable risk, node-positive human papillomavirus (HPV)-associated oropharyngeal cancer (OPC). METHODS AND MATERIALS: Eligible patients included p16+ OPC (AJCC 8th: cT1-3 N1 M0, <10 pack-year smokers). All patients were initially planned to receive 70 Gy with concurrent weekl…
Rank79.7
Risk of High-Grade Cervical Intraepithelial Neoplasia Using human Papillomavirus Extended Genotyping in Chinese Women With Normal Cervical Cytology: A Population-Based Screening Cohort.
Journal of medical virology · 2026 · PMID 42124388
To evaluate the risk of cervical intraepithelial neoplasia, grade 2 or worse (≥ CIN2) in women with normal cervical cytology using extended high-risk human papillomavirus (HR-HPV) genotyping. This study is a population-based, nationwide, multi-center prospective cohort study. A subset of 6853 women with normal cytology and HPV testing results using an extended genotyping assay were included in the analysis. The odds ratio (OR) and adjusted OR (aOR) was calculated using univariate analyses and multivariate logistic …
Rank77.0
Phase I/II clinical study of next-generation photodynamic therapy (L-PDT) using talaporfin sodium (Laserphyrin®) for cervical intraepithelial neoplasia: Efficacy, safety, and fertility preservation.
Photodiagnosis and photodynamic therapy · 2026 · PMID 41638379
BACKGROUND: PDT using Photofrin® (P-PDT) has been applied to over 900 gynecologic tumor cases since 1989, demonstrating excellent efficacy and fertility preservation; however, post-treatment photosensitivity has limited its clinical application for CIN and cervical cancer. This study aimed to establish a safe, effective, and fertility-preserving alternative to cervical conization. METHODS: To overcome photosensitivity, we conducted a prospective Phase I/II clinical study to evaluate the safety, efficacy, oncologica…
Rank76.4
HPV Status and Genotype Associations with Nodal Involvement and Treatment Strategy in Bulgarian Patients with Head and Neck Squamous Cell Carcinoma: A Prospective Multicenter Observational Study.
Medicina (Kaunas, Lithuania) · 2026 · PMID 42356035
Background and Objectives: Head and neck squamous cell carcinoma (HNSCC) is a biologically heterogeneous malignancy with variable clinical behavior and prognosis. Human papillomavirus (HPV)-associated tumors represent a distinct subgroup; however, data from Eastern European populations remain limited. This study aimed to evaluate the association between HPV DNA status and nodal involvement in a Bulgarian HNSCC cohort and to explore whether HPV genotype distribution is related to nodal involvement and therapeutic st…
Rank73.8
Expanded subtype testing for circulating tumor HPV DNA reliably detects the presence of advanced-stage cervical cancer.
Gynecologic oncology · 2026 · PMID 42000375
OBJECTIVES: To demonstrate the detection of circulating human papillomavirus (HPV) DNA fragments can serve as a biomarker for presence of tumor and provide a universal, non-invasive tool for monitoring treatment response in HPV-related cervical cancers (CC). METHODS: A multi-site prospective study of HPV-positive high-grade cervical dysplasia (CIN2/3) and CC was conducted. Serum samples were collected pre-, during, and post-treatment. NavDx® (Naveris,Inc) digital droplet polymerase chain reaction testing was used t…
Rank73.0
Baseline Nutritional Status and Early Treatment Response in Oropharyngeal Cancer: A Prospective Cohort Study by HPV Status (FIS 19 Study).
Nutrients · 2026 · PMID 42451094
Background/Objectives: Human papillomavirus (HPV) is a well-established prognostic marker in oropharyngeal squamous cell carcinoma (OPSCC); however, the short-term treatment response remains heterogeneous, particularly among HPV-positive patients. Given the high prevalence of malnutrition in head and neck cancer, this study examined whether baseline nutritional status, body composition and functional status were associated with early treatment response in OPSCC according to HPV status. Methods: A prospective observ…
Rank73.0
REBACIN® can remove high-risk Human Papillomavirus (HPV) persistent infection efficiently as an effective non-invasive treatment: a multicenter prospective study.
World journal of surgical oncology · 2026 · PMID 42035080
OBJECTIVE: To evaluate the efficacy of REBACIN® as a non-invasive treatment for persistent high-risk HPV (HR-HPV) clearance compared with interferon and no treatment, identify optimal cutoff values for HPV E6/E7 mRNA/DNA assays, analyze clinical predictors, and validate REBACIN® as a safe alternative to invasive interventions for cervical cancer prevention. METHODS: According to the predefined inclusion and exclusion criteria, eligible patients were randomly selected and enrolled after obtaining their informed cons…
Rank70.6
From Awareness to Action Study: Improving Human Papillomavirus Knowledge, Screening and Vaccine Uptake Among Mother-Adolescent Pairs in the HOMINY Study in Nigeria: A Longitudinal Study.
Journal of the International AIDS Society · 2026 · PMID 42499163
INTRODUCTION: Persistent cervical infection with high-risk human papillomavirus (HPV) in women is a leading cause of cervical cancer, and its co-infection among people living with HIV increases the risk of other HPV-associated cancers, including oropharyngeal and anogenital cancers. In sub-Saharan Africa, awareness of HPV is limited, screening and vaccine adoption are critically low, undermining efforts towards sexually transmitted infection (STI) elimination. METHODS: From Awareness to ACTion (FACT) study assessed…
Rank70.1
Conservative Management of CIN2 Within Primary HPV Cervical Cancer Screening Programme: A Cohort Study.
Journal of lower genital tract disease · 2026 · PMID 41589748
OBJECTIVES: To quantify the probabilities of becoming HPV-negative, or receiving delayed treatment within 24 months in women with CIN2 managed conservatively; describing the determinants of the decision for conservative management, losses to follow-up and outcomes. METHODS: This prospective cohort included biopsy-confirmed CIN2 from HPV-based pilot screening in Valcamonica, Italy. Women aged 45 and under, with no glandular lesion, and assessed as low-risk by gynecologists were offered conservative management instea…
Rank70.0
Prospective Multi-Institutional Study of A Provider-Free Educational Intervention to Increase Point-of-Care Adult HPV Vaccination Uptake.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026 · PMID 41451690
OBJECTIVE: To test if a targeted provider-free digital educational intervention increases interest in adults receiving HPV vaccination. METHODS: In this nonrandomized prospective study previously unvaccinated adults (ages 18-45) were surveyed about their willingness to undergo HPV vaccination before and after targeted educational intervention. Data were collected between March 2023 and March 2024 in 2 separate otolaryngology clinics located in Boston, MA. The intervention educated patients about HPV and OPSCC and t…
Rank70.0
The Australian Penile Cancer Clinical Registry: a comprehensive national approach to data collection.
BJU international · 2026 · PMID 41810702
BACKGROUND: Penile cancer is a rare malignancy, with an Australian incidence of 0.6 in 100 000 men, with a wide range of clinical presentations, from localised, curable tumours to aggressive forms with high morbidity and mortality. Epidemiological data and management guidelines for penile cancer in Australia are limited. The Australian Penile Cancer Clinical Registry (APCCR) aims to address this gap through a centralised database studying local risk factors, treatment effectiveness, and outcomes. STUDY DESIGN: The …
Rank69.6
Cervical Cancer Screening With Human Papillomavirus Self-Collection Testing in an Opioid Treatment Program.
JAMA network open · 2026 · PMID 42525415
IMPORTANCE: Individuals with opioid use disorder and substance use disorder have lower cervical cancer screening rates than the general population. Human papillomavirus (HPV) self-collection testing provides opportunities to expand screening access to previously unreached patient populations. OBJECTIVES: To assess the feasibility and uptake of incorporating HPV self-collection testing for cervical cancer screening into routine care for patients with opioid use disorder and substance use disorder, and to track the r…
Rank68.0
Long-Term Prospective Cohort Study of Cervical Cancer Screening Using Triage of Women Who Are Human Papillomavirus-Positive With Dual Stain and Human Papillomavirus Genotyping.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 41701950
PURPOSE: Primary human papillomavirus (HPV) testing has the best tradeoff of benefits and harms for cervical screening but requires triage to determine management among HPV positives. We conducted a prospective observational study to evaluate triage of women who are HPV-positive using dual stain (DS) and HPV genotyping. MATERIALS AND METHODS: We included 9,645 consecutive women who are HPV-positive undergoing cervical screening in two periods between 2015 and 2017 in the organized cervical screening program at Kais…
Quality Of Life61 records
Rank107.1
Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes.
European urology focus · 2026 · PMID 41519649
BACKGROUND AND OBJECTIVE: Treatment options for metastatic or recurrent penile squamous cell carcinoma (PSCC) progressing after first-line platinum-based chemotherapy are limited, and no standard subsequent-line systemic therapy exists. We systematically reviewed the efficacy, safety, and survival outcomes of second- and later-line systemic treatments in this setting. METHODS: A systematic review, compliant with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, was performed across …
Rank105.8
Transoral robotic surgery versus definitive (Chemo)radiotherapy in early HPV-positive oropharyngeal cancer: A systematic review and meta-analysis of oncologic outcomes.
Oral oncology · 2026 · PMID 41806530
INTRODUCTION: Although individual studies suggest similar oncologic outcomes between transoral robotic surgery (TORS) and definitive (chemo)radiotherapy (RT/CRT) for early-stage human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC), oncologic and functional outcomes have not been systematically synthesized. OBJECTIVE: To compare oncologic and functional outcomes of a primary surgery-based strategy versus a primary definitive RT/CRT strategy in early-stage HPV-OPSCC. METHODS: PubMed, Embase…
Rank100.3
Cost-effectiveness of cervical cancer screening among women living with HIV in India: study protocol.
BMJ open · 2026 · PMID 41617241
INTRODUCTION: Women living with HIV (WLHIV) face a higher risk of developing cervical cancer. India carries a significant burden of HIV, with an estimated 2.5 million people living with HIV in 2023. While the introduction of more effective antiretroviral therapy has improved the life expectancy of WLHIV, it has also extended the risk window for persistent human papillomavirus (HPV) infection and cervical disease progression. Cervical cancer prevention through HPV vaccination and regular screening remains the corner…
Rank100.0
Life Experiences of Women Diagnosed With Cervical Cancer in Sub-Saharan Africa: A Systematic Review of Qualitative Studies.
Psycho-oncology · 2025 · PMID 40930811
BACKGROUND: Sub-Saharan Africa (SSA) bears the highest global burden of cervical cancer. Living with the disease is a complex experience, leading to significant changes across various biopsychosocial dimensions, which in turn affect the quality of life of affected women. AIMS: This review aimed to synthesize available scientific evidence on the life experiences of women diagnosed with cervical cancer in SSA in order to generate valuable insights into the care of the affected population. METHODS: Seven electronic da…
Rank99.8
Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.
Journal of gynecologic oncology · 2026 · PMID 41834413
BACKGROUND: Gastric-type endocervical adenocarcinoma (G-EAC) is a distinctive form of adenocarcinoma that is not associated with human papillomavirus. This neoplasm exhibits a low incidence, low screening and biopsy positivity, low preoperative diagnosis, and a high susceptibility to underdiagnosis and misdiagnosis. It is associated with a poor prognosis for patients. Currently, there is an absence of a standardized postoperative adjuvant treatment plan for G-EAC, which constitutes an urgent clinical problem that d…
Rank97.1
Self-Perceived Hearing Outcomes With Radiation and Cisplatin or Radiation and Cetuximab for Patients With Human Papilloma Virus (HPV)-Positive Oropharyngeal Cancer-Results From NRG Oncology RTOG 1016.
International journal of radiation oncology, biology, physics · 2026 · PMID 40829719
PURPOSE: RTOG 1016 was a noninferiority phase III trial comparing the efficacy of radiation with either cisplatin (RT + Cis) or cetuximab (RT + Cetux) for patients with Humman Papillomavirus (HPV)+ oropharyngeal cancer (OPC). Perceived hearing handicap was included as a patient-reported outcome (PRO) secondary endpoint. The primary hypothesis was that perceived hearing handicap would be greater for patients receiving RT + Cis compared with RT + Cetux. METHODS AND MATERIALS: Perceived hearing handicap was measured a…
Rank97.0
Intralesional Interferon Alfa-2b Versus Cryotherapy for Common Warts on the Hands and Feet: A Randomized, Open-Label, Controlled Trial.
Journal of cosmetic dermatology · 2026 · PMID 41693220
OBJECTIVE: To evaluate the clinical efficacy of interferon injection therapy for common warts on the hands and feet and to analyze its associated adverse reactions. METHODS: A total of 326 patients with common warts located on the hands and feet who were treated at our hospital between January 2024 and February 2025 were enrolled. Using a block randomization method, the patients were divided into a control group (n = 163, treated with cryotherapy) and an observation group (n = 163, treated with intralesional interf…
Rank95.5
Effectiveness of acceptance and commitment therapy on sexual function in women infected with human papillomavirus: a randomized controlled trial.
The journal of sexual medicine · 2026 · PMID 42447398
BACKGROUND: Human papillomavirus (HPV) is a prevalent sexually transmitted infection that negatively affects women's psychological, social, and sexual well-being worldwide. AIM: This study aimed to evaluate the effect of group Acceptance and Commitment Therapy (ACT) counseling on sexual function in women diagnosed with HPV infection. METHODS: This single-blind randomized clinical trial was conducted on 56 women with HPV infection. Participants were randomly assigned to an intervention group (n = 28) receiving 8 ses…
Rank95.0
The Effectiveness of Motivational Interviewing on the Sexual Performance of Women With Human Papillomavirus: A Randomized Clinical Trial.
Sexually transmitted diseases · 2026 · PMID 40758983
AIM: Human papillomavirus (HPV) is a common sexually transmitted infection that often affects the reproductive system. Human papillomavirus infection can cause various cancers and clinical symptoms in women, impacting their sexual activity and quality of life. Hence, this study aimed to assess the impact of motivational interviewing on the sexual function of women with HPV. METHODS: This randomized controlled study used a pretest-posttest research design with a control group and involved 62 HPV patients from health…
Rank89.9
De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal Cancer.
JAMA network open · 2026 · PMID 42149594
IMPORTANCE: Standard adjuvant therapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) is radiation therapy 60 Gy with or without cisplatin delivered in 30 fractions during 6 weeks. A phase 3 randomized clinical trial demonstrated decreased toxic effects and improved patient-reported outcomes with de-escalated adjuvant radiation therapy (DART) compared with standard therapy; however, outcomes for patients treated in the clinical practice setting following trial adoption remain u…
Rank88.8
Effectiveness of online supportive counselling on quality of life in women with high-risk human papillomavirus in Iran: study protocol for a randomised controlled trial.
BMJ open · 2026 · PMID 41692527
INTRODUCTION: Human papillomavirus (HPV) is one of the most common sexually transmitted diseases and affects the quality of life (QoL) of individuals, necessitating interventions beyond physical treatments. The aim of this study is to determine the effectiveness of individual supportive counselling on the QoL in women with high-risk HPV. METHODS AND ANALYSIS: This randomised clinical trial will include 80 women with HPV who will be selected from 2025 to 2026 in Babol, Iran. Following selection based on inclusion cr…
Rank85.0
Technological innovations in head and neck radiotherapy: What does the future hold?
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2026 · PMID 42001737
Radiotherapy in head and neck oncology is advancing thanks to technologies that improve treatment precision, adaptation, and tolerance. The most promising approaches are discussed in this narrative review. The use of automatic segmentation through artificial intelligence (deep learning) now allows rapid delineation of organs at risk, thus reducing contouring time and the risk of errors. Several tools are already routinely used and are evaluated for replanning process. Imaging, acquired before each session, ensures …
Rank85.0
Updates on Management of Anal Cancer: A New Era Has Begun.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2026 · PMID 42208017
Squamous cell carcinoma of the anal canal (SCAC) is a rare, human papillomavirus-driven malignancy with a rising global incidence and an increasingly dynamic therapeutic landscape. This review summarizes recent advances and current evidence in the management of SCAC, with a focus on immunotherapy, systemic treatment strategies, and optimization of curative-intent approaches. For locally advanced SCAC, concurrent chemoradiotherapy with fluorouracil and mitomycin C remains the standard of care, on the basis of multip…
Rank80.0
FDG-PET-Based Selective Deescalation of Chemoradiation in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41385605
PURPOSE: We conducted a phase II multicenter clinical trial to test the hypothesis that 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)-based chemoradiation (CRT) dose deescalation would provide noninferior locoregional control compared with historical controls among patients with early-stage p16+ oropharyngeal cancer. We also hypothesized that human papillomavirus (HPV) circulating tumor DNA (ctDNA) changes during treatment predict locoregional recurrence (LRR). PATIENTS AND METHODS: Patients with st…
Rank77.7
Clinical characteristics, treatment patterns, and prognosis in vulvar cancer and vaginal cancer: a national multicenter retrospective study in China.
BMC public health · 2026 · PMID 42032499
BACKGROUND: Vulvar and vaginal cancers significantly impact women’s health and quality of life. This study analyzes the prevalence of human papillomavirus (HPV), clinicopathological characteristics, treatment patterns, and survival outcomes, to understand their relationships and better guide prevention and therapy for Chinese patients with vulvar or vaginal cancer. METHODS: We conducted a retrospective, multicenter study across nine tertiary hospitals located in seven regions of China, including patients diagnosed …
Rank73.7
Long-term predictors of recurrence in pediatric recurrent respiratory papillomatosis.
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026 · PMID 42472951
PURPOSE: To identify predictors of recurrence in pediatric recurrent respiratory papillomatosis (RRP) using a 10-year prospective cohort, evaluating traditional factors (HPV type, lesion characteristics) and novel patient- and disease-specific variables, and their association with Speech-Quality-of-Life (SQOL). METHODS: We conducted a multicenter, prospective cohort study of 740 patients (629 pediatric, 111 adult) with histologically confirmed RRP from 2014 to 2023 at five high-volume ENT centers in Pakistan. The p…
Rank71.0
Development and Psychometric Properties of the Human Papillomavirus-Know Questionnaire (HPV-Know-Q) to Assess the Knowledge of Women on HPV Infection and Related Outcomes.
The journal of obstetrics and gynaecology research · 2026 · PMID 41603215
AIM: To provide the psychometric properties of a novel patient-reported outcomes measurement (PROM), the HPV-Know-Q questionnaire, to assess the HPV-related knowledge in adult women in Spain. METHODS: After reviewing literature and interviewing women with HPV infection, instrument items and domains were developed. A draft self-administered, multiple-choice questionnaire including relevant questions about HPV infection was pilot tested for comprehension and ease of completion. Psychometric evaluation of the final HP…
Rank69.9
Concordance and acceptability of a novel human papillomavirus self-collection tool for cervical cancer screening in economically developed regions: a prospective cohort study in Shanghai, China.
Frontiers in medicine · 2026 · PMID 41868217
BACKGROUND: This study aimed to evaluate the concordance and clinical applicability of a novel cervical self-sampling device for human papillomavirus (HPV) genotyping, and to identify factors influencing women's preference for self-collection in an economically developed setting. METHODS: In this prospective paired-sample study conducted at Shanghai East Hospital (September 2024-February 2025), 276 eligible women from gynecological outpatient clinics underwent sequential cervical sampling: self-collection followed …
Rank53.2
Chemotherapy plus camrelizumab for fertility preservation (NACI-F) in FIGO stage IB1 cervical cancer: a multicenter, single-arm, phase 2 trial.
Journal of gynecologic oncology · 2026 · PMID 42172490
BACKGROUND: The increasing prevalence of cervical cancer in younger women highlights the need for personalized fertility-preserving treatment strategies. Current fertility preservation approaches for early-stage cervical cancer primarily involve cervical conization and radical trachelectomy. However, removing part or all of the cervix can negatively impact reproductive outcomes. These procedures increase the risk of preterm birth and miscarriage, and sometimes require additional surgery due to positive margins. Com…
Rank51.3
Early toxicity prediction using longitudinal cone-beam CT delta-radiomics in HPV-positive oropharyngeal cancer.
Frontiers in oncology · 2026 · PMID 42255209
INTRODUCTION: Long-term survival in human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) has shifted clinical focus toward minimizing treatment-related toxicities, particularly dysphagia, which significantly impacts quality of life. This study investigated whether longitudinal cone-beam computed tomography (CBCT)-based delta-radiomics of the supraglottic region can provide early indication of 6-12 month post-radiotherapy dysphagia. METHODS: Forty-three patients with HPV+ OPSCC treated …
Rank50.7
Mapping the Evolving Trend and Prospect of Transoral Robotic Surgery: A Bibliometric Analysis.
The Journal of craniofacial surgery · 2026 · PMID 41129207
OBJECTIVES: To conduct a comprehensive bibliometric analysis elucidating the global research landscape, collaborative networks, and evolving hotspots in transoral robotic surgery (TORS) from 2005 to 2024. MATERIALS AND METHODS: Publications related to TORS were retrieved from the Web of Science Core Collection database (2005-2024). In addition, the keyword "oropharyngeal cancer" was added to explore research hotspots. The data were primarily analyzed using bibliometric software based on publication date, country, a…
Rank50.5
Dosimetric Results for Organs at Risk From Radiation Therapy Dose De-Escalation to the Subclinical Region in Human Papillomavirus-Associated Oropharyngeal Cancer: A Propensity Score-Matched Analysis.
International journal of radiation oncology, biology, physics · 2026 · PMID 41985762
PURPOSE: The impact of radiation therapy (RT) dose de-escalation on organs at risk (OARs) for human papillomavirus-associated oropharyngeal cancer (OPC) is not known. This study retrospectively assessed OAR dosimetric outcomes of de-escalated RT for OPC. METHODS AND MATERIALS: We conducted a retrospective analysis of dosimetric data for patients with T1 to 4, N0 to 3 human papillomavirus-associated OPC treated with intensity modulated RT at a single academic institution between August, 2014 and January, 2023. All p…
Rank50.2
The effect of human genital warts virus on the quality of women's sexual life: A look at the effective factors.
Journal of education and health promotion · 2026 · PMID 42016412
BACKGROUND: The global prevalence of HPV is rising. Despite numerous studies on its effects on psychological dimensions, quality of life, and sexual performance, its impact on women's sexual quality of life (QoL) remains unclear. This study assesses the sexual QoL among women with genital HPV and the influencing factors. MATERIALS AND METHODS: A cross-sectional study was conducted on 395 women undergoing HPV testing. The data collection instrument comprised a questionnaire covering demographic characteristics, HPV-…
Rank50.0
5-ALA-PDT combined with oral Kangfuxin solution improves HR-HPV outcomes, vaginal microecology and quality of life in patients with HPV-positive cervical erosion.
American journal of translational research · 2026 · PMID 42007140
OBJECTIVE: To evaluate the efficacy, safety, and effects on related indicators of 5-aminolevulinic acid-mediated photodynamic therapy (5-ALA-PDT) combined with oral Kangfuxin liquid in patients with human papillomavirus (HPV)-positive cervical erosion. METHODS: Patients admitted retrospectively from January 2022 to December 2024 were included. A total of 314 patients were initially screened, and 32 were excluded, leaving an original cohort of 282 patients (129 in the observation group and 153 in the control group).…
Rank49.4
Effects of HPV-related psychosocial burden and general psychological health on quality of life and sexual function in women with HPV infection in the initial period after diagnosis.
BJPsych open · 2026 · PMID 41621815
BACKGROUND: Human papillomavirus (HPV) infection has a negative impact on quality of life (QoL) and sexual function, mainly owing to increased levels of anxiety and distress. AIMS: To examine the potentially moderating effects of general psychological health on the relationships between (a) HPV-related psychosocial burden and QoL and (b) HPV-related psychosocial burden and sexual function. METHOD: The HPV Impact Profile, Female Sexual Function Index, General Health Questionnaire-28 and Life Satisfaction Inventory q…
Randomized Controlled Trials61 records
Rank110.0
Human papillomavirus-based vs. cytology for cervical cancer screening: a systematic review with meta-analysis.
Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2026 · PMID 41988240
OBJECTIVE: To evaluate the performance of HPV-based testing compared to cytology in primary cervical cancer screening. STUDY SELECTION: This meta-analysis included randomized trials comparing HPV-based screening with cytology in women aged 20-69 with at least one year of follow-up. Studies with overlapping populations, combining screening methods, lacking outcomes of interest, or study protocols were excluded. CENTRAL, PubMed/MEDLINE, and Embase were searched on April 12, 2025. The main outcome is the detection rat…
Rank108.2
Efficacy and safety of photodynamic therapy for vaginal intraepithelial neoplasia: A systematic review and meta-analysis.
Photodiagnosis and photodynamic therapy · 2026 · PMID 41611005
OBJECTIVE: Vaginal Intraepithelial Neoplasia (VaIN) is a precancerous condition that can progress to vaginal cancer if untreated. Photodynamic Therapy (PDT), recognized for its minimally invasive nature and favorable side effect profile, is increasingly employed for VaIN treatment; however, comprehensive evidence synthesis on its efficacy and safety remains limited. This study aims to comprehensively evaluate the efficacy and safety of 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) in treating VaIN. …
Rank107.1
Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes.
European urology focus · 2026 · PMID 41519649
BACKGROUND AND OBJECTIVE: Treatment options for metastatic or recurrent penile squamous cell carcinoma (PSCC) progressing after first-line platinum-based chemotherapy are limited, and no standard subsequent-line systemic therapy exists. We systematically reviewed the efficacy, safety, and survival outcomes of second- and later-line systemic treatments in this setting. METHODS: A systematic review, compliant with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, was performed across …
Rank106.0
A meta-analysis of photodynamic therapy in the treatment of cervical intraepithelial neoplasia: Based on randomized controlled trials.
Photodiagnosis and photodynamic therapy · 2026 · PMID 41740824
OBJECTIVE: To systematically evaluate the efficacy and safety of photodynamic therapy (PDT) for HPV-infected cervical intraepithelial neoplasia (CIN) based on randomized controlled trials (RCTs). METHODS: A systematic search was performed across PubMed, EMBASE, Web of Science, and the Cochrane Library from 2000 to 2025, targeting RCTs that compared PDT with standard conization methods or placebo. The primary outcomes assessed included histopathological response, human papillomavirus (HPV) clearance, and the rate of…
Rank105.8
Transoral robotic surgery versus definitive (Chemo)radiotherapy in early HPV-positive oropharyngeal cancer: A systematic review and meta-analysis of oncologic outcomes.
Oral oncology · 2026 · PMID 41806530
INTRODUCTION: Although individual studies suggest similar oncologic outcomes between transoral robotic surgery (TORS) and definitive (chemo)radiotherapy (RT/CRT) for early-stage human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC), oncologic and functional outcomes have not been systematically synthesized. OBJECTIVE: To compare oncologic and functional outcomes of a primary surgery-based strategy versus a primary definitive RT/CRT strategy in early-stage HPV-OPSCC. METHODS: PubMed, Embase…
Rank105.1
Surgical and Voice Outcomes of Office-Based Recurrent Respiratory Papillomatosis Surgery: A Systematic Review.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026 · PMID 41848235
OBJECTIVE: To investigate the surgical and voice outcomes associated with office-based laryngeal surgery for the treatment of recurrent respiratory papillomatosis (RRP). DATA SOURCES: PubMed, Google Scholar, and Cochrane databases. REVIEW METHODS: Two independent investigators search databases for studies reporting surgical or voice quality outcomes of patients treated with office-based surgery for RRP according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Primary o…
Rank102.0
Efficacy and safety of superficial radiotherapy in the treatment of cutaneous warts: A meta-analysis.
The Journal of international medical research · 2026 · PMID 42333510
ObjectiveTo systematically evaluate clinical evidence concerning the efficacy and safety of superficial radiotherapy in the treatment of cutaneous warts.MethodsEight major international clinical literature databases were queried according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for superficial radiotherapy studies published prior to 9 August 2025. Randomized controlled trials, prospective/retrospective controlled studies, and case series with sample sizes ≥10 we…
Rank100.6
Comparison of three different hpv self-sampling tools - a subanalysis of the prospective, randomized hannover self-collection study.
Archives of gynecology and obstetrics · 2026 · PMID 42347973
OBJECTIVE: Cervical cancer and its precursor lesions are treatable if detected early; however, screening participation for high-risk human papillomavirus infections (hr-HPV) remains low. In 2021, Germany recorded 4,544 new cervical cancer cases and 2,071 related deaths. The HaSCo study evaluates the feasibility of HPV self-testing to improve screening participation. This sub-study evaluates performance and acceptability of three self-testing tools. METHODS: This prospective, randomized sub-study examined Evalyn-Bru…
Rank100.4
Immunogenicity and safety of co-administered Escherichia coli-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine.
Frontiers in immunology · 2026 · PMID 42292449
BACKGROUND: Human papillomavirus (HPV) and Hepatitis E virus (HEV) infections are major health concerns for women of reproductive age. Administration of HPV and HEV vaccines serves as primary prevention strategies. Our study aimed to demonstrate the immunogenicity and safety of co-administering Escherichia coli-produced bivalent HPV-16/18 vaccine and HEV vaccine compared to HPV-alone/HEV-alone. METHODS: This randomized, multicenter, open-label trial was conducted at 4 clinical study sites in Zhejiang Province, Chin…
Rank100.0
Efficacy of topical treatments for high-risk human papillomavirus in preventing CIN II+ lesions: a systematic review.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026 · PMID 41951281
OBJECTIVE: This study aimed to systematically review the literature regarding topical therapies for reducing the risk of cervical intra-epithelial neoplasia (CIN) grade 2 or higher (CIN II+) lesions among women with high-risk human papillomavirus (HPV) infection and histologically confirmed CIN I or either no cervical lesions. METHODS: We conducted a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and registered the protocol in PROSPERO (CRD4202…
Rank100.0
Oncologic, functional, and economic outcomes of transoral robotic surgery for HPV-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of pathology and treatment strategies.
Journal of robotic surgery · 2026 · PMID 42162526
The incidence of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) has increased substantially. Transoral robotic surgery (TORS) provides detailed pathological assessment that may support risk-adapted treatment strategies; however, integrated evidence on oncologic, functional, and economic outcomes remains limited. To systematically evaluate oncologic, functional, and economic outcomes of TORS-based treatment strategies in patients with HPV-positive OPSCC. A systematic review and met…
Rank99.8
Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.
Journal of gynecologic oncology · 2026 · PMID 41834413
BACKGROUND: Gastric-type endocervical adenocarcinoma (G-EAC) is a distinctive form of adenocarcinoma that is not associated with human papillomavirus. This neoplasm exhibits a low incidence, low screening and biopsy positivity, low preoperative diagnosis, and a high susceptibility to underdiagnosis and misdiagnosis. It is associated with a poor prognosis for patients. Currently, there is an absence of a standardized postoperative adjuvant treatment plan for G-EAC, which constitutes an urgent clinical problem that d…
Rank98.9
An implementation study of text invitation, mailed at-home human papillomavirus (HPV) self-testing and telehealth management in Aotearoa New Zealand, with a nested randomised controlled trial that compared offering an incentive vs. no offer with a repeat test kit.
BMC public health · 2026 · PMID 42120989
INTRODUCTION: In Aotearoa New Zealand, human papillomavirus (HPV) self-testing was introduced simultaneously with HPV primary screening in September 2023 to improve access and reduce inequities for priority populations, including Indigenous Māori, Pacific and under-screened people. To contribute policy-relevant information, we implemented non-standard engagement and screening strategies, including text message invitation, mailed test kits, at-home self-testing, telehealth support and follow-up by a central nurse-le…
Rank98.6
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 41570275
PURPOSE: Patients with human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) and advanced stage and/or significant smoking history are at higher risk of relapse. Induction immunotherapy before chemoradiation (CRT) may improve outcomes. This randomized phase II trial assessed the feasibility and safety of induction nivolumab before CRT in this high-risk population. METHODS: Eligible patients had HPV-positive OPC with either T4 and/or N2/N3 disease or a smoking history >10 pack-years. Patients were randomly …
Rank98.5
Immunogenicity and safety of a quadrivalent recombinant human papillomavirus vaccine (type 6/11/16/18) (Hansenula polymorpha): A randomized controlled phase 2 non-inferiority clinical trial.
Vaccine · 2026 · PMID 41932289
OBJECTIVE: The randomized, double-blind, placebo-controlled Phase II non-inferiority clinical study aimed to evaluate the immunogenicity and safety of the quadrivalent recombinant human papillomavirus vaccine (type 6/11/16/18) (Hansenula polymorpha) in healthy females aged 9-45 years. METHODS: A total of 1800 participants were randomly assigned to the vaccine group and the placebo group in a 2:1 ratio. The immunobridging between the 9-17 and 18-45 age groups adopts a non-inferiority design with a non-inferiority ma…
Rank98.2
Large Language Model Chatbot Conversations vs Public Health Materials and Parental HPV Vaccination Intentions: A Randomized Clinical Trial.
JAMA network open · 2026 · PMID 42258213
IMPORTANCE: Health care systems are increasingly considering large language model (LLM)-based chatbots for vaccine communication, but evidence that they improve durable, behaviorally relevant outcomes beyond existing health materials is limited. OBJECTIVES: To examine whether brief, multiturn interactions with an LLM chatbot increase parental intention to vaccinate children against human papillomavirus (HPV) compared with no intervention and government public health materials and to assess whether any effects persi…
Rank98.0
[Role of human papillomavirus vaccination in prevention of oropharyngeal cancer and recommendations for patients and relatives].
HNO · 2026 · PMID 41565797
BACKGROUND: The incidence of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing worldwide, particularly among younger men without classical risk factors. High-risk HPV types are the primary cause. Prophylactic vaccines offer the first effective means of primary prevention, with efficacy demonstrated primarily through the reduction in oropharyngeal HPV infections. OBJECTIVE: This article aims to present the current evidence on HPV vaccination for prevention of OPSCC, in…
Rank97.9
Efficacy and Safety of PHPV Fusion Factor Vaginal Gel (PHPV®) in Clearing Cervical Persistent High-Risk Human Papillomavirus Infection: A Randomized Controlled Clinical Trial.
Drug design, development and therapy · 2026 · PMID 41868183
PURPOSE: To evaluate the efficacy and safety of PHPV in the treatment of persistent high-risk papillomavirus (hrHPV) infection of the cervix. PATIENTS AND METHODS: A randomized controlled trial (RCT) was conducted on patients with persistent hrHPV infection which were randomly assigned in three groups: PHPV, interferon and control. All participants were followed up at baseline, 3 months and 6 months after enrollment. The primary outcome was hrHPV clearance at 6 months post-enrollment. Secondary outcomes included ef…
Rank97.7
Genotype distribution of human papillomavirus (HPV) types in oral gargle specimens among men living with HIV in Mexico, Brazil, and Puerto Rico: A cross-sectional study.
The Journal of infection · 2026 · PMID 42070588
OBJECTIVES: Assess the distribution of oral HPV genotypes and examine their associations with age and HIV-related factors among men living with HIV. METHODS: This cross-sectional study analyzed baseline data from a randomized, double-blinded, placebo-controlled Phase III trial ('ULACNet-201'; NCT04255849) assessing the 9vHPV vaccine's efficacy in PLWH. Participants included men aged 20-50 years from Brazil, Mexico, and Puerto Rico, on antiretroviral therapy for ≥6 months. Oral HPV genotypes were assessed using the …
Rank97.6
Effect of Self-Sampling HPV DNA Testing on Cervical Cancer Screening in Singapore's Primary Care: Pragmatic Randomized Controlled Trial.
Annals of family medicine · 2026 · PMID 42509175
BACKGROUND: In Singapore, cervical cancer screening rates remain suboptimal, with only clinician sampling included in the national screening program. Self-sampling human papillomavirus (HPV) DNA testing might overcome barriers to clinician-based screening and improve uptake. We assessed the effect of offering self-sampling alongside clinician sampling on screening uptake and high-risk HPV detection compared with clinician sampling alone. METHODS: This pragmatic, 2-arm randomized controlled trial with Zelen design w…
Rank97.6
Efficacy and safety of a topical nitric oxide-releasing solution (NORS) as a noninvasive treatment for plantar warts (verrucae plantaris).
The Journal of dermatological treatment · 2026 · PMID 41493215
BACKGROUND: Plantar warts (verrucae plantaris), caused by human papillomavirus, are common and often resistant to standard therapies, which can be painful and damaging. Novel, noninvasive options are needed. OBJECTIVE: To evaluate the safety and preliminary efficacy of a topical nitric oxide-releasing solution (NORS) as a self-administered therapy for plantar warts. METHODS: In this Phase 2a, multicenter, randomized, double-blind, placebo-controlled trial, 20 participants with ≥3 plantar warts were randomized (1:1:…
Rank97.0
HPVoice: a single-blind three-arm RCT on social media communication strategies among adolescents in Tuscany, Italy.
Vaccine · 2026 · PMID 41855647
INTRODUCTION: Cervical cancer is the first cancer potentially eliminable through widespread HPV vaccination. In Italy, despite free access, vaccine coverage among adolescents remains low. Psychological factors such as information avoidance (IA), the tendency to ignore threatening information, can influence vaccine decisions and contribute to vaccine hesitancy (VH). While social media offers new avenues for health communication, their effectiveness in reducing VH is uncertain. This study investigates the impact of I…
Rank97.0
Vaginal microbiota transplantation for treatment of vaginal dysbiosis without the use of antibiotics: a double-blind, randomised controlled trial in women with vaginal dysbiosis.
The Lancet. Microbe · 2026 · PMID 41905375
BACKGROUND: A vaginal microbiota dominated by Lactobacillus species is associated with reduced risk of infection and adverse reproductive outcomes. Effective interventions to restore healthy microbiota remain scarce. In this study, we aimed to assess the efficacy of vaginal microbiota transplants (VMTs) without antibiotic pretreatment in achieving conversion to a Lactobacillus-dominated vaginal microbiome. METHODS: This single-centre, double-blind, randomised controlled trial was done at Copenhagen University Hospi…
Rank96.5
Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): A randomized, double-blind, placebo-controlled trial.
International journal of cancer · 2026 · PMID 41685810
The nonavalent human papillomavirus (9vHPV) vaccine protects against HPV infection and high-grade squamous intraepithelial lesions (HSIL) when administered prior to exposure, but evidence supporting its potential therapeutic benefit has been inconsistent. This randomized, double-blind, placebo-controlled trial evaluated whether the 9vHPV vaccine reduces recurrence of HSIL or HPV persistence in 27-69-year-old persons previously treated for anal or vulvar HSIL. Participants were HSIL-free at enrollment and received 9…
Rank96.5
Test results and follow-up care stemming from an ED-based cervical cancer intervention.
The American journal of emergency medicine · 2026 · PMID 41579525
BACKGROUND: More than 4300 lives are lost to cervical cancer in the US annually. The survival rate is nearly 100% when precancerous lesions are identified and acted upon appropriately. A randomized controlled trial of two Emergency Department-based (ED) cervical cancer screening interventions demonstrated that patients in each condition received screening at rates far above an untreated historical control group. While screening represents a necessary first step in preventing cervical cancer morbidity and mortality,…
Safety And Adverse Effects64 records
Rank107.1
Efficacy and safety of 5-aminolevulinic acid photodynamic therapy for cervical squamous intraepithelial lesion: a systematic review and meta-analysis.
Lasers in medical science · 2026 · PMID 42470528
To evaluate the efficacy and safety of 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) for cervical squamous intraepithelial lesion (SIL). We systematically searched PubMed and other databases to compare the effectiveness of 5-ALA PDT with observation, ablation, and conization. Outcomes included overall response rate (ORR), complete remission (CR) rate, HPV clearance rate, and other relevant endpoints. Single-arm analyses were additionally performed by lesion grade. A total of 3,354 patients were included ac…
Rank107.1
Subsequent-line Systemic Therapy for Metastatic or Recurrent Penile Cancer: A Systematic Review of Efficacy, Toxicity, and Outcomes.
European urology focus · 2026 · PMID 41519649
BACKGROUND AND OBJECTIVE: Treatment options for metastatic or recurrent penile squamous cell carcinoma (PSCC) progressing after first-line platinum-based chemotherapy are limited, and no standard subsequent-line systemic therapy exists. We systematically reviewed the efficacy, safety, and survival outcomes of second- and later-line systemic treatments in this setting. METHODS: A systematic review, compliant with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, was performed across …
Rank106.4
De-Escalation Treatment Strategies in HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An Umbrella Review of Systematic Reviews and Meta-Analyses.
Head & neck · 2026 · PMID 42230323
BACKGROUND: De-escalation strategies for human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) aim to reduce late morbidity while preserving cure rates, but evidence syntheses provide inconsistent conclusions and may be affected by overlap of primary studies. METHODS: We performed an umbrella review of systematic reviews (SRs) and meta-analyses (MAs) evaluating de-escalation approaches versus standard-of-care therapy in HPV-positive (or p16-positive) OPSCC. MEDLINE (PubMed), Embase, and …
Rank103.0
Efficacy of focused ultrasound for HPV clearance and cervical LSIL treatment: a meta-analysis.
Scientific reports · 2026 · PMID 41904252
Persistent high-risk human papillomavirus (hrHPV) infection is a major risk factor for high-grade squamous intraepithelial lesions (HSIL) and cervical cancer. Although HPV vaccines effectively prevent infections with vaccine-covered HPV types, they do not eliminate established infections. Additionally, not all HPV types associated with cervical cancer are covered by the vaccine. Therefore, treatment strategies for HPV-related cervical lesions remain an important clinical challenge. A systematic search was conducted…
Rank100.0
Serious adverse events following human papillomavirus vaccination: A systematic review and meta-analysis of post-marketing evidence.
Human vaccines & immunotherapeutics · 2026 · PMID 41759030
Human papillomavirus (HPV) vaccines are a critical tool in cancer prevention, yet concerns about serious adverse events (SAEs) have fueled public hesitancy and constrained vaccination uptake. This systematic review aimed to determine the proportion of adverse events that were SAEs, rate of SAEs following HPV vaccination and their association from post-marketing observational studies. We conducted a search in PubMed, EMBASE, and Web of Science databases in March 2025. Studies published in English reporting SAEs afte…
Rank100.0
Intralesional human papillomavirus vaccination for cutaneous verrucae: a systematic review and meta-analysis of therapeutic efficacy.
The Journal of dermatological treatment · 2026 · PMID 42370553
OBJECTIVES: To evaluate the efficacy of intralesional human papillomavirus (HPV) vaccination in the management of cutaneous warts. METHODS: A comprehensive search of PubMed, MEDLINE, Embase, Scopus, and ClinicalTrials.gov was conducted in accordance with a registered PROSPERO protocol (CRD420251170324). Chronic or persistent warts were defined as lesions lasting more than six months or showing inadequate response to conventional therapies. The primary outcome was complete wart clearance, and pooled risk ratios (RRs…
Rank99.8
Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.
Journal of gynecologic oncology · 2026 · PMID 41834413
BACKGROUND: Gastric-type endocervical adenocarcinoma (G-EAC) is a distinctive form of adenocarcinoma that is not associated with human papillomavirus. This neoplasm exhibits a low incidence, low screening and biopsy positivity, low preoperative diagnosis, and a high susceptibility to underdiagnosis and misdiagnosis. It is associated with a poor prognosis for patients. Currently, there is an absence of a standardized postoperative adjuvant treatment plan for G-EAC, which constitutes an urgent clinical problem that d…
Rank97.6
Efficacy and safety of a topical nitric oxide-releasing solution (NORS) as a noninvasive treatment for plantar warts (verrucae plantaris).
The Journal of dermatological treatment · 2026 · PMID 41493215
BACKGROUND: Plantar warts (verrucae plantaris), caused by human papillomavirus, are common and often resistant to standard therapies, which can be painful and damaging. Novel, noninvasive options are needed. OBJECTIVE: To evaluate the safety and preliminary efficacy of a topical nitric oxide-releasing solution (NORS) as a self-administered therapy for plantar warts. METHODS: In this Phase 2a, multicenter, randomized, double-blind, placebo-controlled trial, 20 participants with ≥3 plantar warts were randomized (1:1:…
Rank96.0
Sensorineural hearing outcomes in HPV-positive oropharyngeal cancer: a secondary analysis of the TROG 12.01 randomized trial (SHOUT).
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42034301
PURPOSE: Cisplatin-associated deterioration in sensorineural hearing thresholds is an important survivorship concern in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). Weekly low-dose cisplatin may reduce ototoxicity compared with high-dose schedules, but randomized audiometric data are limited. This secondary analysis of TROG 12.01 compared hearing outcomes between weekly cisplatin + radiotherapy (RT) and cetuximab + RT. METHODS: Audiometric data were available for 101 TROG 12.01 trial participants. Pa…
Rank95.9
Efficacy of live lactobacillus preparations in treating cervical inflammation and clearing viral infections in patients with HPV infection complicated by bacterial vaginosis.
African journal of reproductive health · 2026 · PMID 42454452
This study aimed to evaluate the efficacy and safety of Dingjunsheng, a live Lactobacillus preparation, as adjuvant therapy in patients with human papillomavirus (HPV) infection complicated by bacterial vaginosis (BV). A retrospective analysis was conducted on 152 eligible patients, randomly divided into two groups: the observation group (n=87) receiving standard BV antibacterial therapy plus Dingjunsheng, and the control group (n=65) who received standard BV antibacterial therapy alone. The patients were followed …
Rank95.7
A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026 · PMID 41403292
BACKGROUND: The clearance of high-risk oncogenic human papillomaviruses (hrHPV) and related cervical lesions is associated with the development of a robust T-cell response. Therapeutic vaccination that induces HPV antigen-specific T cells is a promising approach. METHOD: A 2-vector dosing strategy using Chimpanzee Adenovirus Oxford 1-HPV and Modified Vaccinia virus Ankara-HPV, both encoding the same multiantigen HPV cassette was given on a 0/28-day schedule to participants with persistent cervical hrHPV and a histo…
Rank92.3
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial.
The Lancet. Infectious diseases · 2026 · PMID 42379209
BACKGROUND: Cecolin, a bivalent human papillomavirus (2vHPV) vaccine produced with Escherichia coli, has demonstrated safety and efficacy and is now widely used globally. We aimed to report the efficacy, safety, and immunogenicity profile of the nine-valent (9vHPV) vaccine, Cecolin 9. METHODS: We conducted a multicentre, double-blind, randomised, controlled, phase 3 trial at five local health centres in the Jiangsu and Sichuan provinces in China. Eligible participants were healthy, non-pregnant women aged 18-45 yea…
Rank92.0
Assessment and Comparison of Efficacy and Safety of Monotherapy With Topical 50% Urea Cream and Combination Therapy With Topical 50% Urea Cream and Carboxytherapy in Treatment of Recalcitrant Common Wart: A Randomized, Single-Blinded, 2-Split Clinical Trial.
Journal of medical virology · 2026 · PMID 42541394
The treatment of common warts can occasionally be a challenge in recalcitrant cases, either recurrent ones or non-responders to treatment. In the current study, the efficacy and safety of monotherapy with topical 50% urea cream and combination therapy with topical 50% urea cream and carboxytherapy were assessed and compared in the treatment of recalcitrant common wart. Twenty subjects with recalcitrant common warts in the extremities (excluding the plantar surface) were selected. For the lesions of one side of the …
Rank91.5
Loop electrosurgical excision procedure and perinatal outcomes post-human papillomavirus cervical screening: A longitudinal cohort study.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026 · PMID 41709079
OBJECTIVE: This study examines the associations between the loop electrosurgical excision procedure (LEEP) and the risk of adverse perinatal outcomes among women who have undergone primary human papillomavirus (HPV) screening. METHODS: In this longitudinal cohort study, women who received HPV screening and were followed up in a randomized trial in British Columbia (BC), Canada, were linked to a province-wide perinatal registry; those with a singleton live birth after screening (index birth) were included (N = 1765)…
Rank90.7
Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial.
Vaccine · 2026 · PMID 42424856
OBJECTIVE: Papilloguard® is developed by Nivad Pharmed Salamat as a quadrivalent human papillomavirus (HPV) vaccine, uniquely combined with the adjuvant system 04 (AS04). The objective of this study was to evaluate the immunogenicity and safety of the quadrivalent Papilloguard® in comparison with Gardasil® (Merck). METHODS: This study enrolled 670 healthy participants aged 15-25 years. Vaccines were administered at Months 0, 2, and 6. Immunogenicity was assessed by geometric mean concentrations of HPV-specific anti…
Rank89.8
Barriers to cervical cancer screening and experiences using mailed at-home HPV self-collection kits among US and foreign-born Hispanic women in a safety net health system.
Gynecologic oncology · 2026 · PMID 42468446
OBJECTIVE: Mailed self-collection for human papillomavirus (HPV) testing can increase cervical cancer screening among underscreened women, though barriers differ by subgroup. Hispanic/Latina women, especially foreign-born, have lower screening rates than non-Hispanic white women. This study compared barriers to Papanicolaou (Pap) screening and experiences with mailed HPV self-collection among underscreened foreign-born Hispanic, US-born Hispanic, and US-born non-Hispanic women in a safety-net health system. METHODS…
Rank89.8
Topical trichloroacetic acid versus electrocautery for treatment of anal intraepithelial neoplasia in people living with HIV: a multicentre, randomised, non-inferiority trial (TECAIN-study).
Infection · 2026 · PMID 42430115
PURPOSE: To compare efficacy and safety of topical trichloroacetic acid (TCA) versus electrocautery (ECA) for the treatment of human papillomavirus (HPV)-associated anal intraepithelial neoplasia (AIN) in people living with HIV (PLWH). METHODS: The TECAIN-study was a prospective, multicentre, randomised (1:1 block-randomisation), open-label, non-inferiority trial in PLWH with histologically confirmed AIN recruited from seven German proctological units. The primary endpoint (PE) was therapeutic success defined as a …
Rank85.0
Evaluation of the ESMO-magnitude of clinical benefit scale version 2.0 for the definitive treatment of HPV positive oropharynx cancer with radiation therapy.
Oral oncology · 2026 · PMID 42229021
BACKGROUND: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated tool for assessing the clinical benefit of systemic cancer therapies. However, application of the scale to radiotherapy (RT) remains limited. As part of an ongoing initiative to adapt the scale for RT, we applied Form 1a of ESMO-MCBS v2.0 to studies cited in the American Society for Radiation Oncology (ASTRO) guideline for Human Papillomavirus (HPV)-positive oropharyngeal cancer (OPC) to assess feasi…
Rank73.0
Different Pattern of Treatment Failure After Chemoradiation Between p16+ and p16- Patients Affected by Oropharyngeal Carcinoma.
Head & neck · 2026 · PMID 41786623
BACKGROUND: Oropharyngeal cancer (OPC) exhibits distinct clinical behaviors according to HPV/p16 status and smoking exposure. While HPV-positive OPC generally shows superior survival, differences in recurrence patterns remain unclear. METHODS: A retrospective multicenter analysis of 674 AJCC VII edition Stage III-IVa/b OPC patients treated with definitive IMRT ± systemic therapy was conducted across 14 Southern European centers. Recurrence patterns, disease-free survival (DFS), overall survival (OS), and survival a…
Rank72.0
Monitoring the safety of the adjuvanted human papillomavirus vaccine HPV-16/18-AS04 in association with pregnancy and potential immune-related diseases in China: A retrospective observational cohort study.
Human vaccines & immunotherapeutics · 2026 · PMID 42348585
Human papillomavirus (HPV) infection causes cervical cancer. The objective of the study is to monitor AS04-adjuvanted HPV-16/18 vaccine (Cervarix, GSK) safety in a real-world setting in China, using electronic health records from the Yinzhou Regional Health Information Platform (YRHIP). This retrospective observational cohort study included all permanent residents (males and females) aged 9-45 y with ≥12 months continuous YRHIP registration between 1 January 2010 and 31 December 2020. The study analyzed demographic…
Rank60.0
Female allogeneic hematopoietic cell transplant survivors' perspectives on cervical cancer screening: a retrospective study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42527718
PURPOSE: Female allogeneic hematopoietic cell transplantation (AlloHCT) survivors are at increased risk for human papillomavirus (HPV)-related malignancies due to immunosuppression. Guidelines recommend annual cervical cancer screening for AlloHCT survivors with a cervix aged 21-65. This study explored cervical cancer screening knowledge, behaviors, attitudes, experiences, and preferences-specifically provider-collected versus self-collected methods-and identified adherence barriers and facilitators. METHODS: We co…
Rank54.6
Pharmacovigilance signal detection of central nervous system demyelinating diseases following human papillomavirus vaccination: data mining and signal analysis based on the VAERS database.
Naunyn-Schmiedeberg's archives of pharmacology · 2026 · PMID 42118156
The HPV vaccine, as a key tool for the prevention of cervical cancer and related diseases, has shown a rising trend in its vaccination rate year after year. Along with the increase in its vaccination rate, the related adverse events have also received widespread attention. This study employs real-world data to identify potential reporting signals between HPV vaccination and central nervous system demyelinating diseases using rigorous data analysis. This study is based on the HPV vaccination data of the US Vaccine A…
Rank52.8
Beyond dietary habits: ultra-processed food consumption reveals the association with HPV infection in U.S. women.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2026 · PMID 42059104
PURPOSE: Persistent high-risk human papillomavirus (HR-HPV) infection is a major cause of cervical cancer, yet the association between ultra-processed food (UPF) intake and HPV infection remains unclear. METHODS: We analysed 7,555 women aged 18-59 years from NHANES 2003-2016. UPF intake was estimated from 24-hour dietary recalls and expressed as a percentage of total energy using the NOVA classification. HPV status was determined by genotyping self-collected vaginal swabs. Weighted logistic regression, restricted c…
Rank52.5
Optimizing adjuvant therapy selection with machine learning after transoral surgery in HPV-related oropharyngeal cancer.
Oral oncology · 2026 · PMID 42167036
BACKGROUND: De-escalation after transoral surgery (TOS) for HPV-related oropharyngeal squamous cell carcinoma (OPSCC) requires accurate risk stratification to identify patients who can safely omit adjuvant therapy without compromising survival. We evaluated whether machine-learning (ML) survival models improve postoperative risk grouping and guide adjuvant treatment selection. METHODS: Using the National Cancer Database cohort of HPV-positive OPSCC treated with TOS (N = 5,569), we trained three survival ML models (…
Rank51.1
Determinants of HPV vaccination decision-making among South Asian mothers for their adolescent daughters in Hong Kong: A mixed methods study.
Asia-Pacific journal of oncology nursing · 2026 · PMID 41808776
OBJECTIVE: Human papillomavirus (HPV) vaccines are effective preventive measures against HPV-related diseases. Mothers play an important role in HPV vaccination decision-making for their daughters. Ethnic inequality in HPV vaccination uptake is a global problem and is expected to affect the South Asian (SA) ethnic population in Hong Kong. This study explored the factors influencing SA mothers' behaviour regarding HPV vaccination for their daughters. METHODS: This study used a convergent parallel mixed methods desig…
Treatments That Failed Clinical Trials61 records
Rank99.9
Design and initial findings of a natural history study of anal HPV and associated lesions among young adult women in Costa Rica.
International journal of cancer · 2025 · PMID 40815549
Anal cancer is caused by HPV, and its incidence has increased globally over the last five decades. We conducted an anal HPV natural history study nested in the Costa Rica HPV Vaccine Trial (CVT) to quantitatively describe the natural history and clinical outcomes of anal HPV in HIV-negative women. CVT was a randomized clinical trial of the bivalent HPV vaccine, and an anal substudy included women selected based on a priori criteria to enrich for anal disease. For women in the anal substudy, anal samples were collec…
Rank99.8
Ripple effect of temporary self-sampling HPV test on screening uptake in the next round: A secondary analysis of the ACCESS randomized controlled trial.
Journal of medical screening · 2026 · PMID 40567147
The self-sampling human papillomavirus (HPV) test improves participation in cervical cancer screening. However, the ripple effect of this test on participation in the next screening round has not yet been examined. This study, a secondary analysis of the Accelerating Cervical Cancer Elimination by Self-Sampling test (ACCESS) trial, aims to clarify this effect. Women who had not participated in the cervical cancer screening program of Ichihara City for 3 years or more were included. The participants were randomly as…
Rank99.7
Evaluation of primary HPV-based cervical screening among older women: Long-term follow-up of a randomized healthcare policy trial in Sweden.
PLoS medicine · 2024 · PMID 39700313
BACKGROUND: Evidence on invasive cervical cancer prevention among older women is limited, especially with the introduction of human papillomavirus (HPV)-based screening and longer interval. We conducted a long-term follow-up of the first phase of a randomized healthcare policy trial in cervical screening, targeting women aged 56 to 61 years old, to investigate the effectiveness of primary HPV-based screening in preventing invasive cervical cancer (ICC) and the safety of extending screening interval. METHODS AND FIN…
Rank99.5
Randomized Controlled Trial of Impact of Mobile Health Technologies on Human Papillomavirus Vaccination Uptake in Mothers of Vaccine-Eligible Girls in Lagos, Nigeria (mHealth-HPVac).
JCO global oncology · 2025 · PMID 40924973
PURPOSE: Expanding high-risk human papillomavirus (HPV) vaccine coverage in resource-constrained settings is critical to bridging the cervical cancer gap and achieving the global action plan for elimination. Mobile health (mHealth) technology via short message services (SMS) has the potential to improve HPV vaccination uptake. The mHealth-HPVac study evaluated the effectiveness of mHealth interventions in increasing HPV vaccine uptake among mothers of unvaccinated girls aged 9-14 years in Lagos, Nigeria. METHODS: A…
Rank98.7
The importance of spontaneous thought in the willingness to receive the human papillomavirus vaccine.
Vaccine · 2025 · PMID 40712321
After briefly suspending the 2-valent human papillomavirus (HPV) vaccine in 2013, Japan's Ministry of Health, Labour, and Welfare (MHLW) reinstated the recommendation that people receive the newly approved and updated 9-valent HPV vaccine in 2022. We investigated the influence of anticipated regret (AR) and spontaneous thought on individuals' willingness to receive the HPV vaccine, as the 2013 controversy over the HPV vaccine's side effects could lead to public distrust, impeding vaccination coverage despite govern…
Rank98.6
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 41570275
PURPOSE: Patients with human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) and advanced stage and/or significant smoking history are at higher risk of relapse. Induction immunotherapy before chemoradiation (CRT) may improve outcomes. This randomized phase II trial assessed the feasibility and safety of induction nivolumab before CRT in this high-risk population. METHODS: Eligible patients had HPV-positive OPC with either T4 and/or N2/N3 disease or a smoking history >10 pack-years. Patients were randomly …
Rank97.7
Genotype distribution of human papillomavirus (HPV) types in oral gargle specimens among men living with HIV in Mexico, Brazil, and Puerto Rico: A cross-sectional study.
The Journal of infection · 2026 · PMID 42070588
OBJECTIVES: Assess the distribution of oral HPV genotypes and examine their associations with age and HIV-related factors among men living with HIV. METHODS: This cross-sectional study analyzed baseline data from a randomized, double-blinded, placebo-controlled Phase III trial ('ULACNet-201'; NCT04255849) assessing the 9vHPV vaccine's efficacy in PLWH. Participants included men aged 20-50 years from Brazil, Mexico, and Puerto Rico, on antiretroviral therapy for ≥6 months. Oral HPV genotypes were assessed using the …
Rank97.7
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · PMID 39841939
PURPOSE: Radiotherapy (RT)/cetuximab (C) demonstrated superiority over RT alone for locally advanced squamous head and neck cancer. We tested this in completely resected, intermediate-risk cancer. METHODS: Patients had squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity, oropharynx, or larynx, with one or more risk factors warranting postoperative RT. Patients were randomly assigned 1:1 to intensity-modulated RT (60-66 Gy) with once-per-week C or RT alone. The primary hypothesis was that RT + C …
Rank97.5
The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial.
Cancer research communications · 2026 · PMID 41790036
PURPOSE: NRG/RTOG 1016 was a phase III noninferiority trial comparing IMRT + cisplatin versus IMRT + cetuximab for human papillomavirus-positive oropharyngeal squamous cell cancer (HPV+ OPSCC). A germline mutation (the KRAS-variant) previously identified patients with improved outcomes to radiation + cetuximab + cisplatin; thus, we investigated whether there may be similar benefits for IMRT + cetuximab. PATIENTS AND METHODS: 562 patients were tested, with 16% positive for the KRAS-variant. Clinical endpoints were p…
Rank97.3
A multicentre pragmatic randomized controlled trial comparing 50% salicylic acid, liquid nitrogen, 5% 5-fluorouracil cream, and 5% imiquimod cream in previously treated plantar warts. The VRAIE (VeRrues plAntaIres en villE) study.
Annales de dermatologie et de venereologie · 2025 · PMID 40743833
BACKGROUND: Plantar warts are common among the general population. After failure of first-line treatment, they are challenging to treat. OBJECTIVES: To compare 4 second-line treatments - 50 % salicylic acid ointment (SA) under occlusion, liquid nitrogen, 5 % 5-fluorouracil (5-FU) cream under occlusion, and 5 % imiquimod cream - in terms of complete remission after 90 days. METHODS: A multicentre, pragmatic, randomized, controlled trial. Screened patients with plantar warts were initially treated with a 5-week regim…
Rank97.2
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
JAMA · 2025 · PMID 40079944
IMPORTANCE: Treating locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) involves any combination of surgery, radiation, and chemotherapy, followed by routine monitoring for local recurrence or distant metastases. Given the poor patient outcomes, a significant unmet clinical need for improved treatment options remains. OBJECTIVE: To evaluate efficacy and safety of maintenance atezolizumab in patients with LA SCCHN at high risk of disease progression after multimodal definitive treatment. DESIGN…
Rank97.2
A prospective study of vaginal topical pretreatment of compound sea-buckthorn oil suppository in postmenopausal women prior to colposcopy.
Scientific reports · 2025 · PMID 40133564
Postmenopausal women are faced with difficulties in colposcopy, such as easy bleeding from epithelial atrophy, and thinning, atypical colposcopy images, unsatisfactory exposure, and decreased sensitivity of colposcopy. We aimed to improve the sensitivity and satisfaction of colposcopy in postmenopausal women and to evaluate the clinical efficacy of compound sea-buckthorn oil suppository on topical vaginal pretreatment in postmenopausal women prior to colposcopy. Postmenopausal patients who underwent colposcopy in t…
Rank97.1
Self-Perceived Hearing Outcomes With Radiation and Cisplatin or Radiation and Cetuximab for Patients With Human Papilloma Virus (HPV)-Positive Oropharyngeal Cancer-Results From NRG Oncology RTOG 1016.
International journal of radiation oncology, biology, physics · 2026 · PMID 40829719
PURPOSE: RTOG 1016 was a noninferiority phase III trial comparing the efficacy of radiation with either cisplatin (RT + Cis) or cetuximab (RT + Cetux) for patients with Humman Papillomavirus (HPV)+ oropharyngeal cancer (OPC). Perceived hearing handicap was included as a patient-reported outcome (PRO) secondary endpoint. The primary hypothesis was that perceived hearing handicap would be greater for patients receiving RT + Cis compared with RT + Cetux. METHODS AND MATERIALS: Perceived hearing handicap was measured a…
Rank97.0
HPVoice: a single-blind three-arm RCT on social media communication strategies among adolescents in Tuscany, Italy.
Vaccine · 2026 · PMID 41855647
INTRODUCTION: Cervical cancer is the first cancer potentially eliminable through widespread HPV vaccination. In Italy, despite free access, vaccine coverage among adolescents remains low. Psychological factors such as information avoidance (IA), the tendency to ignore threatening information, can influence vaccine decisions and contribute to vaccine hesitancy (VH). While social media offers new avenues for health communication, their effectiveness in reducing VH is uncertain. This study investigates the impact of I…
Rank97.0
Vaginal microbiota transplantation for treatment of vaginal dysbiosis without the use of antibiotics: a double-blind, randomised controlled trial in women with vaginal dysbiosis.
The Lancet. Microbe · 2026 · PMID 41905375
BACKGROUND: A vaginal microbiota dominated by Lactobacillus species is associated with reduced risk of infection and adverse reproductive outcomes. Effective interventions to restore healthy microbiota remain scarce. In this study, we aimed to assess the efficacy of vaginal microbiota transplants (VMTs) without antibiotic pretreatment in achieving conversion to a Lactobacillus-dominated vaginal microbiome. METHODS: This single-centre, double-blind, randomised controlled trial was done at Copenhagen University Hospi…
Rank96.7
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2025 · PMID 40300079
PURPOSE: Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that monalizumab plus cetuximab had clinical activity in R/M HNSCC. PATIENTS AND METHODS: INTERLINK-1 (NCT04590963) was a double-blind, phase III study. Participants with R/M HNSCC who had received immune checkpoint inhibitor therapy and progressed despite platinum-based chemotherapy were…
Rank96.5
Nonavalent HPV vaccine to prevent recurrent anal or vulvar high-grade squamous intraepithelial lesions (VIVA trial): A randomized, double-blind, placebo-controlled trial.
International journal of cancer · 2026 · PMID 41685810
The nonavalent human papillomavirus (9vHPV) vaccine protects against HPV infection and high-grade squamous intraepithelial lesions (HSIL) when administered prior to exposure, but evidence supporting its potential therapeutic benefit has been inconsistent. This randomized, double-blind, placebo-controlled trial evaluated whether the 9vHPV vaccine reduces recurrence of HSIL or HPV persistence in 27-69-year-old persons previously treated for anal or vulvar HSIL. Participants were HSIL-free at enrollment and received 9…
Rank96.5
Effects of passive information dissemination on human papillomavirus vaccination attitudes and knowledge among pharmacy visitors: A cluster randomized controlled trial.
Journal of the American Pharmacists Association : JAPhA · 2025 · PMID 40782983
BACKGROUND: In Japan, human papillomavirus (HPV) vaccination rates remain low, partially owing to safety concerns from media reports. Pharmacies, as accessible health care facilities, often serve as sources of health information. However, the impact of passive information provision in pharmacies on public awareness and behavioral intentions has not been completely evaluated. OBJECTIVES: This study examined whether passive dissemination of HPV vaccine-related information in community pharmacies-through posters and l…
Rank96.4
SEARCH Study: Text Messages and Automated Phone Reminders for HPV Vaccination in Uganda: Randomized Controlled Trial.
JMIR mHealth and uHealth · 2025 · PMID 40324213
BACKGROUND: Cervical cancer is currently the leading female cancer in Uganda. Most women are diagnosed with late-stage disease. Human papillomavirus (HPV) vaccination is the single most important primary preventive measure. While research regarding text message vaccine reminder use is strong in the United States, their use has not yet been demonstrated in a preteen and adolescent population in subSaharan Africa or other low- and middle-income countries. OBJECTIVE: The objective of this pilot randomized controlled t…
Rank96.3
ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma: A Secondary Analysis of the DART Phase 3 Randomized Clinical Trial.
JAMA otolaryngology-- head & neck surgery · 2025 · PMID 40402484
IMPORTANCE: The De-escalated Adjuvant Radiation Therapy (DART) phase 3 randomized clinical trial (RCT) showed that in patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma, postoperative minimal residual disease (MRD), detected through circulating tumor HPV DNA (ctHPVDNA), was associated with a higher risk of disease progression. When considered along with pathologic factors, postoperative ctHPVDNA assessment may improve patient selection for adjuvant treatment de-escalation; how…
Rank96.2
Early colposcopy in non-16/18 high-risk human papillomavirus positivity with normal cytology.
Revista da Associacao Medica Brasileira (1992) · 2026 · PMID 42339905
OBJECTIVE: Very few clinical studies have been done to evaluate the potential clinical benefit of utilizing early colposcopy in women with normal Pap smear cytology but positive for high-risk human papillomavirus types other than human papillomavirus 16 or human papillomavirus 18 in a screening population for cervical cancer. The aim of this study was to compare two follow-up strategies and assess the need for colposcopy at the initial visit, based on cytology, human papillomavirus testing, and colposcopic findings…
Rank96.1
Intralesional measles, mumps, and rubella vaccine versus vitamin D for treatment of warts: A randomised clinical trial.
Indian journal of dermatology, venereology and leprology · 2026 · PMID 40357930
Background Warts are prevalent distressing skin growths caused by the human papillomavirus (HPV). These growths are commonly addressed using methods that destroy the tissue, including chemical cautery, electrocautery, or cryotherapy. These methods have many side effects in contrast to intralesional immunotherapy. Objectives This study was conducted to assess the effectiveness, safety, and tolerability of utilising the intralesional measles, mumps, and rubella (MMR) vaccine compared to vitamin D in warts treatment. …
Rank96.0
Comparison of topical potassium hydroxide 5% solution with cryotherapy in the treatment of patients with genital warts: A randomized controlled clinical trial.
International journal of STD & AIDS · 2025 · PMID 39600100
BACKGROUND: Given the therapeutic challenge of wart treatment and the need for an ideal treatment that is effective, noninvasive, cost-effective, and has minimal side effects, this study aims to compare the local impact of a 5% potassium hydroxide (KOH) solution with cryotherapy, the current standard treatment for genital warts. METHODS: Two groups, each consisting of 49 patients: the first group was treated with a daily topical application of 5% KOH solution using a swab, while the second group underwent cryothera…
Rank95.9
Acceptability, feasibility and appropriateness of integrating HPV self-sampling for cervical cancer screening into voluntary family planning services in Malawi.
BMC public health · 2025 · PMID 40750852
INTRODUCTION: Despite being preventable, the cervical cancer burden remains high in Malawi and other low-income countries. The World Health Organization recommends cervical cancer screening (CCS) using human papillomavirus (HPV) testing. The coverage of HPV-based CCS is low but may increase with self-sampling of vaginal fluid. We assessed the acceptability, feasibility and appropriateness of two models for integrating HPV self-sampling for CCS into family planning (FP) services in Malawi. METHODS: We conducted a mi…
Rank95.7
A multifaceted, targeted intervention to improve human papillomavirus vaccination rates in general practice: A pragmatic cluster-randomized controlled trial.
Vaccine · 2025 · PMID 40617087
BACKGROUND: Human papillomavirus (HPV) vaccination rates are low in Switzerland. The aim of the study was to test a pragmatic multifaceted targeted intervention among general practitioners (GPs) to increase HPV vaccination (HPVv) rates in general practice. METHODS: In this cluster-randomized controlled trial, two equally sized groups of GPs each received an educational session on vaccination in general and on the national vaccination schedule. Treatment group GPs additionally received detailed information about HPV…
i
Research information notice
Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.